Clinical trial NCT03384784
Conditions: HIV Associated Cognitive Motor Complex
Keywords: HIV Neurocognition Inflammation Galantamine Nicotine Tobacco Use
Sponsor: University of Pennsylvania
Start date: 2017-10-30; Completion date: 2022-05-31
Enrollment: 63 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo (arms switched). Outcomes are monocyte/macrophage and T cell activation and neurocognitive performance.

Detailed description:
Although anti-retroviral therapy (ART) enhances life expectancy and overall quality of life (QoL), HIV-infected individuals are increasingly vulnerable to non-AIDS-related diseases including HIV-associated neurocognitive disorders (HAND). Inflammation is a primary mechanism in the pathogenesis of HAND and tobacco use may further exacerbate inflammation. Conversely, nicotine alone has anti-inflammatory effects suggesting that stimulating the cholinergic pathway via pharmacological treatment \[e.g., galantamine (GAL)\] may suppress inflammation and reverse or prevent neurocognitive deficits in HIV-1 infection. In this double-blind, placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers, 60 nonsmokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo (arms switched). All subjects will be stable on ART and the GAL dose will follow FDA guidelines. At the beginning and end of each treatment phase, inflammatory biomarkers and viral load will be assessed. Monocyte transcriptomics will also be assessed on a subset of the sample (n=60; 30/group). Neurocognition and clinical outcomes (e.g., QoL) will be measured at baseline and at 4-week intervals during each treatment phase. The primary outcomes are monocyte/macrophage and T-cell activation (CD16, CD163, and CC chemokine receptor type 2 or CCR2 expression; plasma CC chemokine ligand type 2 or CCL2 \[MCP-1 or monocyte chemoattractant protein-1\], sCD14; CD38/HLA-DR \[cluster of differentiation 38/Human Leukocyte Antigen- antigen D Related\] on CD8 \[cluster of differentiation 8\] cells) and neurocognitive performance (processing speed, verbal learning/memory, executive function). Exploratory outcomes include monocyte gene expression patterns and broad plasma cytokine analysis. This study will provide insight into the interactions among nAChR activation, HIV immune activation and pathogenesis, and tobacco use and has translational and therapeutic implications that could improve health outcomes among HIV-infected individuals.

Arms: arm 1: This is a crossover study such that all participants receive both placebo and galantamine. Participants were randomized to receive galantamine first and placebo second. Timepoints Week 0 through Week 12 represent the first period and Weeks 16 through 28 represent the second period.

This study follows the FDA-recommended dosing regimen for galantamine extended release (GAL ER): 4 weeks at 8 mg (once a day), 4 weeks at 16 mg (once a day), and 4 weeks at 24 mg (once a day).

The University of Pennsylvania Investigational Drug Service (IDS) will oversee the randomization of all study medication, purchase study medication, manufacture matched placebo, encapsulate and package them in blister packs to maintain double-blind procedures. arm 2: This is a crossover study such that all participants receive both placebo and galantamine. Participants were randomized to receive galantamine first and placebo second. Timepoints Week 0 through Week 12 represent the first period and Weeks 16 through 28 represent the second period.

Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at the University of Pennsylvania. Both active medication and placebo will look identical.

The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take galantamine during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by galantamine during the second medication period.
Interventions: intervention 1: Galantamine intervention 2: Placebo
Intervention descriptions: intervention 1: The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food. intervention 2: Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.

Protocol documents:
Prot_SAP_000.pdf: 
University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 1 of 54 
Application for Review of Human Research: IRB Protocol Summary 
Biomedical Research   
Section II 
 
Version 16: February 22, 2021 
IRB#: 828125 
 
 
Principal Investigators:  Rebecca Ashare, Ph.D. 
 
 
 
Ronald Collman, M.D. 
 
 
 
Co-Investigators & Study Physicians:  
Ian Frank, M.D. 
 
Co-Investigators:  
 
Robert Schnoll, Ph.D. 
David Metzger, Ph.D. 
E. Paul Wileyto, Ph.D. 
Mohamed Abdel-Mohsen, Ph.D. 
 
 
 
 
 
PROTOCOL TITLE 
1.  Full Title 
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction 
 
2.  Brief Title 
Effect of galantamine on inflammation and cognition  
 
BRIEF DESCRIPTION 
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind 
placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized 
to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo (arms switched). 
Outcomes are monocyte/macrophage and T cell activation and neurocognitive performance.  
 
STUDY SPONSORSHIP 
1.  Funding Sponsor 
National Institutes of Health  
 
2.  Primary Sponsor 
Rebecca Ashare, Ph.D. 
 
ClinicalTrials.gov IDENTIFIER 
NCT03384784 
 
PROTOCOL ABSTRACT 
Although anti-retroviral therapy (ART) enhances life expectancy and overall quality of life (QoL), HIV-infected individuals 
are increasingly vulnerable to non-AIDS-related diseases including HIV-associated neurocognitive disorders (HAND). 
Inflammation is a primary mechanism in the pathogenesis of HAND and tobacco use may further exacerbate inflammation. 
Conversely, nicotine alone has anti-inflammatory effects suggesting that stimulating the cholinergic pathway via 
pharmacological treatment [e.g., galantamine (GAL)] may suppress inflammation and reverse or prevent neurocognitive 
deficits in HIV-1 infection. In this double-blind, placebo-controlled crossover study, HIV-infected individuals (N=120; 60 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 2 of 54 
smokers, 60 nonsmokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 
weeks of GAL or placebo (arms switched). All subjects will be stable on ART and the GAL dose will follow FDA guidelines. 
At the beginning and end of each treatment phase, inflammatory biomarkers and viral load will be assessed. Monocyte 
transcriptomics will also be assessed on a subset of the sample (n=60; 30/group). Neurocognition and clinical outcomes 
(e.g., QoL) will be measured at baseline and at 4-week intervals during each treatment phase. The primary outcomes are 
monocyte/macrophage and T-cell activation (CD16, CD163, and CCR2 expression; plasma CCL2 [MCP-1], sCD14; 
CD38/HLA-DR on CD8 cells) and neurocognitive performance (processing speed, verbal learning/memory, executive 
function). Exploratory outcomes include monocyte gene expression patterns and broad plasma cytokine analysis. This 
study will provide insight into the interactions among nAChR activation, HIV immune activation and pathogenesis, and 
tobacco use and has translational and therapeutic implications that could improve health outcomes among HIV-infected 
individuals.  
 
OBJECTIVES – Main Study 
1.  Overall Objectives  
Aim 1: To test whether a pharmacological approach to target cholinergic function reduces neurocognitive consequences 
of HIV-infection.  We predict that galantamine (vs. placebo) will improve neurocognition, including working memory, 
executive function, verbal learning/memory, and processing speed. 
Aim 2: To examine whether a pharmacological approach to target cholinergic function mitigates HIV-related 
inflammation. We predict that galantamine (vs. placebo) will reduce markers of residual inflammation (monocyte CD16, 
CD163, and CCR2 expression; plasma CCL2 [MCP-1] and sCD14; CD38/HLA-DR on CD8 cells). 
Aim 3: To evaluate the interaction between cholinergic modulation via GAL and chronic tobacco use. We predict that 
the effects of galantamine on residual inflammation and neurocognitive performance will be significantly greater among 
HIV+ smokers, compared to HIV+ non-smokers. 
2. Primary Outcome Variables 
The primary outcomes are neurocognitive function and inflammatory markers following 4 weeks of treatment with GAL 
vs. PLA (within-subjects; order counterbalanced). 
 
3. Secondary Outcome Variables 
Aim 4: To define monocyte gene expression patterns in HIV+S (vs. HIV+NS) and identify pathways altered by GAL. Given 
the central role of M/M in HIV residual inflammation and HAND, we will identify global patterns of monocyte activation 
in HIV/ART subjects that are impacted by chronic tobacco use and the effect of immunomodulation by galantamine, by 
analyzing monocyte transcriptomic patterns in HIV+ smokers and HIV+ non-smokers, and changes with galantamine 
treatment, in a subset of the population (n=60; 30 per group). 
 
BACKGROUND – Main Study 
HIV-Associated 
Neurocognitive 
Disorders 
(HAND) 
Persist 
Despite 
ART 
and 
Impair 
Quality 
of 
Life.  
The widespread use of antiretroviral therapy (ART) has greatly improved survival rates for those diagnosed with HIV/AIDS 
(Brugnaro et al, 2015; Deeken et al, 2012; Palella et al, 2006). Despite this achievement, rates of new HIV infections have 
remained constant, increasing the number of people living with HIV/AIDS (2011; Hall et al, 2008; Palella et al, 1998). 
Between 2001 and 2008, the percentage of adults living with HIV who are aged 50 or older has increased from 17% to 
31% and the rates continue to rise (Mahy et al, 2014; Prevention., 2010). Although ART enhances life expectancy and 
quality of life, HIV-infected individuals are increasingly vulnerable to non-AIDS-related diseases including cardiovascular 
disease, bone disease, frailty, and HIV-associated neurocognitive disorder (HAND) (D'Abramo et al, 2016; Leng and 
Margolick, 2015; Nasi et al, 2016; Palella et al, 2006; Rubinstein et al, 2014; Vaccher et al, 2014). Identifying novel 
treatments to address HAND, in particular, has become a critical priority, given its prevalence and impact (Nahvi and 
Cooperman, 2009; Pacek and Cioe, 2015). HAND is classified into three categories: HIV-associated dementia (HAD), mild 
neurocognitive disorder (MND), and asymptomatic neurocognitive impairment (ANI) (Antinori et al, 2007; Robertson and 
Yosief, 2014). Since the advent of ART, the incidence of HAD, the most severe form of HAND, has substantially decreased 
(Heaton et al, 2010; Heaton et al, 2011; Sacktor et al, 2016). Yet, MND and ANI persist despite ART, and 25-47% of HIV-
infected people exhibit deficits in multiple cognitive domains including memory, verbal fluency, processing speed, and 
executive function (Heaton et al, 2015; Sacktor et al, 2016). These cognitive deficits are associated with functional 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 3 of 54 
disabilities including unemployment, difficulty driving, and poor ART adherence (Doyle et al, 2013; Schouten et al, 2011; 
Thames et al, 2013). Two common factors across these comorbidities are persistent chronic inflammation, that often 
incompletely reverses with ART, and tobacco use. 
Inflammation is a Primary Mechanism Contributing to HAND.  
HAND in the pre-ART era was driven by systemic immune activation, reflected in an expanded population of CD16+ 
monocytes believed to transmigrate into the brain, and neuroinflammation, reflected by the accumulation of activated 
and/or infected brain macrophages/microglia (M/M) and elevated inflammatory markers in the CNS (Gannon et al, 2011; 
Gonzalez-Scarano and Martin-Garcia, 2005; Yadav and Collman, 2009). In the post-ART era, a common feature underlying 
many comorbidities including HAND, is persistent inflammation that does not completely reverse with viral suppression 
(Butler et al, 2011; Hunt et al, 2016; Lederman et al, 2013). In blood, persistent inflammation is reflected by monocyte 
and T cell markers including sCD14, sCD163, MCP-1/CCL2, monocyte CD16; CD8 T cell CD38/HLA-DR, activated coagulation 
products, and other cellular and soluble markers (Kamat et al, 2012; Lyons et al, 2011). Importantly, these monocyte, T 
cell and other soluble markers are associated with cognitive deficits observed in HIV+/ART-treated individuals (Burdo et 
al, 2013; Lyons et al, 2011; Schrier et al, 2015; Tiraboschi et al, 2015). In the CNS, persistent neuroinflammation is reflected 
by CSF inflammatory markers (McGuire et al, 2015; Saylor et al, 2016). Moreover, expression levels of genes involved with 
immune regulation (e.g., TNF-α, IL-1β) are correlated with HAND severity (Venkatachari et al, 2016). Thus, HAND in the 
post-ART era may be driven by persistent systemic inflammation (particularly monocytes) and neuroinflammation, which 
may be targeted by nicotinic receptor (nAChR) modulation. 
Tobacco Use Exacerbates Inflammation and Cognitive Dysfunction.  
Abundant evidence suggests that chronic smoking increases the risk of neurocognitive dysfunction and global cognitive 
impairment in the general population (Durazzo et al, 2012; Paul et al, 2006; Weiser et al, 2010) and among HIV-infected 
individuals (Bryant et al, 2013; Durazzo et al, 2007). Our preliminary data also show that HIV-infected smokers (HIV+S) 
perform worse on working memory and attention tasks compared to HIV-uninfected smokers (Harrison et al, under 
review). Tobacco smoking induces inflammatory markers including CRP, IL-6, MCP-1, and activated macrophages (D'Hulst 
A et al, 2005; Sopori, 2002; Spira et al, 2004; Stampfli and Anderson, 2009; Wannamethee et al, 2005) and may 
downregulate expression of genes involved with regulation of immune function (Spira et al, 2004), suggesting a 
mechanism by which smoking exacerbates HAND. Indeed, higher levels of CRP and sCD14 have been observed in both 
smokers with and without HIV, compared to nonsmokers (Kooij et al, 2016). Chronic tobacco exposure may also 
compromise the integrity of the blood-brain barrier and increase the likelihood of monocyte transmigration into the brain 
and/or direct CNS exposure to tobacco constituents, which, in turn, enhances the risk for neurodegeneration (Manda et 
al, 2010). Taken together, evidence suggests that tobacco use may increase the risk of HAND through effects on 
inflammation. 
Modulation of Nicotinic Receptors and their Role in Inflammation and Neurocognition.  
Despite the adverse effects of tobacco use on neurocognition and inflammation, nicotine alone, the main psychoactive 
ingredient in cigarettes, may have opposite effects. Nicotine attenuates pro-inflammatory cytokines IL-1β, IL-6, TNF-α 
(Wei et al, 2015) and inhibits NFkB-signaling (Sugano et al, 1998). Many of nicotine’s anti-inflammatory properties are 
attributed to its activation of the α7 nAChRs (Baez-Pagan et al, 2015; Wei et al, 2015; Wittebole et al, 2007). For instance, 
activation of α7 nAChRs suppresses abnormal activation of microglia and expression of CD14, ICAM-1, CD40, and TNF-α 
(De Simone et al, 2005; Hamano et al, 2006; Suzuki et al, 2006), and the α7 nAChR antagonist mecamylamine reverses 
these effects (Hamano et al, 2006). Nicotine also has neuroprotective effects (Evans and Drobes, 2009; Heishman et al, 
2010; Levin et al, 2006; Swan and Lessov-Schlaggar, 2007) and improves attention, learning, and memory in patients with 
schizophrenia (Jones et al, 2012; Lieberman et al, 2013; Winterer et al, 2013) and Alzheimer’s disease (Chen et al, 2006; 
Leiser et al, 2009; Srivareerat et al, 2011). Nicotine attenuates inflammation-induced cognitive deficits (Wei et al, 2015), 
indicating that enhancing cholinergic function may be an important therapeutic strategy to mitigate the effects of 
inflammation on HAND. 
Interactive Effects of HIV and Nicotine on Inflammation.  
Mounting evidence indicates important interactions between the cholinergic system and HIV-1 pathogenesis on 
neurocognition and inflammation. In vitro evidence suggests nicotine and HIV work synergistically to alter synaptic 
plasticity and neuronal cells (Atluri et al, 2014). For instance, the HIV-1 envelope glycoprotein (gp120), which activates 
M/M (Gonzalez-Scarano et al, 2005; Hong and Banks, 2015; Yadav et al, 2009) and has neurotoxic effects (Haughey and 
Mattson, 2002), is also reported to bind to nAChRs (Bracci et al, 1992). Moreover, stimulation of the cholinergic pathway, 
particularly α7 nAChRs, suppresses gp120-induced inflammation (Loram et al, 2010) and reverses neurocognitive deficits 
produced by gp120 (Nesil et al, 2015) in rats. Nicotine alters gene expression profiles in HIV-1 infected microglia (Rock et 
al, 2008) and in rodent models of HIV (Yang et al, 2016). Although nicotine upregulates some genes (e.g., TGF-β1, IL-4, 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 4 of 54 
CCR2, CXCR6, IL-1α) and downregulates others (e.g., TNF, CCL2, IL-8, IL-10, CXCR4, IRF4) (Rock et al, 2008; Yang et al, 
2016), nAChR antagonists reverse these changes in gene expression (Rock et al, 2008). Thus, while tobacco cessation 
remains a critical priority to increase healthy outcomes among HIV+ individuals, evaluating the effects of cholinergic 
activation on inflammation is essential to identifying novel and effective therapeutic strategies to reduce HAND. 
Galantamine’s Effects on Inflammation, Cognition, and Cholinergic Function.  
Consistent with this RFA (#11 under Research Objectives), we will evaluate a pharmacological therapeutic that targets 
cholinergic function and attenuates inflammation, in order to mitigate HIV-related adverse health consequences, including 
neurocognition. Although α7 nAChRs are important for neurocognition and inflammation, the rapid desensitization of 
these receptors (Briggs and McKenna, 1998; Quick and Lester, 2002) limits the therapeutic potential of α7 agonists, 
including nicotine (Echeverria et al, 2016; Kalkman and Feuerbach, 2016). Indeed, chronic tobacco use leads to 
upregulation of nAChRs (Benwell et al, 1988; Breese et al, 1997) which may be due to increased trafficking of nAChRs to 
the cell surface and increased receptor assembly and/or maturation (Govind et al, 2009). Thus, alternative methods of 
modulating cholinergic function must be explored. Galantamine (GAL), which is an FDA-approved medication for treating 
the cognitive symptoms of Alzheimer’s disease (Birks, 2006; Brodaty et al, 2005; Lockhart et al, 2009), modulates 
cholinergic function in two ways. First, as a cholinesterase inhibitor (AChEI), it increases acetylcholine (ACh) by inhibiting 
the enzyme that degrades ACh, acetylcholinesterase (Ashare and Schmidt, 2014; Sofuoglu et al, 2013). Second, as a 
positive allosteric modulator (PAM) of the α7 nAChRs (Maelicke and Albuquerque, 2000; Samochocki et al, 2003), GAL 
modifies the conformation of the receptor to enhance the likelihood that it will open and increases the efficacy of an 
agonist by decreasing the desensitized state of the receptor (Uteshev, 2014). Thus, GAL enhances cholinergic function 
without resulting in receptor desensitization caused by typical nAChR agonists (Freitas et al, 2013). In addition to its pro-
cognitive effects, GAL has anti-inflammatory properties in rodents (Gowayed et al, 2015; Pavlov et al, 2009; Satapathy et 
al, 2011) and humans (Reale et al, 2005). Indeed, 
GAL suppresses markers of inflammation important 
in the neuropathogenesis of HAND, including TNF-
α, IL-6, and CCL2 (MCP-1) (Gowayed et al, 2015; 
Pavlov et al, 2009; Satapathy et al, 2011) and GAL’s 
pro-cognitive effects may be mediated, in part, by 
its modulation of microglial nAChRs (Takata et al, 
2010). In a rodent model of HIV, acute treatment 
with GAL and nicotine synergistically attenuated 
gp120-induced inflammation (Giunta et al, 2004). 
As shown in Figure 1, we propose that among all 
ART-treated 
individuals, 
GAL 
will 
enhance 
neurocognition (Aim 1) and reduce inflammation 
implicated in the pathogenesis of HAND (Aim 2). 
Given the opposing effects of nicotine versus 
tobacco smoking, we will evaluate whether chronic 
tobacco use (i.e., exposure) modulates GAL’s effects 
on inflammation and neurocognition (Aim 3). Lastly, we will analyze transcriptomic patterns of monocytes and changes 
with GAL treatment in a subset of the sample (Aim 4). This innovative approach has the potential to clarify the mechanisms 
that underlie persistent inflammation despite ART, evaluate a potential therapeutic that could improve health outcomes 
among HIV-infected individuals, and identify those most likely to benefit.  
 
BACKGROUND – Recruitment & Retention Pilot Study 
Nearly one in three clinical trials closes prematurely due to under-enrollment. Reports of clinical trials consistently state 
that initial approaches to recruitment are rarely successful, take longer and are more costly than planned, and the pool of 
participants is overestimated. Unfortunately, many studies implement recruitment strategies without taking a systematic 
approach to identifying the most efficient and cost-effective approaches to enrolling subjects. With the increasing ubiquity 
of cell phones, text messaging (SMS) interventions have the potential to increase reach and reduce costs. In the United 
States, it is estimated that 85 to 91% of adults (18 and over) own a mobile phone, and these rates are observed across 
low- and high-income individuals. SMS interventions for improving adherence to antiretroviral treatment in people living 
with HIV as well as smoking cessation have demonstrated efficacy. However, few studies have explicitly examined 
strategies to optimize the use of SMS to enhance clinical trial enrollment. Behavioral economic strategies, including 
information provision and incentives, may represent useful approaches to overcoming barriers to clinical research and 
 
Figure 1. Hypothesized model of cholinergic modulation of HIV-
related          inflammation and neurocognitive performance. 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 5 of 54 
ultimately advancing science. Information provision includes utilizing descriptive and injunctive norms, personalization, 
and reciprocity. Framing messages to shape social norms regarding research participation may increase engagement. For 
example, in addition to “personal medical benefit”, patients cite “contributing to research that could help other people” 
and “giving something back in return” as the most important reasons to participate in clinical research. Another common 
strategy for improving recruitment and retention is to offer incentives, including monetary payments or other rewards 
that target motivation. For instance, contingency management (CM), where tangible reinforcement is provided in close 
temporal proximity to a participant performing a target behavior (e.g., on-time attendance) is highly efficacious in 
engendering target behaviors. Although information provision and incentives are effective strategies for behavior change, 
they may target different aspects of motivation: intrinsic (i.e., the behavior itself is purposive) vs. extrinsic motivation (i.e., 
the prospect of gaining the incentive motivates the behavior), respectively. Although numerous studies comparing 
intrinsic vs extrinsic strategies to enhance motivation have yielded inconsistent results, a recent meta-analysis suggested 
intrinsic and extrinsic factors may act synergistically. Thus, we propose to employ information provision and incentive 
strategies independently and in combination to evaluate the optimal approach for recruiting and retaining subjects in 
clinical research studies. 
 
OBJECTIVES - Recruitment & Retention Pilot Study 
Aim 1: To evaluate the effects of information provision and incentives, alone and in combination, on study enrollment 
rates. 
Hypothesis: Behavioral economic interventions will (Information provision & contingency management) will produce higher 
rates of enrollment compared to standard recruitment. 
 
CHARACTERISTICS OF THE STUDY POPULATION 
1. Target Population 
One hundred and twenty (60 smokers and 60 nonsmokers) adults living with HIV 30 years of age or older who are stable 
on ART regimens will complete the study.  Smokers will report smoking at least 5 cigarettes per day and provide a breath 
CO sample greater than 5 ppm at Intake and at the beginning of each treatment period.  Non-smokers will report smoking 
fewer than 100 cigarettes in their lifetime, or, less than 5 pack years of smoking and no cigarettes smoked in the last year. 
They will self-report no current use of any tobacco or nicotine product and will provide a CO sample of less than 3 ppm at 
Intake and at the beginning of each treatment period. If CO sample does not reflect self-report, the PI will be consulted to 
determine eligibility. Participants in the smoking and non-smoking groups will be matched according to key demographics 
such as age, race, education and history of substance use. 
 
2.  Accrual 
For this trial, we expect to screen ~2000 patients, 77% of whom will be current smokers (HIV+S n=1540 and HIV+NS n=460). 
Based on our recent GAL trial (Ashare et al, 2016) and the present inclusion/exclusion criteria, we expect ~30% of these 
patients to be eligible via phone screen (n = ~462 and 138 for HIV+S and HIV+NS, respectively). Of these, we expect 60% 
to attend the Intake visit and enroll in the study (n=~277 and 83 for HIV+S and HIV+NS, respectively). Because we anticipate 
differences in rates of smokers and nonsmokers, efforts will be made to oversample nonsmokers.  To be conservative, 
given the possible health problems evident in this population of smokers, we will project less than 20% of participants will 
withdraw from the trial and more than 80% of subjects will complete. We will enroll 150 subjects (75/group) to account 
for attrition. This will require enrolling 4 subjects per month over the course of a 38-month recruitment period. 
 
3.  Key Inclusion Criteria 
Eligible subjects will be males and females: 
1. At least 30 years old 
2. Diagnosed with HIV-1 infection 
3. On stable ART regimens (no changes to treatment within 4 weeks of Intake visit)  
4. Viral load of less than or equal to 200 copies/mL completed 12 months prior to enrollment 
5. CD4 counts greater than 200 completed 12 months prior to enrollment (if most recent) 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 6 of 54 
6. If current or past diagnosis of bipolar disorder, eligible if: 
a) No psychotic features 
b) MADRS: total score less than 8 (past 4 weeks), suicidal item score less than 1 (past 4 weeks) 
c) Y-MRS: total score less than 8 (past 4 weeks), irritability, speech content, disruptive or aggressive 
behavior items score less than 3 (past 4 weeks) 
d) No psychiatric hospitalization or Emergency Room visits for psychiatric issues in the past 6 months 
e) No aggressive or violent acts or behavior in the past 6 months 
7. Able to communicate in English and provide written informed consent 
8. Will be residing in the geographic area for at least 7 months 
9. Not currently trying to quit smoking  
10. Smoking Status  
a) Smokers (HIV+S) will report at least 5 instances of smoking per day, on average for the past year and 
provide a breath CO sample greater than 5 ppm at Intake and at the beginning of each treatment 
period. 
b) Non-smokers (HIV+NS) will report smoking fewer than 100 cigarettes in their lifetime, or, less than 5 
pack years of smoking and no cigarettes smoked in the last year. They will self-report no current use of 
any tobacco or nicotine product and will provide a CO sample of less than 3 ppm at Intake and at the 
beginning of each treatment period. If CO sample does not reflect self-report, the PI will be consulted to 
determine eligibility. 
 
4.  Key Exclusion Criteria 
Subjects who present with and/or self-report the following criteria will not be eligible to participate in the study. 
 
Smoking Behavior 
1. Current enrollment or plans to enroll in another smoking cessation program in the next 7 months. 
2. Regular (daily) use of electronic cigarettes, chewing tobacco, snuff, snus, cigars, cigarillos, or pipes. 
3. Current use or plans to use nicotine substitutes (gum, patch, lozenge, e-cigarette) or smoking cessation treatments 
in the next 7 months. 
 
Alcohol/Drug Use 
1. Current untreated and unstable diagnosis of substance abuse or dependence (if past use and if receiving 
treatment and stable for at least 30 days, eligible) 
2. Positive urine drug screen for cocaine, methamphetamines, PCP, barbiturates, ecstasy (MDMA), at Intake or Lab 
visits. Those who screen positive for amphetamines, benzodiazepines, methadone, oxycodone, and/or opiates 
(low level cut-off 300 ng/mL) and who are prescribed these medications will be reviewed on a case-by-case basis 
by the study physician and PI (see Measures and Table 1 for details). Participants believed to have a false-
positive result on the drug screen may continue in the study, with investigator approval. 
 
Medical/Psychiatric Conditions 
1. Women who are pregnant, planning a pregnancy or lactating 
2. Current diagnosis of unstable and untreated major depression (if stable for at least 30 days, eligible) 
3. Current or past diagnosis of psychotic disorder  
4. Cancer diagnosis within the past 6 months (except basal cell carcinoma)  
5. Major heart disease or stroke within the past 6 months 
6. Uncontrolled hypertension (SBP greater than 160 or DBP greater than 100). 
7. Medical conditions contraindicated for use with galantamine: 
a. Diagnosis of Alzheimer’s disease or dementia  
b. Epilepsy or other seizure disorder  
8. Bladder outflow obstruction 
9. Active HCV co-infection (if cured, requires study physician approval) 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 7 of 54 
10. Liver function tests more than 20% outside of the normal range; Gamma-glutamyl Transpepsidase (GGT) values 
more than 20% outside of the normal range. If Albumin/Globulin ratios are 20% outside of normal range the 
abnormal value will be evaluated for clinical significance by the Study Physician and eligibility will determined on 
a case-by-case basis. 
11. Renal disease or renal dysfunction (e.g., serum creatinine levels greater than 1.5 X upper limit of normal). Those 
with moderate hepatic impairment or creatinine clearance 9 to 59 mL/min shall not exceed the 16mg/day dose. 
12. Peptic ulcer disease (requires study physician approval) 
13. Suicide risk as indicated by at least one of the following on the Columbia Suicide Severity Rating Scale (the PI 
&/or PM (LCSW) will be consulted to assess safety and determine eligibility in cases close to the eligibility 
cutoffs): 
a. Current suicidal ideation (within 30 days of enrollment) 
b. Two or more lifetime suicide attempts or episodes of suicidal behavior 
c. Any suicide attempt or suicidal behavior within 2 years of enrollment 
 
Medication 
1. Current use or discontinuation within the last 14 days of:  
a. Quit smoking medications including varenicline (Chantix), bupropion (Wellbutrin) 
b. Anti-psychotic medications (e.g., Zyprexa, Clozaril, Seroquel, Risperdal). If used to treat psychotic 
symptoms. Other uses may be eligible pending physician approval.  
c. Systemic Steroids (e.g., Prednisone). 
d. Alzheimer's disease medications (e.g., Acetylcholinesterase inhibitors (ACIs), Aricept/donepezil, 
Exelon/rivastigmine, Tacrine, or memantine) 
e. Irritable bowel syndrome medication (e.g., Dicylomine/Bentyl) 
f. 
Heart medications (e.g., quinidine).  
g. Muscle relaxants (e.g., Anectine/succinylcholine) 
h. Anti-seizure medications (e.g. Ativan, Banzel, Carbatrol, Dilantin, Lamictal, Gabitril, Lyrica, Neurontin, 
Tegretol, Topomax). If used to treat a seizure disorder or epilepsy. Other uses may be eligible. 
i. 
Urinary retention medications (e.g., Duvoid/bethanechol, Proscar/finasteride, Avodart/dutasteride, 
Dibenzyline/ phenoxybenzamine, Regitine/phentolamine) 
 
2. Daily use of: 
a. Opiate-containing medications for chronic pain (Duragesic/fentanyl patches, Percocet, Oxycontin). 
Smokers who report taking opiate-containing medications on an “as-needed” basis will be instructed to 
refrain from use until their study participation is over and that they will be tested to ensure they have 
complied with this requirement. 
b. COPD medication (e.g., Atrovent/Ipratropium Bromide) 
3. Known allergy to study medication.  
 
Subjects will be instructed to refrain from using any study prohibited drugs/medications (both recreational and 
prescription) throughout their participation in the study. 
 
5.  Vulnerable Populations  
Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study.  
 
6.  Populations vulnerable to undue influence or coercion 
Educationally or economically disadvantaged persons are included but not solely targeted for recruitment.  Cognitively 
impaired persons are not included in the current study.  Because of our recruitment efforts for this study, it is possible 
that University of Pennsylvania employees and students may be invited to participate.  Status of participation in the study 
will be independent of the subject’s work or school activities.  
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 8 of 54 
7.  Subject Recruitment  
Participants will be recruited from the Infectious Disease practices at the Hospital of the UPENN, Presbyterian Hospital, 
and Pennsylvania Hospital. Dr. Frank will oversee the integration of this study into the clinics, ensuring access to 
participants, collection of medical data (through UPHS PennChart medical record reviews and laboratory result requests), 
and access to private consulting rooms for screening at the CFAR clinics. These practices see over 500 patients monthly 
and more than 200 new patients each year.  
 
After obtaining the necessary training and clinic clearances to access PennChart for participating UPHS clinics, Research 
Assistants (RAs) will review the electronic medical records to identify potential subjects on a weekly basis (each site has 
patient smoking status indicated on the record). Individual medical records will be evaluated for eligibility based on the 
inclusion and exclusion criteria for this study. Daily clinic schedules will be ascertained and RAs will approach patients prior 
to or after consultation or treatment at the clinic. In addition to in-clinic recruitment, RAs will contact potentially eligible 
patients (after EMR review) by telephone based on their clinic provider’s specified research contact preference. Providers 
may choose one of the following contact options: 1) all patients identified as initially eligible may be contacted 2) all 
patient records identified as initially eligible will be sent to the provider via PennChart for review and approval prior to 
contact 3) all patient records identified as initially eligible may be sent to the provider, who assumes full responsibility and 
discretion regarding the research contact (no contact may be made by the research staff). Those patients deemed eligible 
for contact will be contacted by telephone. RAs will introduce the research study and the collaboration between the 
researchers, infectious disease clinic, and the patient’s provider. After assessing the patient’s interest, HIV status, and 
smoking status, the patient will then be provided with additional study information and an opportunity to assess his/her 
intake eligibility based on a screening questionnaire. Research Recruitment Best Practice Advisories (BPAs) will also be 
integrated into electronic medical record recruitment. BPAs are designed to fire passive alerts within PennChart at the 
point of care, notifying providers that a patient may be eligible for a specific study. This specific BPA will evaluate if a 
patient meets specific criteria associated with the trial and will present the provider with the option to indicate if a patient 
is interested in participating in the study or not. This BPA will only present if the patient meets the initial screening criteria 
based on smoking status and problem list diagnoses and will only present in specified departments. This indication of 
interest only serves to trigger a notification to study staff that a patient has met initial screen criteria and further follow-
up is requested to determine eligibility of the patient. This alert is a passive alert and will not interrupt the provider’s 
workflow, but will be listed in the same section as other clinically warranted BPAs. 
 
If our accrual rate is lower than anticipated based on our feasibility data, Dr. Metzger and the CFAR CAB will use their 
connections with community-based HIV/AIDS organizations in the Delaware Valley region to promote the trial and 
enhance accrual rates. The CFAR CAB, comprised of people with HIV/AIDS or professionals in the treatment of substance 
use among those with HIV, has numerous linkages to community-based organizations that can be used to enhance 
participant recruitment should that be necessary. We will also advertise the study using poster, newspaper, and internet 
based advertisements (this includes in-app advertising, Craigslist, and Twitter). Information about the study will be 
available on the CIRNA and iConnect websites. In addition, research staff will attend HIV/AIDS community events and 
community clinic intake hours to provide information about the study, distribute recruitment materials, and collect 
participant contact information via a secure, web-based data collection service. Additionally, we will place recruitment 
data requests with electronic research data warehouses such as Penn Data Store, PennOmics, and PennSeek to obtain 
lists of pre-consented potential participants. ResearchMatch, a national health volunteer registry that was created by 
several academic institutions and supported by the U.S. National Institutes of Health as part of the Clinical Translational 
Science Award (CTSA) program, will also be utilized. ResearchMatch has a large population of volunteers who have 
consented to be contacted by researchers about health studies for which they may be eligible.  
 
RAs and UPHS medical personnel will screen patients from UPENN and community-based HIV/AIDS clinics to identify 
potentially eligible and interested participants by phone or in person. Participants recruited through other methods will 
also be screened by phone or in person. Participants who are eligible and interested in the study will complete the Intake 
session (Week -2) with research staff. The participant will review and sign an informed consent and HIPAA form, complete 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 9 of 54 
eligibility and baseline assessments, and be scheduled for a Week 0 visit. The participant’s eligibility will be confirmed by 
Drs. Frank and Ashare. 
 
To ensure a high level of retention and adherence in this trial we will: 1) educate subjects about the benefits of protocol 
compliance; 2) schedule in-person sessions at convenient times (e.g., evenings); 3) provide modest financial compensation 
for session completion and transportation costs. 
 
Referral Bonus Program 
Participants who achieve their final study visit (Week 28) will be given the opportunity to receive a small bonus for referring 
others to the program. If the person who is referred completes the initial eligibility phone screen, regardless of outcome, 
the study participant will be awarded $20 per referral, for a maximum of 3 referrals ($60). 
 
Social Media 
Methods of social media: Twitter & Social Networking Applications (Grindr & Growlr). Content: 140 Characters or less 
advertisement - "HIV+? You may be eligible for a research study at UPenn. Time & travel compensated. Call 215-746-
7155." Method for posting: Twitter (Center for AIDS Research Twitter accounts); Social Networking Applications (direct 
message through application sent directly by vendor). 
 
STUDY DESIGN 
1.  Phase 
n/a. 
 
2. Design 
Main Study. This is a randomized placebo-controlled cross-over study with one within-subjects factor of medication (GAL 
vs. PLA; order counterbalanced) and one between-subject factor of smoking status (HIV+ smoker vs. HIV+ non-smoker). 
Smokers (n=60) will be defined as those who smoke at least 5 cigarettes per day for the past year; non-smokers (n=60) 
will be those who report smoking fewer than 100 cigarettes lifetime and who self-report no current use of any tobacco or 
nicotine product, confirmed with carbon monoxide (CO) and saliva cotinine (self-reported smokers only). Subjects will 
complete this 28-week study, which consists of two 12-week treatment phases separated by a 4-week washout period.  
The dosing regimen follows FDA-approved guidelines for GAL extended release (ER), which recommends 8 mg per day for 
the first 4 weeks and increasing to 16 mg per day for the next 4 weeks before increasing to 24 mg (Aronson et al, 2009; 
Brodaty et al, 2005). During each phase, M/M activation markers (and T cell activation markers), soluble inflammatory 
biomarkers, neurocognition, viral load, clinical outcomes (e.g., medication adherence, health-related quality of life), and 
monocyte transcriptomics will be assessed at baseline (week 0 and 16) and at the end of each phase (weeks 12 and 28). 
Monocyte transcriptomics will be assessed on a subset of the sample (n=60; 30/group). In addition, neurocognition, and 
clinical outcomes will be assessed after 4 weeks at each intermediate dose (weeks 4, 8, 20, and 24). Subjects will also 
receive a phone call after 2 weeks at each dose to assess for potential side effects or contraindications. The primary 
outcome for Aim 1 is neurocognitive performance (a composite score comprised of processing speed, verbal 
learning/memory, and executive function) during each treatment phase. The primary outcomes for Aim 2 are M/M and T 
cell activation (CD16, CD163, and CCR2 expression; plasma CCL2 (MCP-1) and sCD14; CD38/HLA-DR on CD8 cells). Aim 3 
will test the interaction between smoking status and treatment (GAL vs. PLA) on Aim 1 and 2 outcomes. Aim 4 will evaluate 
monocyte gene expression patterns.  
 
Recruitment & Retention Pilot. This pilot study will utilize a randomized controlled trial design to evaluate two 
components of behavioral economic strategies to improve recruitment and retention. To be eligible for the pilot study 
participants must meet all eligibility criteria for one of the four participating studies (828958, 824061, 824860, 828125), 
have a phone capable of receiving SMS messages, and consent to receive SMS messages. ~576 participants will be enrolled 
across the four participating research studies. All subjects will receive standard text messages and will be randomized to 
one of four groups (blocked within each study to ensure balanced groups): (1) Standard recruitment (SR): subjects will 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 10 of 54 
receive text messages ~2 days prior to their Intake visit with relevant information about the time, date, and location of 
the visit as well as contact information for study staff (“You have a study visit on [Date] at [Time]. Visit comp is $10. Reply 
Y to confirm. See http://j.mp/2222222 for reminders. Reply or appt may be canceled.”); (2) SR + Information Provision 
(IP): Subjects will receive personalized messages designed to target injunctive norms regarding participating in research 
(e.g., “[Name], wondering why you should volunteer for research? Many find it a rewarding way to advance science and 
be a part of a community http://j.mp/2222222.”); (3) SR + Contingency Management (CM): CM will be provided in the 
form of a randomization table with a high proportion of numbers that correspond to “chips” with little ($1) monetary 
value. Participants draw by choosing numbers between 1-500  upon completion of an objectively verified target behavior 
(e.g., attending an Intake visit), and bonuses are often provided for continued performance. A similar strategy has been 
successful in augmenting visit compliance in several treatment studies. All text reminders will be delivered using the Way 
2 Health (W2H) software platform. Upon completion of all requirements for a given visit, participants will receive 5 lottery 
draws for that visit. Attendance at all visits earns participants bonus draws upon completion of the study. Failure to attend 
an in-person visit without prior approval or failure to complete all visit requirements results in no draws for that visit. The 
lottery contains 500 “chips” (numbers that correspond to monetary values within a table): 250 have a value of $0, 219 
have a value of $1, 30 have a value of $5, and 1 has a value of $100. The study completion bonus will be 5 extra draws. 
Thus, at each visit, subjects will have the opportunity to make 5 draws, for maximum possible earnings of $120; (4) SR + 
IP + CM (IC): In this group, subjects will receive the targeted text messages and receive CM. The design of our study allows 
us to examine each strategy independently as well as combined to evaluate the optimal approach. 
 
3. Study Duration  
Length of Subject’s Participation in Study 
Subjects will participate in study related activities for approximately 7 months from initial eligibility assessment in the 
clinic through follow-up. A subject’s length of participation may be affected by center or subject scheduling conflicts. 
Additionally, subjects may be contacted after study participation to clarify self-report data collected during their active 
participation, if necessary for data analysis. The Recruitment & Retention Pilot Study will conclude when all participants 
have completed the study. 
 
Projected date of completion of the proposed study  
We expect to complete accrual in approximately 42 months, with all follow-up visits complete by January 2022. We expect 
to obtain our numbers in this timeframe by enrolling approximately 3-4 subjects per month.   
 
DRUGS OR DEVICES 
Galantamine  
Figure 2. Study Timepoints and Outcomes 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 11 of 54 
The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER, which is currently 
marketed for the treatment of Alzheimer’s disease. The dosing regimen will be an initial 4 week of drug run-up at the 
lowest 8mg q.d. dose. Unless there are moderate to severe adverse events (see definitions below), the dose will be 
increased to 16mg q.d. for the following 4 weeks. If moderate to severe adverse events are reported, participants will be 
monitored and remain at the 8mg dose before titrating to 16mg.  The dose will be increased for the last 4 weeks to 24mg 
followed by assessments.  If moderate to severe adverse events are reported, participants will be monitored and remain 
at the 8mg or 16mg dose before titrating to the next highest dose.  Side effects will be monitored and assessed at all study 
visits during the treatment phase as well as during monitoring phone calls scheduled throughout the medication run-up. 
Based on current study of galantamine in smokers (IRB#815789), the medication is well-tolerated and we expect few 
moderate and severe side effects (no severe side effects have been recorded to date in our current study). 
 
The dosing regimen is documented to be safe and well tolerated in prior clinical studies (Aronson et al, 2009; Brodaty et 
al, 2005). Galantamine will be purchased and packaged into blister packs by the Investigational Drug Service at the 
University of Pennsylvania. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) 
every morning, preferably with food, for a 12-week medication period prior to and then again following a 4 week washout.  
Participants will be blindly randomized to placebo at one of the two medication periods.  
 
Impact of antiretrovirals on galantamine 
Galantamine is metabolized by CYP3A4 and CYP2D6, so there is likely to be inhibition of the clearance of the drug by 
ritonavir and cobicistat, two cytochrome P450 isoenzyme inhibitors.  There is no data describing the drug-drug 
interactions of galantamine and antiretrovirals.  However, there are no recommendations to decrease the dose of 
galantamine when administered with other potent inhibitors of CYP3A4 or CYP2D6. (Razadyne ER prescribing information) 
Ketoconazole, a potent inhibitor of CYP3A4 and an inhibitor of CYP2D6, when administered at a dose of 200 mg twice daily 
for four days increased the AUC of galantamine by only 30%.  Paroxetine, a strong inhibitor of CYP2D6, when administered 
at a dose of 20 mg daily for 16 days increased the bioavailability of galantamine by approximately 40%.  In addition, a total 
of 356 patients with Alzheimer’s disease enrolled in two Phase 3 studies were genotype with respect to CYP2D6 (n=210 
hetero-extensive metabolizers, 126 homo-extensive metabolizers, and 20 poor metabolizers). Population 
pharmacokinetic analysis indicated that there was a 25% decrease in median clearance in poor metabolizers compared to 
extensive metabolizers. Dosage adjustment is not necessary in patients identified as poor metabolizers.   
In this study we will monitor participants for adverse events.  The most common adverse events associated with 
galantamine, including nausea, vomiting, dizziness, and anorexia, which occurred in 20.7%, 10.5%, 7.5%, and 7.4% of 
participants, respectively, in 8 placebo controlled, double-blind studies of galantamine.  Subjects in our study who 
experience more than mild adverse events thought to be associated with galantamine will not be dose escalated, and 
subjects who experience more than mild adverse symptoms thought to be associated with galantamine will be dose 
reduced, if taking the highest dose of medication. 
Impact of galantamine on pharmacokinetics of antiretrovirals 
In vitro studies show that galantamine did not inhibit metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, 
CYP2D6, or CYP2E1.  This indicates that the inhibitory potential of galantamine towards the major forms of cytochrome 
P450 is very low.  (Razadyne ER prescribing information).  Therefore, the impact of galantamine on the activity of 
antiretroviral agents is likely minimal.  
 
Supply, Preparation, Storage, Packaging and Dispensing of Study Medication 
Galantamine-ER will be purchased and supplied via the University of Pennsylvania Investigational Drug Service (P1536). 
Matched placebo will be made in-house using lactulose filler in gel capsules. The IDS will store the medication as per the 
manufacturer guidelines. Specifically, medication will be stored at room temperature (20 – 25 degrees centigrade) and in 
airtight containers. Galantamine and the matching placebo will be packaged in blister packs.  IDS will oversee the labeling 
of all study medication, and will assign each kit, which contains medication for one subject, a unique Pharmacy 
Randomization Number (PRN). 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 12 of 54 
Once the Study Physician/Nurse Practitioner signs the prescription and a subject is assigned to treatment, medication kits 
will be ordered and picked up from IDS by a member of the research staff. IDS will assign a PRN to a subject, and provide 
the appropriate blister packs (8mg, 16mg, or 24mg). IDS’ labeling will include the subject’s study ID number and initials. 
In the event study staff are not able to pick up study medication, or a subject is unable to attend their visit in-person to 
collect their study medication, staff will work with IDS to determine the possibility of shipping the medication to the 
subject. Staff will confirm with the subject prior to shipment that they are able to receive deliveries and confirm their 
address. 
 
Each medication kit will consist of four weeks of 8mg galantamine (or placebo), four weeks of 16mg (or placebo), and four 
weeks of 24mg (or placebo). If no moderate or severe adverse events are reported at week 4 or week 8, we will proceed 
with the next highest dose (e.g., subjects will receive the 16 mg dose at week 4 and the 24 mg dose at week 8). If moderate 
or severe adverse events are reported, the study physician will be consulted and a decision will be made as to whether to 
proceed with the default or provide an alternative blister pack with a reduced dose of study medication. The PRN and 
study ID number must match for each blister pack a subject receives. Medication will be stored at CIRNA as per 
manufacturer’s guidelines. 
 
Regular study drug reconciliation will be performed to document drug assigned, drug consumed, and drug remaining. This 
reconciliation will be logged on the drug reconciliation form, and signed by the research staff member who completed the 
reconciliation. 
 
At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, and drug remaining.  
This reconciliation will be logged on the drug reconciliation form, signed and dated by the research staff. Any discrepancies 
noted will be investigated, resolved, and documented prior to return or destruction of unused study drug.  Drug destroyed 
on site will be documented in the study files. 
 
SUICIDAL IDEATION AND BEHAVIOR 
The C-SSRS will be administered remotely (via phone or videoconferencing) as part of the Intake visit by a trained member 
of the staff. Individuals who endorse current (past month) suicidal ideation, suicidal behavior in the past two years, or 
multiple lifetime attempts will be ineligible to participate. Because these assessments may cause an adverse emotional 
reaction, staff will be trained to deal with such reactions and to provide additional referrals if needed. If necessary, 
referrals to appropriate psychological services will be provided.  
 
STUDY PROCEDURES 
1. Procedures 
 
Initial Eligibility Screening. 
Recruited subjects will complete an initial eligibility assessment in the HIV/AIDS clinic or over the telephone. This 
assessment reduces the likelihood that participants attend an Intake Session only to learn that they are ineligible or to 
allow us to ascertain physician’s clearance should the participants have a medical condition that requires approval (e.g., 
mild hypertension). If a potential participant cannot be reached by phone, staff may send a text for the purposes of 
scheduling an initial eligibility screening phone call. This will help to reach potential participants who express interest in 
the study but do not answer phone calls from unrecognized numbers or do not regularly listen to voicemail messages. 
Texts will be sent from a central study account and not from the personal cellphones of any research staff. Participants 
who are initially eligible will be screened against our registration database to confirm that they are not currently 
participating in another research study at our Center and have not previously reported a condition or circumstance that 
would make them ineligible for the current study. Those participants who remain initially eligible will move forward with 
eligibility-determining tasks as part of the Intake session, which will be completed remotely and in-person. The Intake 
session must occur within 60 days of the initial eligibility screening or the participant will have to be re-screened. 
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 13 of 54 
Visit Reminders. 
Participants will receive study visit reminders 24 – 48 hours prior to their scheduled study visits by text via the W2H 
software platform. Participants who cannot receive text reminders or who do not agree to receive text reminders will still 
be able to participate and will receive reminders via phone call or email. 
 
Way to Health (W2H) is a software platform developed by the Penn Center for Health Incentives and Behavioral Economics 
(CHIBE), operated through a partnership between CHIBE and the Penn Medicine Center for Health Care Innovation and 
housed on Penn Medicine Academic Computing Services (PMACS) servers. W2H is an integrated, cloud-based platform 
that blends behavioral science with scalable digital technology to improve clinical outcomes. W2H automates many 
research functions necessary for conducting randomized controlled trials of healthy behavior interventions. 
 
Remote Study Participation. 
If needed, study sessions may be carried out remotely, including some Intake tasks. This enables us to continue 
collection of data in a rigorous way while maintaining the safety of subjects. Additionally, if a participant is unable to 
attend an in-person visit, either due to personal reasons or office closure, procedures will be modified to allow for 
remote collection of data. The procedure for visit reminders will remain the same. Participants will be contacted via call 
or text to remind them of the time of their session, as well as to remind them that the session will be conducted by 
phone. Staff will call participants to complete all measures that can be completed by phone. If collected on-site using 
session paperwork, these data will be stored in the participants’ charts and locked in secure filing cabinets, as is 
standard procedure. In the event that research staff are off-site, paperwork will be completed via RedCap. If RedCap is 
unavailable, they will utilize Pulse Secure to enable a secure, remote connection to their desktops and the secure server. 
Data collected remotely will be stored on our secure server, and later transcribed to paper measures and stored in 
participant charts or entered into RedCap. Items that are typically dispensed to participants at certain visits may be 
shipped to the participant, including study medication and a ClinCard, for payment purposes. 
 
Intake Session (Week -2): Consent, Eligibility Determination, Baseline Measures.  
Subjects who pass the pre-screening will be asked to complete tasks to determine their eligibility for the study. Tasks 2-6 
listed below may be completed remotely by phone or videoconference using BlueJeans (HIPAA-compliant), to reduce the 
length of in-person tasks. If remote, measures will be administered using RedCap surveys. The tasks may take up to 2.5-
hours if completed entirely in-person. Subjects will be asked to:  
 
1. Provide lab work to confirm recent viral load of less than or equal to 200 copies/mL and CD4+ counts of greater 
than or equal to 200 cells/mm3. If a participant is unable to provide lab work, their clinic may be contacted to 
obtain the necessary documentation. 
2. Complete the consenting process remotely (per procedure outlined in the Informed Consent section) or in-person. 
Staff will review the consent form and answer all questions. Staff will then administer a comprehension 
questionnaire and review incorrect answers as needed. If completed remotely, subjects who are unable to provide 
an electronic signature may be mailed a physical version of the consent that must be signed and returned to us 
prior to continuing with the Intake tasks.  
3. Complete mental status examinations (Mini International Neuropsychiatric Interview, QIDS, and CSSRS and 
MADRS, YMRS, Bipolar Disorder Additional Screener, if necessary) with a trained research staff member. 
4. Complete a medical history and concomitant medication review. 
5. Complete the Shipley Institute of Living Scale.  
6. Complete baseline measures to assess 1) background variables that may serve as covariates and will allow for the 
assessment of the study’s external validity (e.g., smoking history, demographics, infection history), and 2) baseline 
smoking behavior. 
7. Provide urine specimens for drug and (if applicable) pregnancy tests. Participants who test positive for study 
prohibited drugs (see Exclusion Criteria above and Measures below) may be ineligible. Participants believed to 
have a false-positive result on the drug screen may continue in the study, with investigator approval. 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 14 of 54 
8. Complete a carbon monoxide (CO) breath assessment to confirm smoking or non-smoking status.  The handheld 
device uses a disposable mouthpiece, reports CO in parts per million (ppm), and takes about 3 minutes. 
9. Complete physiological measures such as blood pressure, height and weight. 
10. Complete a brief physical examination (led by a medical professional). If the provider is off-site, this will be 
conducted via telehealth. 
11. Provide a blood sample drawn for the assessment of liver function (LFTs and GGT enzyme levels) and creatinine 
levels. Participants will receive final confirmation of eligibility via phone call based on the blood test results. 
 
Final Eligibility Phone Call.   
When liver function tests have been reviewed and authorized by the Study Physician, a study staff member will call the 
subjects to inform them of their final eligibility.  
 
Final Eligibility is defined as: Liver function test results and GGT liver enzyme levels that are no more than 20% outside the 
normal, clinical range and serum creatinine levels less than 1.5 X upper limit of normal. Albumin/Globulin ratios 20% 
outside of normal range will be evaluated for clinical significance by the Study Physician and eligibility will determined on 
a case-by-case basis. 
 
Eligible subjects will confirm the study schedule and be randomized to medication group. Ineligible subjects may be 
referred to other studies at our center.   
 
Laboratory Visits (Weeks 0, 12, 16 and 28).  
At the beginning and end of each treatment period, subjects will be scheduled for 2-hour laboratory visit.  The HIV+S group 
will be asked to smoke as usual and not change their smoking behavior.  At each visit, subjects will: 
1. Provide urine for drug screen and pregnancy test (if applicable) 
2. Smoking status will be confirmed via breath CO and saliva cotinine. Cotinine will be stored and analyzed as a 
covariate at the end of the trial.   
3. Subjects will complete self-report measures (see Table 1).* 
4. Subjects will undergo examinations with the MADRS, YMRS, and Bipolar Additional Screener, if necessary.* 
5. Subjects will complete neurocognitive tasks (see Measures and Outcomes) 
6. Provide a total of 80 mL of blood for the following assays: 
a. FACS analysis of monocytes, T cell surface markers 
b. Plasma for soluble biomarkers 
c. PBMCs for monocyte transcriptomics  
d. HIV-1 RNA viral load monitoring   
*Some tasks may be completed remotely to reduce the length of in-person visits. 
 
Monitoring Phone Calls (Weeks 2, 6, 10, 18, 22 and 26).  
During each treatment period, subjects will receive three brief (15-min) phone calls (after 2 weeks on each galantamine 
dose) to assess side effects and other self-report measures (see Table 1). Subjects who report moderate or severe side 
effects may be maintained at a lower dose of galantamine or may be withdrawn from the study. The calls will also serve 
to maintain contact throughout the trial and enhance retention. 
 
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 15 of 54 
Mid-treatment Visits (Weeks 4, 8, 20 and 24).  
Twice during each treatment period (after 4 weeks on 8 mg and again after 4 weeks on 16 mg of galantamine), subjects 
will attend a 1 hour visit.  Side effects of galantamine will be assessed by study staff and reviewed by the study physician 
prior to initiating the dose increase. The HIV+S group will not be asked to change their smoking behavior and will be 
instructed to follow their urges to smoke.  Subjects will: 
1. Provide a breath CO sample.  
2. Complete self-report questionnaires.*  
3. Undergo examinations with the MADRS, YMRS, and Bipolar Additional Screener, if necessary.* 
4. Complete the cognitive task battery.  
 
*Some tasks may be completed remotely to reduce the length of in-person visits. 
 
Washout Period (Between Weeks 12-16).  
After completing the first treatment period, subjects will undergo a 4-week washout period before the second period 
commences.  During the washout, subjects will not take any study medication or have any study visits.  The HIV+S will be 
instructed to smoke ad libitum.  
 
End of Recruitment and Retention Pilot Debriefing Call.  
After the participant has completed their final visit (due to completion, withdrawal or ineligibility), study staff will reach 
out to all participants enrolled in the recruitment and retention pilot to provide additional details about their participation 
in the pilot. 
 
Post-Study Follow-up. 
If necessary, subjects may be contacted after study participation to clarify, via phone, self-report data collected during 
their active study participation. Participants will be asked to provide verbal consent before any data is collected. No 
additional PHI will be collected during this follow-up. Although procedures are in place to ensure data accuracy during 
active participation, there are instances when it may be necessary to conduct a post-study follow-up to maintain data 
accuracy when analyzing study outcomes. If study staff are unable to contact a subject for follow-up, no further action will 
be taken.  
 
Side Effect Monitoring. 
Monitoring for adverse events will be conducted in real time by Dr. Ashare and Dr. Frank, the study physician. At each 
contact, participants will complete a side effect checklist, administered by trained staff. The SEC will assess the frequency 
and severity of common side-effects associated with galantamine (e.g., headache, nausea). These items will be rated by 
participants on a 0 (none) to 3 (severe) scale, and can be summed to provide an overall side effects index. Second, trained 
staff will ask participants a non-structured, open-ended question (SEC Open-ended) at each session to assess if participants 
are experiencing any additional symptoms or medical concerns that may be related to their participation in the study. 
Research staff are trained to inquire (time of onset, nature of issue reported, possible relation to galantamine treatment, 
review of previously reported side effects or concerns, etc.) about any notable side effects or medical concern reported 
by participants. Any severe (or a pattern of moderate) side effects or notable medical concerns will be reported to the 
PM/CRC, Study Physician, and Principal Investigators to determine a course of action (e.g. continue to monitor, reduce 
medication, stop medication). This consult, including all relevant information, will be documented.  
Based on published reports and data from our current study using the doses of galantamine in the proposed study we 
expect few side effects and we expect these side effects to be mild and transient in nature. However, in the unlikely 
event of an adverse event (AE) the study physician will determine the severity of the AE, the relationship of the event to 
the study drug and decide the course of action for the study subject. The study physician will determine the relationship 
of toxicity of the study medication as not related, possibly related, probably related, or definitely related using standard 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 16 of 54 
criteria. All adverse events occurring during each study period will be recorded. The clinical course of each event will be 
followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not 
the cause. Serious adverse events that are still ongoing at the end of the study period must be followed up to determine 
the final outcome. Any serious adverse event that occurs after the study period and is considered to be possibly related 
to the study treatment or study participation will be recorded and reported immediately. 
 
Screening/Covariate Measures. 
 
Demographics and Smoking History.  
Standard questionnaires will be administered remotely or in-person, to collect demographic information (e.g., age, 
gender, race). For HIV+S, smoking history (e.g., age at initiation, prior quit attempts, current rate) and the Fagerström Test 
for Nicotine Dependence (FTND) will also be collected. The FTND is a 6-item self-report measure of nicotine dependence 
with satisfactory internal consistency and high test-retest reliability.  
 
Physical Examination/Medical History.  
A medical history and a physical examination will be conducted as part of the Intake visit to review for any 
contraindications listed previously. The medical history (including height and weight) will be completed by a research staff 
member and participants will undergo a brief physical examination led by a medical professional, remotely or in-person. 
If the NP/provider is off-site, staff will coordinate a telehealth visit for the participant while they are at the center, via 
phone, FaceTime or BlueJeans (both HIPAA-compliant). Current medical conditions and medications will be documented. 
Duration since HIV diagnosis, mode of transmission, viral load, and CD4 counts will be assessed.  
 
Urine Drug Screen.  
The urine drug screen will be administered at Intake and at all Laboratory Visits. The urine drug screen requires about 
30ml of urine and indicates whether the subject has recently taken any of the following: cocaine, PCP, amphetamines, 
methamphetamines, tricyclic antidepressants, ecstasy, opiates, methadone, benzodiazepines, THC, and barbiturates). 
Participants with a positive urine drug screen for cocaine, PCP, methamphetamines, ecstasy, and barbiturates will be 
deemed ineligible. Participants prescribed other medications and screening positive will be considered on a case-by-case 
basis by the study physician and PIs. Participants believed to have a false-positive result on the drug screen may continue 
in the study, with investigator approval. In an effort to remain CLIA-compliant, results from urine drug screening will not 
be shared with participants and will not be placed in their electronic medical record. Participants will be informed that the 
testing is for research purposes only and that they will be informed of their eligibility status, but not of the specific testing 
results. 
 
Urine Pregnancy Test.  
At the Intake session and at all Laboratory Visits, participants will be supplied with a simple, CLIA-waived urine pregnancy 
screen and informed that pregnant women are not advised to participate in this research study. Participants will then be 
instructed to administer the pregnancy test independently and will inform study staff if they would like to continue 
participation after they have administered the pregnancy screen. Participants will be informed that there is no penalty for 
discontinuing participation at this point in the visit and that they will still receive travel reimbursement for the visit. 
 
Blood Pressure.  
At the Intake, participants presenting with elevated blood pressure (i.e., systolic blood pressure greater than 160 and/or 
diastolic blood pressure greater than 100) will have a second blood pressure reading taken after a ten minute period in 
which the participants will be instructed to sit comfortably.  If, after the second reading, systolic blood pressure remains 
greater than 160 and/or diastolic remains greater than 100, the participant will be ineligible for the study. 
 
Blood pressure will be measured at all subsequent in-person visits.  If participants present with elevated blood pressure 
(i.e., systolic blood pressure greater than 160 and/or diastolic blood pressure greater than 100) at any subsequent visit, 
the staff will follow the same steps listed above. If, after the second reading, systolic blood pressure remains greater than 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 17 of 54 
160 and/or diastolic remains greater than 100, the subject will be told to not take the next dose of study medication. The 
research staff will notify the Study Physician/Health Care Provider who will review the blood pressure reading and 
determine whether it is safe for the subject to continue. Research staff will follow up with the participant accordingly. 
 
Shipley Institute of Living Scale (SILS).  
At the Intake, subjects will complete the SILS remotely or in-person, which is a self-administered test to assess general 
intellectual functioning in adults (Zachary, 2000). The SILS correlates with the Wechsler Adult Intelligence Scale (WAIS-R) 
Estimated IQ Test and has good internal consistency (Cronbach’s α=0.92). The SILS will be used to control for baseline 
cognitive function. 
 
Liver Function, Gamma-glutamyl Transpepsidase, and Creatinine tests.  
One 8.5ml blood sample will be drawn at the Intake visit.  Blood will be collected and placed in a serum-separator tube 
(SST) and mixed thoroughly.  Samples will be centrifuged at 3100 rpm for 10 minutes. An additional 5 minutes will be 
added, if necessary for complete separation. The following chemistry will be assessed:  
1. Total protein. 
2. Albumin. 
3. Globulin. 
4. Albumin:Globulin ratio. 
5. Bilirubin (total, conjugated and unconjugated) 
6. Aspartate amino transferase (AST). 
7. Alanine amino transferase (ALT). 
8. Alkaline phosphatase (AP). 
9. Gamma glutamyl transferase (Gamma-GT) 
10. Creatinine. 
 
Psychiatric History.   
The prevalence of depression, substance abuse, and suicidality will be determined by the MINI International 
Neuropsychiatric Interview (MINI) (Sheehan et al, 1998) and the Columbia Suicide Severity Rating Scale (C-SSRS) (Posner 
et al, 2011). The MINI and C-SSRS will be administered remotely or in-person at Intake. If a diagnosis of bipolar disorder is 
self-reported or revealed via the MINI at intake, the Montgomery-Asberg Depression Rating Scale (MADRS), Young Mania 
Rating Scale (YMRS), and a Bipolar Disorder Additional Screener will be completed at all study sessions to evaluate and 
monitor the presence and severity of bipolar disorder symptoms.  An abbreviated version of the MINI may also be used 
to assess and monitor symptoms.  
 
Adverse Childhood Experiences Questionnaire.  
The occurrence of adverse experiences during childhood will be assessed using the Adverse Childhood Experiences 
Questionnaire (Felitti et al, 1998). Adverse childhood events are associated with health and social problems as an adult 
and may influence measures collected in this study. 
 
Hep C Infection History.  
At the Intake, participants will be asked to complete a measure to indicate any past diagnoses of Hepatitis C, as well as 
treatment history, if applicable. Some medical conditions, like Hepatitis C, may affect nicotine metabolism, and so, 
influence smoking behavior. This may be completed remotely or in-person. 
 
HIV Related Health Outcomes. 
 
HAART Adherence  
HAART adherence will be assessed with a self-report measure, the Adult AIDS Clinical Trials Group Adherence to 
Antiretrovirals Instrument (Chesney et al., 2000) (collected at all in-person study visits).  
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 18 of 54 
Viral Load and CD4+ Assessment 
A viral load assessment and CD4+ count will be collected for research purposes at Intake through medical record review 
and recorded. Participants may also be asked to sign a HIPAA authorization form to allow research staff to request lab 
results from their healthcare provider, if they are unable to obtain results. At each lab visit (weeks 0, 12, 16, and 28) one 
10 mL blood sample will be drawn to assess HIV-1 RNA via quantitative real-time PCR. For the HIV-1 RNA sample, whole 
blood will be collected in an EDTA tube and 3 mL plasma will be separated and sent for analysis. 
 
Quick Inventory of Depressive Symptomatology- Self Report (QIDS).  
The QIDS is a 16-item self-report measure designed to assess the severity of depressive symptoms using the criterion 
symptoms designated by the DSM-IV. 
 
Functional Impairment.  
The Patient’s Assessment of Own Functioning Inventory (PAOFI) will be used to assess cognitive difficulties in everyday 
life. The PAOFI assesses areas such as mental acuity, employment, social functioning, shopping, cooking, housekeeping, 
laundry, driving, use of public transportation, maintaining schedules, medication management, financial management, 
understanding media events, and child care (Chelune et al, 1986). The degree of functional impairment is used to 
distinguish between categories of HANDs (Antinori et al, 2007).  
 
Quality of Life: HAT-QoL 
The HIV/AIDS-Targeted Quality of Life scale (HAT-QoL; Holmes & Shea, 1998; 1999) measures overall functioning, which 
will be the primary measure of QOL for this study, but several subscales of QOL are also included such as life satisfaction, 
health worries, HIV mastery, financial worries, and disclosure worries. This measure will be administered at each visit after 
the Intake Session. 
 
Subjective Cognitive Complaints:  
The PROMIS (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that 
evaluates and monitors physical, mental, and social health in adults and children. The PROMIS Short Form v2.0 Cognitive 
Function Abilities Subset 8a will be used to assess subjective cognitive complaints. Each of the 8 items are scored from 1 
(Not at all) to 5 (Very much). This measure has been validated in medical outpatient samples (Saffer et al., 2015) and 
among those living with HIV (Solorio et al., 2016). 
 
Fatigue:  
The FSS (Fatigue Severity Scale) is a set of statements that explore severity of fatigue symptoms.   
 
Treatment Measures.  
 
Concomitant Medication Review.   
Subjects will be asked about their use of medications (over the counter and prescription) and substances that may alter 
subjects’ response to the study medication. The Study Physician/Health Care Provider will advise as to whether other 
medications being taken are contraindicated and prescribe appropriate action from there (i.e., discontinuation of the 
study medication). The concomitant medication review will be completed at every study visit following the Intake. 
 
Adherence to Study Medication.  
Medication adherence will be assessed, remotely or in-person, by pill count at each session that follows the first Lab Visit 
of each treatment period (Ray et al, 2009). 
 
Side Effects.  
A checklist of side effects based on the product insert will be administered remotely or in-person to participants at all sessions 
after the Intake, including at monitoring calls. The frequency and severity of common side effects of galantamine will be 
rated on a 0 (none) to 3 (severe) scale. An open-ended side effects question will also be included. Furthermore, participants 
will receive written instructions to call the Health Care Provider/Study Physician should they experience any severe side 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 19 of 54 
effects or adverse events between study visits. There are no documented HAART/GAL interactions (see Drugs or Devices 
above).  
 
Smoking Related Measures 
 
Smoking Rate: 
We will assess cigarettes smoked during the first laboratory session (dating back to the Intake visit), and throughout study 
participation. A standard timeline follow-back (TLFB) method will be used (Brown et al, 1998), as we have done previously 
(Lerman et al, 2004a) to assess self-reported smoking rate. This will only be administered to self-reported smokers and 
will be done remotely or in-person. 
 
Biochemical Verification:  
CO breath samples and saliva cotinine will be collected to biochemically verify self-report as in prior work (Lerman et al, 
2004b; Lerman et al, 2015; Schnoll et al, 2015; Schnoll et al, 2010). As per convention, cotinine levels greater than 50ng/ml 
indicate smoking within the past 7 days. 
 
Nicotine Withdrawal: 
The Revised Minnesota Nicotine Withdrawal Scale (MNWS-R) (Hughes and Hatsukami, 2007) is a 15-item self-report 
measure. Subjects rate withdrawal symptoms on a scale of 0 (none) to 4 (severe). This will only be administered to self-
reported smokers and will be done remotely or in-person. 
 
Smoking Urges: The 10-item Questionnaire on Smoking Urges–Brief (QSU-B) (Cox et al, 2001) will be used to assess 
cravings to smoke. It contains 2 subscales (anticipation of reward, relief from negative affect). This will only be 
administered to self-reported smokers and will be done remotely or in-person. 
 
Neurocognitive Outcomes 
Neuropsychological tests will be administered in a quiet laboratory testing room on a Dell® desktop computer running on 
the most recent and compatible version of Windows at the CIRNA. Unless otherwise noted, all tasks will be administered 
via E-Prime 2.0 (Psychology Software Tools, Inc.). The computerized battery is administered in a random order using 
clickable icons.  Total administration time is about 30 minutes. The outcomes and associated tasks are: 
 
Working Memory 
In the traditional N-back task, sequences of letters or numbers are displayed, and subjects respond with a button press to 
a single target using the following rules. During the 1-back condition, subjects respond if the image is identical to the one 
preceding it. In the 2-back condition, they respond if the stimulus is identical to the one two trials before. In the 3-back 
condition they respond if the image is identical to the one three trials before. The active baseline condition (0-back) is a 
simple target detection task. The version of the N-back used in this study utilizes fractal images in place of letters or 
numbers. The primary outcomes will be total correct and correct reaction time (task duration: ~18 minutes).  
 
Executive Function 
Color Shape Task: The Color Shape Task is a measure of flexibility. In each trial of this task (Miyake, Emerson, Padilla, & 
Ahn, 2004), a cue letter (C or S) appears above a colored rectangle with a shape in it (outline of a circle or triangle). 
Participants are instructed to indicate whether the color is red or green when the cue is C, and whether the shape was a 
circle or triangle when the cue is S. The colored rectangles are approximately 1.7” wide and 1.4” high, the circles were 
approximately 1.1” in diameter, and the triangles were 1.25” on each side. The color-shape figure appears in the center 
of the screen and the cue letters are centered 3/8” above its top edge. 
 
Verbal Learning and Memory 
The Hopkins Verbal Learning Test – Revised (HVLT-R) assesses verbal learning and memory (immediate and delayed recall, 
delayed recognition) (Brandt, 1991). The task has been validated in individuals 16 to 92 years old and within cognitively 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 20 of 54 
impaired populations (Benedict et al, 1998). The 6 alternate forms (to reduce practice effects) consist of a list of 12 nouns 
(targets) with 4 words drawn from each of 3 semantic categories. The HVLT-R has high test-retest reliability, and its 
construct, concurrent, and discriminant validity have been well-established (Shapiro et al, 1999). Raw scores are derived 
for Total Recall, Delayed Recall, Retention (% retained), and a Recognition Discrimination Index. Verbal memory has been 
shown to be a cognitive domain negatively affected by HIV infection (Antinori et al, 2007; Robertson et al, 2014; Woods 
et al, 2004). Task duration is 10 min with a 25-min delay. The primary outcomes are Total and Delayed Recall. 
 
Processing Speed and Response Inhibition 
The Stop Signal Task (SST) is a measure of response inhibition used in previous work with smokers (Ashare and Hawk, 
2012; Tsaur et al, 2015). Subjects are instructed to respond to left and right-facing arrows (go-trial) on the computer 
screen. Following practice trials, subjects complete three 64-trial blocks with stop signals (800-Hz, 100-ms, 70-dB tone) 
presented on 25% of trials. The initial stop delay in each block is 250ms and adjusts ±50ms depending on whether the 
subject successfully inhibits (Logan et al, 1997). Trials consist of a 500-ms warning stimulus, a 1,000-ms go-trial, and 1,000-
ms blank screen inter-trial interval. Task duration is 10 min. The primary outcome is stop signal reaction time (SSRT), 
calculated as the mean RT on go-trials minus mean stop delay.  
 
Inflammation Outcomes 
 
Cellular Markers of Immune Activation: 
Activation markers will be analyzed at the beginning and end of each treatment period by staining in whole blood. PBMC 
will be stained with flow panels for CCR2 (the receptor for CCL2/MCP-1, a key factor in monocyte migration in HAND (Ragin 
et al, 2006; Williams et al, 2014a; Williams et al, 2014b)), CD14, CD16, CD163, CX3CR1, CCR5 and CXCR4. We will also 
assess monocyte surface tissue factor (TF) given evidence that monocyte TF is activated by microbial products, one of the 
drivers of residual inflammation in HIV/ART, and upregulated in HIV infection (Brenchley et al, 2006; Deeks, 2009; Mudd 
and Brenchley, 2016; Wallet et al, 2010). Although monocyte activation is our primary focus, we will also stain cells in 
parallel for established T cell activation markers (CD3, CD4, CD8, CD38 and HLA-DR) (Ganesan et al, 2011; Liu et al, 1998). 
Cells are analyzed on a BD LSRII using FlowJo software. We have extensive experience with polychromatic FACS analysis 
and this panel is currently in place. Primary outcome measures are monocyte CD16, CD163 and CCR2; TF, CX3CR1 and 
other markers are secondary. Primary outcome measure for T cells will be CD38/HLA-DR on CD8 cells. 
 
Soluble Markers of Immune Activation: 
The following soluble markers will be measured in plasma or serum at the beginning and end of each treatment period: 
CCL2/MCP-1, sCD14, sCD163, TNF-α, sTF (by ELISA; R&D) (Cassol et al, 2010; Neuhaus et al, 2010). Primary outcomes are 
CCL2 (MCP-1) and sCD14. sCD163, sTF, and TNF-α are secondary. We will also carry out broader cytokine & chemokine 
analyses using Luminex Multiplex bead-based 25-plex human cytokine kit that measures 25 human cytokines/chemokines 
(Barqasho et al, 2009; Seoane et al, 2008). Luminex analysis will be carried out by the CFAR Immunology Core using the 
BioPlex 200 platform (Bio-Rad). This Luminex analysis is exploratory, but we expect it to provide both a broad pattern 
analysis of GAL effects, and valuable hypothesis-generating information. The Immunology Core just purchased a Simoa 
Digital ELISA machine (Quanterix), which offers Luminex-type multiplex bead-based analysis with several orders of 
magnitude greater sensitivity without loss of upper range detection (Rissin et al, 2010; Wilson et al, 2016); over the next 
few months, this machine will be operationalized and we will determine whether to migrate to this platform for this study. 
We predict that GAL will reduce monocyte and T cell surface activation and soluble markers, including those linked to HAND 
(Aim 2), and that the magnitude of the effect may be enhanced in smokers (Aim 3).  
 
Monocyte Transcriptomics: 
Gene expression analysis will be performed on a randomly-selected subset of the sample (n=60; 30/group). As in our 
prior work (Gekonge et al, 2012; Giri et al, 2009) and ongoing project analyzing atorvastatin modulation of immune 
activation (R01-MH061139), monocytes will be isolated by negative selection (Miltenyi), stored in RNAlater, and batched 
for RNA extraction and QC by Bioanalyzer. Gene expression analysis will be carried out at the UPenn Molecular Profiling 
Facility with the Clariom S Human platform (Affymetrix), which provides gene-level expression profiling for all known 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 21 of 54 
well-annotated human genes, using the GeneTitan plate array system. Comparison of expression levels at baseline 
between two groups will be done using a two sample SAM test. We will use an FDR less than 0.2 significance threshold 
for general gene set enrichment analysis and FDR less than 0.1 significance with greater than 1.5 fold threshold to 
generate final gene sets. Differentially expressed gene lists will be analyzed for enrichment of genes sharing biological 
functions and pathways using Ingenuity Pathway Analysis (IPA) and DAVID. We will also carry Gene Set Enrichment 
Analysis (GSEA) on genes pre-ranked by SAM d-score and 1000 permutations to find significantly associated pathways 
(MSigDB sets C2cp and C5bp), using FDR less than 25% as a significance threshold.  Where appropriate, enrichments of 
Gene Ontology (GO) terms, KEGG & BIOCARTA pathways in a gene list will be performed using DAVID software. We will 
analyze differences in monocyte gene expression between HIV+S vs NS analyzed at baseline (beginning of each 
treatment arm); and monocyte genes that are modulated by GAL in both HIV+S and NS, comparing GAL vs PLA. Gene 
expression patterns will also be correlated with soluble and cell surface markers of inflammation.  
Additional analysis described in Sample Analysis Addendum, dated 06/22/2018.  
 
Recruitment & Retention Pilot Outcomes 
 
Meeting Eligibility Criteria:  
The primary outcome is the percentage of subjects who meet final eligibility criteria (i.e., enrollment). We chose this as 
the outcome based on our data suggesting that subjects who meet these criteria are highly likely to reach ITT status. 
 
Impressions of Research: 
Attitudes towards research; motivations for participation; perceived risks/benefits of research; personal financial 
wellbeing and perceptions of influence or coercion will be assessed via text survey at baseline (following phone screen), 
mid-way through participation and at study completion. Study staff will attempt to contact subjects who withdraw or 
are lost-to-follow up to identify reasons for withdrawal. We will assess overall satisfaction with the study, acceptability 
of the frequency and content of messages (IP and IC groups only). For all models, a term will be included for individual 
study as well as other relevant covariates (e.g., sex, age, income). 
 
Table 1. Study Time Points and Measures 
Study Week: Period 1 
 
-2 
0 
2 
4 
6 
8 
10 
12 
 
Study Week: Period 2  
 
 
16 
18 
20 
22 
24 
26 
28 
 
Activity  
Phone 
Screen 
Intake 
L1 
C1 
M1 
C2 
M2 
C3 
L2 
Post-
Study 
SCREENING/COVARIATES  
Demo/Smoking Hx/FTNDf 
 
X 
 
 
 
 
 
 
 
 
Physical Examg/Medical Historyf 
 
X 
 
 
 
 
 
 
 
 
Urine Drug/Pregnancy Screen 
 
X 
X 
 
 
 
 
 
X 
 
Blood Pressure 
 
X 
X 
 
X 
 
X 
 
X 
 
Shipley IQ (SILS) f 
 
X 
 
 
 
 
 
 
 
 
LFTs & Creatinine 
 
X 
 
 
 
 
 
 
 
 
Psychiatric Hx (MINI/C-SSSRS) f 
 
X 
 
 
 
 
 
 
 
 
Bipolar Disorder Symptoms (MADRS, YMRS, additional screener)af 
 
X 
X 
 
X 
 
X 
 
X 
 
Adverse Childhood Experiencesf 
 
X 
 
 
 
 
 
 
 
 
Hep C Infection Historyf 
 
X 
 
 
 
 
 
 
 
 
Debriefing Phone Call 
 
 
 
 
 
 
 
 
 
X 
HIV-RELATED HEALTH OUTCOMES  
Adherence to Anti-retroviralsf  
 
 
X 
 
X 
 
X 
 
X 
 
Viral load/CD4+ 
 
Xb 
X 
 
 
 
 
 
X 
 
Depression/Anxiety (QIDS) f 
 
 
X 
 
X 
 
X 
 
X 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 22 of 54 
Functional Impairment (PAOFI) f 
 
 
X 
 
X 
 
X 
 
X 
 
Quality of Life (HAT-QoL) f 
 
 
X 
 
X 
 
X 
 
X 
 
Subjective Cognitive Complaintsf  
 
 
X 
 
X 
 
X 
 
X 
 
Fatigue (FSS) f 
 
 
X 
 
X 
 
X 
 
X 
 
TREATMENT MEASURES 
Concomitant Medication Reviewf 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
GAL Adherencef  
 
 
 
X 
X 
 X 
X 
X 
X 
 
GAL Side Effects (SEC) f 
 
 
X 
X 
X 
X 
X 
X 
X 
 
SMOKING-RELATED OUTCOMES   
Smoking Rate (TLFB)cf 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Carbon Monoxide (CO) 
 
X 
X 
 
X 
 
X 
 
X 
 
Cotininec 
 
 
X 
 
 
 
 
 
X 
 
Withdrawal (MNWS)cf 
 
 
X 
 
X 
 
X 
 
X 
 
Craving (QSU-B)cf 
 
 
X 
 
X 
 
X 
 
X 
 
NEUROCOGNITIVE OUTCOMES   
Working Memory (N-back) 
 
 
X 
 
X 
 
X 
 
X 
 
Executive Function (Color Shape Task) 
 
 
X 
 
X 
 
X 
 
X 
 
Verbal Learning/Memory (HVLT) 
 
 
X 
 
X 
 
X 
 
X 
 
Response Inhibition (Stop task) 
 
 
X 
 
X 
 
X 
 
X 
 
INFLAMMATION OUTCOMES   
Surface and Soluble Markers 
 
 
X 
 
 
 
 
 
X 
 
Monocyte Transcriptomics 
 
 
Xd 
 
 
 
 
 
Xd 
 
RECRTUITMENT PILOT OUTCOMES 
% Eligible at Intake 
 
X 
 
 
 
 
 
 
 
 
Attitudes Toward Researche 
X 
 
 
 
 
 
 
 
 
X 
Compared Riskiness Scalef 
X 
X 
 
 
 
 
 
 
 
 
Perceived Coercion Scalef 
 
X 
 
 
 
 
 
 
 
 
Previous Experience with Research Studies 
X 
 
 
 
 
 
 
 
 
 
Prior Persuasion Questionsf 
 
X 
 
 
 
 
 
 
 
 
Personal Financial Well-Being 
X 
 
 
 
 
 
 
 
 
 
Note. L = Laboratory session; C = Phone call; M = Monitoring visit; MINI = Mini International Neuropsychiatric Interview; C-SSRS = Columbia Suicide Severity Rating 
Scale; DCCS = Dimensional Change Card Sort Test; HVLT = Hopkins Verbal Learning Test  
aOnly administered if a diagnosis of bipolar disorder is self-reported or revealed via MINI at intake 
b Ascertained via EMR only  
cOnly administered to self-reported smokers 
d Subset of sample (n=30 per group) 
eInterim survey will also be administered in Week 1 of the Washout Period (25 days before Period 2 Lab Visit 1) 
fMeasures may be completed remotely via phone or videoconference to limit the length of in-person visits (if applicable) 
gPhysical examination may be conducted via telehealth 
 
2.  Statistical Analysis 
 
Power Analysis and Sample Size.  
The goal of the study is to evaluate the effects of nAChR modulation by GAL on neurocognition (Aim 1) and inflammation 
(Aim 2) and test whether smoking status modulates these effects (Aim 3). We will maintain power greater than or equal 
to 80% using a global 5% type-1 error, corrected for multiple testing within each aim. Power and sample size were 
calculated using Stata software (StataCorp, College Station, TX) for a repeated measures ANOVA with a 2x2 cross-over 
design. The effect size for medication effects (GAL vs. PLA) came from two sources: (1) GAL improves working memory 
accuracy and processing speed compared to PLA in smokers; and (2) GAL attenuates inflammation (Reale et al, 2005). For 
neurocognition (Aim 1), processing speed mean differences were 83 ms (SD=190) and -30.1 ms (SD=180) for the GAL and 
PLA groups, respectively. For accuracy, mean differences were 3 (SD=6.2) and 1.2 correct responses (SD=8.9) for the GAL 
and PLA groups, respectively. Thus, the estimated effect size required for neurocognition is d=0.5. For Aim 2, the effect 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 23 of 54 
size of GAL on inflammation was derived from a study comparing patients with Alzheimer’s disease (n=21) to age-matched 
controls (n=10) (Reale et al, 2005). Following 1 month of AChEI treatment, reductions were observed for IL-6 (mean = 
1989.1 pg/ml/106, SD=440) and IL-1β (mean = 1093.7 pg/ml/106, SD=350.9) yielding effect sizes of d=4.5 and 3.1, 
respectively. For our linear regression evaluating change from baseline to week 12 for GAL vs. PLA, in order to have 90% 
power to detect a medium effect size of d=0.5, using a type-1 error of 0.01 to correct for multiple comparisons, we would 
require 120 subjects. For Aim 3, the effect size for smoking status (HIV+S vs. HIV+NS) modulating the effect of GAL came 
from literature comparing smokers to non-smokers in samples with and without HIV. Among 962 adults (548 non-smokers, 
414 smokers), current smoking was associated with differences in inflammation markers including CCL17, CCL11, IL-1β, IL-
1Ra, CRP, IL-16, sIL-6R, and SCF, with effect sizes ranging from d=0.45 to 0.78 (Shiels et al, 2014). In a study of HIV+S 
(n=170) and HIV+NS (n=172), effect sizes for differences in sCD14 and sCD163 were d=0.83 and 0.36, respectively (Kooij 
et al, 2016). Collectively, these studies yield an average effect size of d=0.6. In two studies comparing neurocognition in 
HIV+S (n=74 (Bryant et al, 2013) and 27 (Durazzo et al, 2007)) to HIV+NS (n=26 (Bryant et al, 2013) and 27 (Durazzo et al, 
2007)), effect sizes were d=0.45 for global cognition (Bryant et al, 2013), d=0.8 for learning/memory (Durazzo et al, 2007), 
and d=1.1 for working memory and executive function (Durazzo et al, 2007). In order to have 80% power to detect a 
medium effect size of d=0.45, using a type-1 error of 0.01, we would require 120 subjects. We plan to recruit 150 subjects 
to account for a conservative attrition rate of 20%. For Aim 4, 30 subjects/group provides 80% power to identify 
differential gene expression between HIV+S and NS if fold change is 2 and FDR less than 0.2. This assumes  20,000 genes 
are tested and the top 200 are prognostic (Guo et al, 2014). Thus, all aims are sufficiently powered. 
 
Recruitment & Retention Pilot: 
Power is provided for our primary aim. The analysis will compare the enrollment rates between the four intervention 
arms, and examine main and interaction effects. For SR arm, we expect a 28% of subjects who schedule an Intake will be 
eligible and enroll (based on existing data across the four studies). With the proposed sample of 576, we have >80% power 
(α=.05) to detect a difference between the SR arm and the IP and CM arms of 12%, corresponding to an OR of 1.75. For 
the interaction term, we have 80% power (α=.05) to detect a departure from additivity of the main effects corresponding 
to a ratio of odds ratios (ORR) of 5.5. 
 
Data Analysis. 
Data Screening and Missing Data: Analyses will be conducted using Stata, SAS, or R-Language software. Preliminary 
analyses will determine whether data meet distributional assumptions, and use appropriate transformations where they 
do not. We will also determine whether subject characteristics (e.g., gender, education, CD4 nadir) are associated with 
smoking status or outcomes using either chi-square, t-tests, or correlations. Variables with potential to predict outcome 
(p=0.2) will be tested for entry as controlling variables. Items missing at random on survey measures will be imputed prior 
to calculating final scores using conditional means, estimated with an iterated version of Buck’s method (Gleason and 
Staelin, 1975). Dropout and missed sessions present a more serious issue. However, our medication studies maintain 
greater than 80% compliance and retention rates, thanks to our monitoring of participants and use of incentives to offset 
costs for travel. Nevertheless, we will examine the characteristics of subjects who drop out, and test whether there is an 
association between dropout and drug sequence. These analyses will be descriptive, as we expect few dropouts. Thus, 
primary analyses will be as-randomized and include all subjects who complete at least one treatment phase. 
Main Effect of GAL on Neurocognition (Aim 1) and Inflammation (Aim 2). We will conduct multiple linear regression using 
a Generalized Estimating Equations (GEE) framework to test our primary hypothesis that GAL will attenuate inflammation 
and improve neurocognitive performance. These models are similar to repeated measures ANOVA, but can handle the 
correlation due to multiple observations from the same subject as well as missing observations (Hardin and Hilbe, 2003; 
Liang and Zeger, 1986). The model is a 2 (drug: GAL vs. PLA) x 2 (time: baseline vs. week 12) crossover design and will 
include all subjects (HIV+S and NS). GAL effect hypotheses will be addressed by the within-subject contrast between the 
outcomes under GAL vs. PLA. A two-level variable for treatment order will be included and a treatment by order 
interaction would indicate carry-over effects. The primary outcomes will be change in neurocognition (composite score) 
and inflammation (CD16, CD163, and CCR2 expression; plasma CCL2/MCP-1 and sCD14; CD38/HLA-DR on CD8 cells) 
following 12 weeks of treatment. Secondary outcomes include monocyte CX3CR1 & TF, plasma TNF, sCD163 & sTF. 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 24 of 54 
Although the groups will be matched on key variables, we may include potential covariates (e.g., history of substance 
abuse, duration since HIV diagnosis, Shipley IQ), admitted at p=0.1.  
Smoking Status by Treatment Interaction (Aim 3). Analyses for Aim 3 are similar to Aims 1 and 2, except that the smoking 
status (HIV+S vs HIV+NS) by treatment (GAL vs PLA) interaction term will be tested using the difference score (change 
from baseline to end of treatment) to represent responses to treatment. Aim 2 will use the same methods in Aim 1. 
Importantly, Aim 2 is still clinically relevant, even if GAL does not have significant main effects (Aims 1 and 2). Thus, Aim 2 
is not dependent on Aim 1. 
Modulation of Monocyte Gene Expression (Aim 4). See above for description of analytical and statistical tools for 
determining important genes in the monocyte transcriptomics. The two-sample SAM test will be used to determine 
candidate genes that differ in monocyte gene expression between HIV+S vs NS at baseline (beginning of each treatment 
arm). Testing for changes in these monocyte genes over time and potential modulation by GAL will be performed using 
GEEs, similar to Aims 1 and 2. 
 
3.  Confidentiality  
All subject information will be kept in a secure filing cabinet that is accessible only to authorized study personnel.  All 
databases containing subject information will be password protected, and again, accessible only to authorized study 
personnel. Each subject will have a unique study ID number for all data collected. In all data sets we will use ID numbers, 
only. A separate data set linking names with ID numbers will be accessible only by the senior project staff.  All 
communications about subjects will use the ID number only and never include names or other personal information. All 
data will be stored until all analyses are completed. No data will be shared with any unauthorized party (i.e., aside from 
study personnel and regulatory officials). Any publication of data will not identify subjects by name or with an identifier 
that could be used to reveal identity. 
 
Data collected in MS Access and REDCap databases will be stored on a secure server administered by the Penn Medicine 
Academic Computing Services (PMACS) organization and will be restricted to only those individuals who are authorized to 
work on the trial. Individual user accounts with passwords will be used to restrict access to the database. Specific privilege 
assignments will also be employed so a user has access only to the functions necessary to complete applicable operations 
appropriate for their role in the trial. Additional measures to prevent unauthorized external access to the database 
environment will be employed using network firewall technologies. The Data Manager will maintain the database in an 
appropriate manner for the retention period required by regulation. Database administration includes user account 
maintenance, database security, performance monitoring, and database change management. Daily backups are 
performed to protect data against accidental destruction or corruption. 
 
Remote study sessions will be conducted via phone or via BlueJeans, which is a HIPAA-compliant platform with security 
features including a room lock to ensure that communications within the platform remain private. 
 
Data will be accessible the study Principal Investigator, Co-Investigators, the Study Physician, other study staff and the 
UPenn IRB and Office of Human Research. 
 
How will confidentiality of data be maintained?  Check all that apply. 
 Paper-based records will be kept in a secure location and only be accessible to personnel involved in the study. 
 Computer-based files will only be made available to personnel involved in the study through the use of access privileges and 
passwords. 
 Prior to access to any study-related information, personnel will be required to sign statements agreeing to protect the security and 
confidentiality of identifiable information. 
 Whenever feasible, identifiers will be removed from study-related information.  
 A Certificate of Confidentiality will be obtained, because the research could place the subject at risk of criminal or civil liability or 
cause damage to the subject’s financial standing, employability, or liability. 
 A waiver of documentation of consent is being requested, because the only link between the subject and the study would be the 
consent document and the primary risk is a breach of confidentiality.  (This is not an option for FDA-regulated research.)  


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 25 of 54 
 Precautions are in place to ensure the data is secure by using passwords and encryption, because the research involves web-based 
surveys.   
 Audio and/or video recordings will be transcribed and then destroyed to eliminate audible identification of subjects.  
 Other (specify): 
 
The PMACS will be the hub for the hardware and database infrastructure that will support the project and is where the 
W2H web portal is based. W2H uses a role-based access control (RBAC) approach to assure that participant confidentially 
and study integrity is preserved. The PMACS provides a secure computing environment for a large volume of highly 
sensitive data. 
 
4. Subject Privacy/Protected Health Information 
The following personal health information will be collected as part of this study: 
• 
Name, address, telephone number, email address 
• 
Date of birth 
• 
Social Security Number (W-9 form) 
• 
Some personal information that may be considered sensitive, such as medical history, psychological history, 
alcohol use history, etc.  
• 
Results from physical examinations, tests or procedures 
• 
Information on smoking, cognition, or HIV-related biomarkers from the blood samples provided at the Intake 
Session  
• 
Medical Record Number 
• 
Results from urine for drug screening/pregnancy test 
 
Every possible precaution, as described above, will be taken to ensure that the privacy of subjects’ personal health 
information will be maintained. Potential participants will be contacted over the phone after responding to recruitment 
advertisements. Participants will undergo an initial phone screening where preliminary eligibility for the research study 
will be determined. Only if a participant is initially eligible, will they complete Intake tasks, remotely or in-person, to 
confirm eligibility. All data collected over the phone and during in-person visits will be collected by research staff who 
have completed the CITI Protection of Human Subjects Research Training as well as HIPAA Compliance Training. 
Information will never be recorded with identifiers other than study ID. A separate list of names with ID numbers will be 
accessible only by authorized personnel. All records will be kept in locked filing cabinets to maintain confidentiality. Results 
will not be communicated to other personnel or to the subjects. All analyses will be conducted on de-identified data. Data 
will be accessible to the Study Investigators, Study Physician, study staff, UPenn IRB, Office of Clinical Research, authorized 
UPenn staff (e.g. accounting and billing matters, provide treatment, etc.). 
 
Future use of Data and/or Biospecimens 
Participants will be given the option to let us store their biospecimens and information for use in future research. This 
storage may be for an indefinite amount of time. The information and samples provided may be shared with other 
research institutions, e.g. The Abramson Cancer Center at Penn, or researchers working with research institutions who 
want to learn more about neurocognitive disease in people living with HIV. Whole genome sequencing will not be 
conducted on samples. We will protect participant confidentiality by first labeling their information and samples with an 
identification number only (not their name). We will restrict access to the databases that hold their personal information. 
Samples will be stored in a locked, private bank, accessible only by authorized personnel. Permission to store their 
information and samples for use in future research is optional and they can indicate their choice at the end of the consent 
form. Participants may withdraw their permission at any time by contacting study staff and letting us know they no longer 
want their information and samples to be stored for use in future research. Participant samples may be used to create 
products, including some that may be sold and/or make money for others. If this happens, there are no plans to tell the 
participant, or to pay them, or to give any compensation to them or their family. Additionally, we will not follow up with 
participants about the specific research that will be done, and individual research results obtained as part of future 
research will not be shared with them. 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 26 of 54 
5.  Tissue Specimens 
Blood.  
One 8.5 mL sample of blood will be drawn at the Intake visit to evaluate liver and renal function.  At weeks 0, 12, 16, and 
28, subjects will provide blood samples for FACS analysis of monocyte and T cell surface markers (done in real time on 
fresh whole blood), plasma for soluble biomarkers (stored and run batched) and monitoring of viral load (total of 80 mL 
per visit). All specimens are to be collected solely for research purposes.  Whole blood will not be stored.  Blood samples 
will be processed upon arrival to the Collman lab for PBMCs, monocytes and plasma and will be analyzed.  Monocytes and 
plasma will be stored at -80 so that assays may be run at a later time. A record of all samples will be maintained using the 
LDMS database software    
 
Urine.   
A urine sample will be required at the Intake Session and each Laboratory visit for drug screenings.  Subjects who test 
positive for study prohibited drugs may be deemed ineligible. Participants believed to have a false-positive result on the 
drug screen may continue in the study, with investigator approval. All female participants of child-bearing potential will 
complete urine pregnancy tests.  
 
Saliva.   
A saliva sample will be collected from self-reported smokers at each Laboratory visit to assess cotinine levels and 
biochemically verify smoking status. 
 
6. Genetic Testing 
N/A 
 
RISK/BENEFIT ASSESSMENT 
1.  Potential Study Risks 
A detailed description of the study will be given to all subjects, which will include the risks of participation, assurance of 
full confidentiality, and the knowledge that their freedom to refuse participation or withdraw from the project will not 
affect the availability of treatment at the University of Pennsylvania. Informed consent procedures will comply with 
current standards of the IRB at the University of Pennsylvania. Subjects can choose, as an alternative, to not enroll in this 
study. Adverse reactions will be assessed and reported as required by Federal law and the regulations of PENN.  
 
Potential Risks of Galantamine. The following are the common side effects that have been reported with galantamine 
treatment: The most common were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.  All of these 
side effects have been mild and transient in nature.   
In addition to the side effects mentioned above, other less common (less than 5% of patients) side effects include 
depression, stomach discomfort, stomach pain, heartburn, weight loss, extreme tiredness, tremor, slowed heartbeat, and 
muscle spasms. Rare, but potentially serious side effects occurring in less than 1% of patients include dysgeusia (change 
in sense of taste), burning or tingling sensation in hands, arms, legs, or feet, fainting, shortness of breath, difficulty falling 
asleep or staying asleep, and excessive sweating. All of these side effects shall be queried using a side effects checklist at 
the first laboratory visit of each treatment period (to obtain a baseline estimate of any side effects prior to starting 
medication) as well as all subsequent visits and phone calls (up to 14 times throughout the study).  
Stringent exclusion criteria are in place to limit the chance of these side effects. Additionally, participants will be informed 
about these possible side effects and be made aware to watch for any of these symptoms and report them as soon as 
possible to the research staff. All side effects will be closely monitored and the study physician consulted should moderate 
or severe side effects be reported. In case any participant experiences severe side effects or an adverse event they will be 
encouraged to contact the Health Care Provider/Study Physician immediately for appropriate intervention. The Study 
Physician’s emergency contact numbers shall be on the medication blister pack, the study consent form, as well on an 
emergency card all participants will be provided with once they enroll into the study. 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 27 of 54 
Reproductive Risks. In a study in which pregnant rats were dosed from the beginning of organogenesis through day 21 
post-partum pup weights were decreased at 8 and 16 mg/kg/day, but no adverse effects on other postnatal 
developmental parameters were seen. The doses causing the above effects in rats produced slight maternal toxicity. No 
major malformations were caused in rats given up to 16 mg/kg/day. No drug related teratogenic effects were observed in 
rabbits given up to 40 mg/kg/day (32 times the MRHD on a mg/m2 basis) during the period of organogenesis. There are 
no adequate and well-controlled studies of galantamine hydrobromide ER in pregnant women. Thus, galantamine 
hydrobromide must not be used during pregnancy. All female participants of child bearing potential will be given a 
pregnancy test at the Intake session and the Baseline visit at the beginning of each treatment period; and must agree in 
writing to use an approved method of contraception through the study. 
Risk from Blood Draw.  Blood draws may result in bruising and/or slight bleeding at the needle site.  This is rare and 
happens infrequently.  Occasionally, blood drawing results in a feeling of faintness.  This too is rare.  A trained professional 
will draw blood, so the chances of these discomforts are minimal. Procedures are in place to ensure that PHI is not linked 
with the results of this research.   
Potential Loss of Confidentiality. Every attempt will be made by the investigators to maintain all information collected in 
this study strictly confidential.  We will store subject information in a secure room with limited access. Only people working 
on this research project can access subject information. We will control access to the computer files that hold this 
information. This information will not be released to anyone. When the results of the study are published, no names or 
identifying information will be used. The final risk relates to potential disclosure of HIV status through participating in this 
study. 
2.  Potential Study Benefits 
Participants who enroll in this study will benefit from the knowledge that they are contributing in an important way to 
potentially furthering scientific knowledge concerning neurocognitive disease and ways to improve its treatment in HIV-
infected individuals.  
 
3.  Alternatives to Participation 
As an alternative to enrolling in this study, participants may choose to continue to smoke or to seek assistance with quitting 
smoking through other treatment programs located in their area, including contacting the national quit-line. At any point 
in this trial, subjects may decide not to continue in their participation.   
4.  Data and Safety Monitoring 
Who will monitor this study? Check all that apply. 
 Principal Investigator 
 Sponsor or contract research organization 
 NCI sponsored cooperative group 
 Cancer Center (if mandated by CTSMRC) 
 Medical monitor 
 Safety monitoring committee 
 Data and safety monitoring board 
4.1 Data and Safety Monitoring Committee 
Data and Safety Monitoring will be conducted by the Principal Investigators and the Study Physician. They will review all 
possible Adverse Events (AEs) and Serious Adverse Events (SAEs). They will ensure that this information is captured in a 
comprehensive manner and reported according to Good Clinical Practice (GCP). The Principal Investigators, Study 
Physician, Project Manager, and the research staff will oversee and complete the monitoring process.  Monitoring will be 
performed on an ongoing basis in accordance with the University of Pennsylvania Sponsor-Investigator Standard 
Operating Procedure PM 004. 
 
The Principal Investigators are responsible for: 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 28 of 54 
1. Obtaining IRB review and approval of a clinical investigation before the investigation is initiated and ensuring 
continuing review of the study by the IRB in accordance with 21 CFR Part 56; 
2. Obtaining informed consent in accordance with 21 CFR Part 50; and 
3. Assuring that all staff and subjects understand and accept the obligations incurred in undertaking this double-
blind placebo-controlled study in accordance with 21 CFR Parts 312, 511, 812, 813 and any other applicable 
regulations.  
 
The research staff is responsible for collecting and recording all clinical data.  This includes ensuring that all source 
documents exist for the data on the Case Report Forms (CRFs), ensuring all fields are completed appropriately, and all 
corrections are done according to GCPs.  Any inconsistencies/deviations will be documented on the CRFs and such findings 
will be reviewed at the weekly study meetings. 
 
The Project Manager will oversee staff training. Training will include a review of the study protocol, informed consent, 
telephone screen, CRFs and the procedures that are in place regarding session check-in, data collection, data entry and 
quality control. All applicable regulations will be reviewed and the roles/responsibilities of each staff member will be 
explained.   All questions will be answered and the training will be documented in a training log, which will be initialed by 
those involved.  The Project Manager will also confirm all appropriate documentation of informed consent and storage of 
consents in a separate consent binder, and will maintain the study regulatory binder. 
 
The Project Manager, PIs, Nurse Practitioner, and Study Physician will work together to confirm eligibility criteria. The 
Study Physician/Nurse Practitioner and Dr. Ashare, will review charts for each subject to confirm eligibility and will 
document this review by signing/initialing and dating each chart or providing the determination via email.  
 
The research staff and CRC/Project Manager will ensure all medication is properly ordered and received from IDS, stored 
at the center, labeled, and distributed to subjects.   
 
The Project Manager, Stephanie Josephson, LCSW, will review all completed MINIs on an ongoing basis. In the event the 
PM is unavailable, the Principal Investigator Rebecca Ashare, Ph.D., will complete all review. 
 
The data managers will be responsible for creating all CRFs and ensuring that all data will be entered and stored in a 
manner consistent with the design of the approved CRFs. They will also be responsible for developing the data 
entry/quality control producers for this study. 
 
Enrollment will be complete when 120 subjects complete all study requirements.  On average, ~4 subjects will be enrolled 
per month. During the course of the study, safety and data quality monitoring will be performed on an ongoing basis in 
accordance with the University of Pennsylvania Sponsor-Investigator Standard Operating Procedure PM 004 and any 
findings will be reviewed on a regular basis with the Investigators at the regular study meeting. The monitoring will include 
a regular assessment of the number and type of serious adverse events. The first monitoring day will occur no more than 
two weeks after the first subject is entered. 
4.2 Adverse Event Reporting and Monitoring 
Adverse Event (AE) 
An Adverse Event (AE) is a subcategory of the broader category of "Unanticipated Problems Posing Risk to Subject or 
Others." An adverse event is defined as: 
 
• 
Any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease occurring at any 
stage of the study 
• 
Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality: 
• 
results in study withdrawal 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 29 of 54 
• 
is associated with a serious adverse event 
• 
is associated with clinical signs or symptoms leads to additional treatment or to further diagnostic tests 
• 
is considered by the investigator to be of clinical significance 
• 
May include an exacerbation of a pre-existing condition, intercurrent illness or injury, drug interaction, drug 
overdose, failure of expected action or significant worsening of the disease under study 
• 
An event that may compromise the rights, safety, or welfare of research subjects 
 
Any event that could be characterized by the definitions above is an AE whether or not considered related to the study 
or product. 
 
Serious Adverse Event (SAE) 
Adverse events are classified as serious or non-serious.  A serious adverse event is any AE that is:  
• fatal 
• life-threatening 
• requires or prolongs hospital stay 
• results in persistent or significant disability or incapacity 
• a congenital anomaly or birth defect 
• an important medical event 
 
Important medical events are those that may not be immediately life threatening, but are clearly of major clinical 
significance. They may jeopardize the subject, and may require intervention to prevent one of the other serious outcomes 
noted above. For example, drug overdose or abuse, a seizure that did not result in in-patient hospitalization, or intensive 
treatment of bronchospasm in an emergency department would typically be considered serious. 
All adverse events that do not meet any of the criteria for serious will be regarded as non-serious adverse events.  
 
Adverse Event Reporting Period 
The study period during which adverse events must be reported is the period from the initiation of any study procedures 
to the end of the study treatment follow-up.  For this study, the study treatment follow-up is defined as 7 days following 
the last administration of study treatment.  
 
Preexisting Condition 
A preexisting condition is one that is present at the start of the study.  A preexisting condition will be recorded as an 
adverse event if the frequency, intensity, or the character of the condition worsens during the study period. 
 
General Physical Examination Findings 
At screening, any clinically significant abnormality will be recorded as a preexisting condition.  At the end of the study, any 
new clinically significant findings/abnormalities that meet the definition of an adverse event must also be recorded and 
documented as an adverse event.  
 
Post-study Adverse Event 
All unresolved adverse events will be followed by the investigators until the events are resolved, the subject is lost to 
follow-up, or the adverse event is otherwise explained.  At the last scheduled visit, a research team member will instruct 
each subject to report any subsequent event(s) that the subject, or the subject’s personal physician, believes might 
reasonably be related to participation in this study. 
 
Hospitalization, Prolonged Hospitalization or Surgery 
Any adverse event that results in hospitalization or prolonged hospitalization will be documented and reported as a serious 
adverse event unless specifically instructed otherwise in this protocol.  Any condition responsible for surgery should be 
documented as an adverse event if the condition meets the criteria for and adverse event.  


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 30 of 54 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an adverse event in the 
following circumstances: 
• Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures for a preexisting 
condition.  Surgery will not be reported as an outcome of an adverse event if the purpose of the surgery was 
elective or diagnostic and the outcome was uneventful. 
• Hospitalization or prolonged hospitalization required to allow efficacy measurement for the study. 
• Hospitalization or prolonged hospitalization for therapy of the target disease of the study, unless it is a worsening 
or increase in frequency of hospital admissions as judged by the clinical investigator. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other 
situations, such as important medical events that may not be immediately life-threatening or result in death or 
hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed 
in the definition above. These should also usually be considered serious.  Other kinds of events can be labeled “serious 
adverse events” at the discretion of the investigator.   
 
To ensure no confusion or misunderstanding of the difference between the terms "serious" and "severe," which are not 
synonymous, the following note of clarification is provided: The term "severe" is often used to describe the intensity 
(severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the event itself, however, may be of 
relatively minor medical significance (such as severe headache). This is not the same as "serious," which is based on 
patient/event outcome or action criteria usually associated with events that pose a threat to a patient's life or 
functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  
 
Severity Grading Scale for Adverse Events  
Many disease specific groups have developed toxicity grading scales. For example, most cancer clinical trials use the 
Common Terminology Criteria for Adverse Events (CTCAE) developed by the NCI. The CTCAE provides a descriptive 
terminology which is utilized for adverse event reporting. A grading (severity) scale is provided for each adverse event 
term (http://ctep.info.nih.gov). If no guidelines exist, then the following scale can be used:  
• Mild:  Noticeable to the subject, does not interfere with the subject’s daily activities, usually does not require 
additional therapy, dose reduction, or discontinuation of the study.  
• Moderate:  Interferes with the subject’s daily activities, possibly requires additional therapy, but does not require 
discontinuation of the study.   
• Severe:  Severely limits the subject’s daily activities and may require discontinuation of the study.   This would include 
all adverse events defined as “serious adverse events”.  
 
Attribution/Association with the Drug or Intervention:   
An assessment of the relationship between the adverse event and the drug/intervention will be made for each 
occurrence by the Principal Investigator.   
 
Adverse Event Attribution Categories:  
• Unrelated- The AE is clearly NOT related to the intervention  
• Possible- The AE may be related to the intervention  
• Probably- The AE is likely related to the intervention  
• Definitely- The AE is clearly related to the intervention 
4.3 Recording of Adverse Events 
At each contact with the subject after the Intake, the study research assistant will seek information on adverse events by 
specific questioning using a side effect checklist and, as appropriate, by examination. Side effects will be monitored 
through a two-pronged approach. First, participants will complete a side effects checklist (SEC) at each study visit after 
the Intake, administered by trained staff, reporting with a frame of reference since their last study visit. The SEC will assess 
the frequency and severity of common side-effects associated with galantamine-ER treatment (e.g., nausea, vomiting).  


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 31 of 54 
These items will be rated by participants on a 0 (none) to 3 (severe) scale, and can be summed to provide an overall side 
effects index.   
 
Second, trained staff will ask participants a non-structured, open-ended question (SEC Open-ended) at each study visit 
with a one-week frame of reference to assess if participants are experiencing any additional symptoms or medical 
concerns that may be related to their participation in the study. 
 
Research staff are trained to inquire (time of onset, nature of issue reported, possible relation to galantamine treatment, 
review of previously reported side effects or concerns, etc.) about any notable side effects or medical concern reported 
by participants. Based on published reports using the 8mg and 16mg galantamine-ER doses we expect some side effects 
with galantamine-ER treatment; however we expect these side effects to be mild and transient in nature. Any severe (or 
a pattern of moderate) side effects or notable medical concern will be treated as adverse events, and reported to the 
Study Physician to determine the severity, relationship of the event to the study drug and decide the course of action for 
the study subject. This consult, including all relevant information, will be documented via email. The Study Physician is 
knowledgeable of side effects related to galantamine and is qualified to manage possible side effects. Mild side effects 
will not be reported as adverse events, but will be recorded and monitored by study staff. 
 
All adverse events occurring during the study period will be recorded. The clinical course of each event will be followed 
until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause.  
Serious adverse events that are still ongoing at the end of the study period must be followed up to determine the final 
outcome. Any serious adverse event that occurs after the study period and is considered to be possibly related to the 
study treatment or study participation will be recorded and reported immediately. 
4.4 Reporting of Serious Adverse Events and Unanticipated Problems 
The following information about adverse events will be reported:   
• 
Study identifier 
• 
Study Center 
• 
Subject number 
• 
A description of the event 
• 
Date of onset 
• 
Current status 
• 
Whether study treatment was discontinued 
• 
The reason why the event is classified as serious 
• 
Investigator assessment of the association between the event and study treatment 
•  Welfare of subjects. 
4.5 Investigator reporting: notifying the Penn IRB 
This section describes the requirements for safety reporting by investigators who are Penn faculty, affiliated with a Penn 
research site, or otherwise responsible for safety reporting to the Penn IRB. The University of Pennsylvania IRB (Penn 
IRB) and the CTSRMC DSMC require expedited reporting of those events related to study participation that are 
unforeseen and indicate that participants or others are at increased risk of harm.  The Penn IRB will not acknowledge 
safety reports or bulk adverse event submissions that do not meet the criteria outlined below.  The Penn IRB requires 
researchers to submit reports of the following problems within 10 working days from the time the investigator becomes 
aware of the event: 
• Any adverse event (regardless of whether the event is serious or non-serious, on-site or off-site) that occurs any 
time during or after the research study, which in the opinion of the principal investigator is: 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 32 of 54 
Unexpected (An event is “unexpected” when its specificity and severity are not accurately reflected in the 
protocol-related documents, such as the IRB-approved research protocol, any applicable investigator brochure, 
and the current IRB-approved informed consent document and other relevant sources of information, such as 
product labeling and package inserts.) 
AND 
Related to the research procedures (An event is “related to the research procedures” if in the opinion of the 
principal investigator or sponsor, the event was more likely than not to be caused by the research procedures.) 
 
Reporting Process 
Unanticipated problems posing risks to subjects or others as noted above will be reported to the Penn IRB using the 
form: “Unanticipated Problems Posing Risks to Subjects or Others Including Reportable Adverse Events” or as a written 
report of the event (including a description of the event with information regarding its fulfillment of the above criteria, 
follow-up/resolution and need for revision to consent form and/or other study documentation). 
Copies of each report and documentation of IRB notification and receipt will be kept in the Clinical Investigator’s study 
file. 
 
Reporting Deaths:  more rapid reporting requirements 
Concerning deaths that occur during the course of a research study, the following describes the more rapid reporting 
requirement of the Penn IRB for specific situations: 
• Report the event within 24 hours when the death is unforeseen (unexpected) and indicates participants or others 
are at increased risk of harm. 
• Report the event within 72 hours, for all other deaths, regardless of whether the death is related to study 
participation. 
 
For reportable deaths, the initial submission to the Penn IRB may be made by contacting the IRB Director or Associate 
Director. The AE/Unanticipated Problem Form is required as a follow up to the initial submission. 
 
Reporting SAEs to the DSMC 
• Penn Subjects (including subjects at networks, affiliates or investigator-initiated sites);   
All on-site grade 3 or higher AEs or ADRs regardless of attribution or expectedness will be  submitted to the DSMC within 
30 days.  SAEs or SADRs for Penn subjects regardless of attribution or expectedness will be submitted to the DSMC 
within 10 days. Reports will continue to be sent to the DSMC for 90 days following the last date the subject received 
study treatment/therapy or was exposed to an investigational device.   All unexpected deaths or deaths related to the 
study agent(s)/device(s) must be reported within 24 hours.  All other deaths should be reported within 30 days.   
 
• IND Safety Updates/Alerts  
IND Safety Updates/Alerts (sent by sponsors), that are specifically for the protocol open in the ACC,  with a grade 3 or 
higher, regardless of attribution or expectedness will be submitted to the DSMC within 30 days.  Events for studies using 
a novel agent, on any protocol in the Cancer Center, not specifically the protocol open in the ACC, shall be sent within 30 
days.  All other IND Safety Updates/Alerts shall be sent within 60 days of receipt.  Once the study closes to accrual at 
Penn, reports shall be sent to the DSMC for 30 days from the date the last Penn subject was treated. Events for studies 
using a novel agent or agents manufactured on campus will be sent until the protocol terminates.  
 
Reporting Events  
All events will be entered into the ACC Clinical Trials Management System (CTMS) AE/SAE form.   
   
Other Reportable events: 
- 
For clinical drug trials, the following events are also reportable to the Penn IRB: 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 33 of 54 
- 
Any adverse experience that, even without detailed analysis, represents a serious unexpected adverse event that 
is rare in the absence of drug exposure (such as agranulocytosis, hepatic necrosis, Stevens-Johnson syndrome). 
- 
Any adverse event that would cause the sponsor to modify the investigators brochure, protocol or informed 
consent form, or would prompt other action by the IRB to assure protection of human subjects. 
- 
Information that indicates a change to the risks or potential benefits of the research, in terms of severity or 
frequency. For example:  
- 
An interim analysis indicates that participants have a lower rate of response to treatment than initially expected. 
- 
Safety monitoring indicates that a particular side effect is more severe, or more frequent than initially expected. 
- 
A paper is published from another study that shows that an arm of your research study is of no therapeutic value. 
- 
Change in FDA safety labeling or withdrawal from marketing of a drug, device, or biologic used in a research 
protocol. 
- 
Breach of confidentiality 
- 
Change to the protocol taken without prior IRB review to eliminate apparent immediate hazard to a research 
participant. 
- 
Incarceration of a participant when the research was not previously approved under Subpart C and the 
investigator believes it is in the best interest of the subject to remain on the study. 
- 
Complaint of a participant when the complaint indicates unexpected risks or the complaint cannot be resolved by 
the research team. 
- 
Exception: A one time, intentional action or process that departs from the IRB and CTSRMC approved study 
protocol, intended for one occurrence. If the action disrupts the study progress, such that the study design or 
outcome (endpoints) may be compromised, or the action compromises the safety and welfare of study subjects, 
advance documented IRB and DSMC approval is required. 
- 
For exceptions on Industry or Cooperative group sponsored protocols, written approval must be obtained from 
the Sponsor prior to submitting your exception request to the DSMC. 
- 
For in-house studies with a Medical Monitor or Safety Monitoring Committee (not DSMB), approval must be 
obtained from the Medical Monitor or Safety Monitoring Committee prior to submitting your exception request 
to the DSMC. 
- 
Deviation: A one time, unintentional action or process that departs from the IRB and DSMC approved study 
protocol, involving one incident and identified retrospectively, after the event occurred. If the impact on the 
protocol disrupts the study design, may affect the outcome (endpoints) or compromises the safety and welfare of 
the subjects, the deviation must be reported to the DSMC within 5 business days and the IRB within 10 business 
days. 
 
Data, Safety and Monitoring Report.  The PI will provide a summary of the DSM report on an annual basis as part of the 
progress report.  The DSM report will include the expected versus actual recruitment rates, treatment retention rates, any 
quality assurance or regulatory issues that occurred during the past year, summary of AEs and SAEs, and any actions or 
changes with respect to the protocol.   
 
Evidence of Training in Human Subject Research.  All research personnel associated with this study have completed the 
CITI-Protection of Human Subjects Research Training as well as HIPAA Compliance Training. 
 
5. Management of Information for Multi-center Research where a Penn Investigator is the Lead Investigator of a multi- 
center study, or Penn is the lead site in a multi-site study.  
This is a single-site study. 
 
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 34 of 54 
6.  Risk/Benefit Assessment 
There is minimal risk for serious adverse events. The treatments and procedures used in this study have been shown to 
be relatively safe. Galantamine has also been studied in several clinical trials and shown to be safe and efficacious. 
Nevertheless, there are risks in participating in this trial, which are described above. 
 
Participants who enroll in this study will benefit from the knowledge that they are contributing in an important way to 
potentially furthering scientific knowledge concerning neurocognitive disease and ways to improve its treatment in HIV-
infected individuals.  
 
SUBJECT COMPENSATION 
Subjects will be compensated for participation up to $590 (Table 2). Subjects will also be reimbursed for transportation 
expenses related to their participation in the study with $10 for each in-person visit. In place of $10/session to cover travel 
expenses, subjects may elect to use a round-trip car ride service (i.e., Lyft) which will be arranged and paid for in full by 
the research study. If they choose to use the ride service, they will not receive $10 for travel reimbursement and their 
total visit compensation may be up to $500. Travel will not be reimbursed for sessions designated as “in-person”, if they 
have to be completed by phone. 
 
The “task completion” compensation will depend on participant compliance (arriving on time for sessions, returning 
medication blister packs for adherence verification etc.). If a subject does not follow study instructions, the task 
completion compensation may be withheld.  
 
The Greenphire ClinCard will be the primary form of payment for this study. The ClinCard is a reloadable, pre-paid card 
for the purposes of compensation. Compensation will be loaded onto the ClinCard within 24 hours of completed visits. 
Staff may ask participants to provide a Social Security Number, or complete a W-9 for this purpose, after determining 
eligibility so that a ClinCard can be assigned. Clincards may be mailed to subjects following the eligibility determination for 
the study.  
 
If a subject is found ineligible at any session due to any of the above-mentioned criteria, they will only be compensated 
$10 for travel, unless they have elected to use the ride service for that session.  
 
Subjects who successfully refer others to the program (i.e., person referred to program completes initial phone screen) 
will be awarded $20 per referral, for a maximum of 3 referrals.  
 
Upon completion of all requirements for a given visit, participants randomized to CM will receive 5 lottery draws for that 
visit. Attendance at all visits earns participants bonus draws upon completion of the study. Failure to attend a visit without 
prior approval or failure to complete all visit requirements results in no draws for that visit. The study completion bonus 
will be 5 extra draws. Thus, at each visit, subjects will have the opportunity to make 5 draws, for maximum possible 
earnings of $120 per visit (and a maximum of $145 at the final visit if participants have earned the additional 5 draws). 
Compensation distribution is shown in the table below. 
 
Compensation Schedule 
Week 
Period 
Study Visit 
Visit  
Compensation 
Task 
Completion 
Travel3 
Bonus 
Total 
Lottery4 
-2 
N/A 
Intake  
$20  
 
$10  
$30  
5 draws 
0 
1 
Lab Visit 1 
$35  
$15 
$10  
  
$60  
5 draws 
2 
1 
Monitoring Call 1 
$10 
 
$0  
  
$10  
 
4 
1 
Mid-Tx Visit 1 
$25  
$15 
$10  
  
$50  
5 draws 
6 
1 
Monitoring Call 2 
$10  
 
$0  
  
$10  
 
8 
1 
Mid-Tx Visit 2 
$25  
$15 
$10  
  
$50  
5 draws 
10 
1 
Monitoring Call 3 
$10 
 
$0  
  
$10  
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 35 of 54 
12 
1 
Lab Visit 2 
$25  
$15 
$10  
$401  
$90  
5 draws 
16 
2 
Lab Visit 1 
$35  
$15 
$10  
  
$60  
5 draws 
18 
2 
Monitoring Call 1 
$10  
 
$0  
  
$10  
 
20 
2 
Mid-Tx Visit 1 
$25  
$15 
$10  
  
$50  
5 draws 
22 
2 
Monitoring Call 2 
$10 
 
$0  
  
$10  
 
24 
2 
Mid-Tx Visit 2 
$25  
$15 
$10  
  
$50  
5 draws 
26 
2 
Monitoring Call 3 
$10  
 
$0  
  
$10  
 
28 
2 
Lab Visit 2 
$25  
$15 
$10  
$401  
$90  
Up to 10 
draws 
 
 
 
 
 
Study Total: 
$590 
 
N/A 
2 
Referral Bonus 
 
 
 
$602 
$60 
 
 
Total w/ Referrals: 
$650 
 
1 Bonus awarded to participants that complete every visit in a period, at the end of each period. 
2 Table shows total compensation for three successful referrals 
3 Only paid if you opt out of the round-trip car ride service; will not be paid if a visit has to be completed by phone. 
4 Participants may be given 5 draws for the chance to earn additional monetary incentives. As a bonus for completing 
the study, participants will get an additional 5 draws during their final visit.   
 
Traveling via the Ride Service 
Participants may elect to use “Roundtrip”, which is a car ride service that partners with Lyft to coordinate roundtrip rides to 
study appointments. Participants will be asked for their preference when scheduling the Intake session via phone, and at 
each session preceding an in-person session once enrolled. Study staff will schedule each ride using participants’ first name, 
last name, and phone number via Roundtrip’s HIPAA compliant platform. Participants will receive a reminder call within 24-
48 hours prior to their study visit to confirm their visit, interest in using the ride service, and preferred pickup/drop-off 
locations. If the study staff cannot reach participants by 5pm the day prior to their study visit, their ride will be cancelled. 
Participants will still be permitted to attend the visit and will receive $10 to cover travel expenses. If participants need to 
cancel a previously confirmed ride, they must do so by contacting the study staff immediately, preferably by 5pm the day 
before their appointment. If participants fail to notify study staff within this timeframe, they may no longer be permitted to 
use the ride service at future study visits. 
 
INFORMED CONSENT 
1. Consent Process 
Informed consent will be obtained using the combined consent and HIPAA form approved by the PENN IRB. This process 
will take place before study data are collected and prior to any treatment. The consenting process may occur remotely in-
person as part of the Intake session. If completed remotely, subjects will be contacted via Blue Jeans (HIPAA-compliant) 
for a videoconference or by phone. Reviewing the consent form will be completed using a RedCap survey and PowerPoint 
to visualize key points. Staff will email or text the survey link to subjects. The PowerPoint will either be sent to participants 
or shared using screen share via BlueJeans. Whether in person or remote, staff will review the study description, and all 
study procedures, potential risks, and information about the study medication will be addressed. Subjects will be given 
the opportunity to read the consent form in full. Following this, subject questions will be answered, and staff will 
administer comprehension questions to ensure subject understanding. Any incorrect answers will be addressed by the 
staff member completing consent. If remote, subjects will indicate within the RedCap survey if they wish to participate 
and will then be prompted to enter their First and Last name and sign the form using their finger or mouse. Subjects who 
are unable to provide an electronic signature may be mailed a physical version of the consent that must be mailed back 
to us prior to continuing with the Intake tasks. If needed, staff may also ask subjects to sign a physical version of the form 
at their first in-person visit for record keeping. Subjects will be able to download their signed version of the form from 
RedCap, and staff will also download a version to be saved to the electronic regulatory binder on our secure server, or, 
printed and placed in our physical binder. If in-person, subjects will receive a physical copy of the combined consent and 
HIPAA form for their records. Subjects will also be given the PI and Study Physician’s contact information should they wish 
to speak to either of them during the course of the study regarding their consent or the study procedures. The consent 
process will take place in English, there will be no waiting period, no coercion to participate, and all subjects will be 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 36 of 54 
considered competent to provide informed consent (i.e., they will be asked if they understand what they are consenting 
for). 
 
2.  Waiver of Authorization 
Verbal consent will be attained from participants via phone for contact that occurs after their study participation has 
ended. This contact will only be made to collect data that they have already consented to provide as part of the study, 
and no additional PHI will be collected. Participants will have the option to not answer additional questions related to 
their participation in the study. If we are unable to get into contact with a participant, the data will be marked as missing. 
 
RESOURCES NECESSARY FOR HUMAN RESEARCH PROTECTION 
 
Training and Quality Assurance 
Given ongoing trials (R01 DA033681), systems for training and QA are established to ensure accurate eligibility screening 
and recruitment, accurate data collection, entry, and management, and optimal delivery of the study protocol. A new 
Manual of Operations (MOP) will be devised for this study, given unique procedures and measures. Dr. Metzger, who 
coordinates behavioral research within the PENN CFAR, will assist with staff training to ensure that unique issues related 
to the population are integrated into the MOP. Training sessions will occur over the first 3 months and annually. Monthly 
team meetings will review progress, assess adherence, and determine the need for protocol changes or additional 
training/QA. A study-specific Data and Safety Monitoring Committee will provide oversight. The MOP will ensure that the 
trial is conducted in a uniform manner over time and across staff. The MOP will describe roles and responsibilities for 
personnel and provide a detailed description of procedures for each point of contact with participants. For each 
visit/week, a checklist of events (e.g., measures, counseling) will be created that will be completed by study personnel. 
CRFs will be created for each measure at each week, and every participant will have a study binder, with sections for every 
visit/week. Every visit will be “milestoned” (e.g., attended, missed, scheduled) to ensure proper tracking of participants 
through the trial. Lastly, a manual for data collection and entry is developed for the RAs and the PM/Dr. Ashare will train 
the RAs and provide supervision. Ms. Ware, who oversees this DMS, has already developed this DMS for use in other trials. 
QA focuses on protocol adherence and data validity. We conduct 100% QA checks on study data. This involves comparison 
of all hard copy CRFs to computer data.  


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 37 of 54 
References 
 
(2011). World Health Organization. Global summary of the AIDS epidemic. . 
 
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al (2007). Updated research nosology for HIV-
associated neurocognitive disorders. Neurology 69(18): 1789-1799. 
 
Aronson S, Van Baelen B, Kavanagh S, Schwalen S (2009). Optimal dosing of galantamine in patients with mild or 
moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs and 
Aging 26(3): 231-239. 
 
Ashare RL, Hawk LW, Jr. (2012). Effects of smoking abstinence on impulsive behavior among smokers high and low in 
ADHD-like symptoms. Psychopharmacology 219(2): 537-547. 
 
Ashare RL, Kimmey BA, Rupprecht LE, Bowers ME, Hayes MR, Schmidt HD (2016). Repeated administration of an 
acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers. Transl 
Psychiatry 6: e713. 
 
Ashare RL, Schmidt HD (2014). Optimizing treatments for nicotine dependence by increasing cognitive performance 
during withdrawal. Expert Opin Drug Discov 9(6): 579-594. 
 
Atluri VS, Pilakka-Kanthikeel S, Samikkannu T, Sagar V, Kurapati KR, Saxena SK, et al (2014). Vorinostat positively 
regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression 
of HIV-associated neurocognitive disorder. Molecular brain 7: 37. 
 
Baez-Pagan CA, Delgado-Velez M, Lasalde-Dominicci JA (2015). Activation of the Macrophage alpha7 Nicotinic 
Acetylcholine Receptor and Control of Inflammation. Journal of neuroimmune pharmacology : the official journal of the 
Society on NeuroImmune Pharmacology 10(3): 468-476. 
 
Barqasho B, Nowak P, Tjernlund A, Kinloch S, Goh LE, Lampe F, et al (2009). Kinetics of plasma cytokines and chemokines 
during primary HIV-1 infection and after analytical treatment interruption. HIV medicine 10(2): 94-102. 
 
Benedict RH, Schretlen D, Groninger L, Brandt J (1998). Hopkins Verbal Learning Test–Revised: Normative data and 
analysis of inter-form and test-retest reliability. The Clinical neuropsychologist 12(1): 43-55. 
 
Benwell ME, Balfour DJ, Anderson JM (1988). Evidence that tobacco smoking increases the density of (-)-[3H]nicotine 
binding sites in human brain. Journal of neurochemistry 50(4): 1243-1247. 
 
Birks J (2006). Cholinesterase inhibitors for Alzheimer's disease. The Cochrane database of systematic reviews(1): 
CD005593. 
 
Bracci L, Lozzi L, Rustici M, Neri P (1992). Binding of HIV-1 gp120 to the nicotinic receptor. FEBS letters 311(2): 115-118. 
 
Brandt J (1991). The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. The 
Clinical neuropsychologist 5(2): 125-142. 
 
Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, Collins AC, et al (1997). Effect of smoking history on [3H]nicotine 
binding in human postmortem brain. J Pharmacol Exp Ther 282(1): 7-13. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 38 of 54 
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al (2006). Microbial translocation is a cause of 
systemic immune activation in chronic HIV infection. Nature medicine 12(12): 1365-1371. 
 
Briggs CA, McKenna DG (1998). Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by 
agonists. Neuropharmacology 37(9): 1095-1102. 
 
Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR (2005). Galantamine prolonged-release 
formulation in the treatment of mild to moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 20(2-
3): 120-132. 
 
Brown R, Burgess E, Sales S, Whiteley J (1998). Reliability and validity of a smoking timeline follow-back interview. Addict 
Behav(12): 101-112. 
 
Brugnaro P, Morelli E, Cattelan F, Petrucci A, Panese S, Eseme F, et al (2015). Non-AIDS definings malignancies among 
human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era. World 
journal of virology 4(3): 209-218. 
 
Bryant VE, Kahler CW, Devlin KN, Monti PM, Cohen RA (2013). The effects of cigarette smoking on learning and memory 
performance among people living with HIV/AIDS. AIDS care 25(10): 1308-1316. 
 
Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC (2013). Elevated sCD163 in plasma but not 
cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS 27(9): 1387-1395. 
 
Butler SL, Valdez H, Westby M, Perros M, June CH, Jacobson JM, et al (2011). Disease-modifying therapeutic concepts for 
HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 58(3): 297-303. 
 
Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, et al (2010). Persistent microbial translocation 
and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. The Journal of 
infectious diseases 202(5): 723-733. 
 
Chelune GJ, Heaton RK, Lehman RA (1986). Neuropsychological and personality correlates of patients’ complaints of 
disability. Advances in clinical neuropsychology. Springer, pp 95-126. 
 
Chen L, Yamada K, Nabeshima T, Sokabe M (2006). alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in 
hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 50(2): 254-268. 
 
Cox LS, Tiffany ST, Christen AG (2001). Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory 
and clinical settings. Nicotine & Tobacco Research 3(1): 7-16. 
 
D'Abramo A, Zingaropoli MA, Oliva A, D'Agostino C, Al Moghazi S, De Luca G, et al (2016). Higher Levels of 
Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and 
Endovascular Damage in HIV-Suppressed Patients. PloS one 11(2): e0149601. 
 
D'Hulst A I, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA (2005). Time course of cigarette smoke-induced pulmonary 
inflammation in mice. The European respiratory journal 26(2): 204-213. 
 
De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L (2005). Activation of alpha7 nicotinic acetylcholine receptor by 
nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 
2(1): 4. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 39 of 54 
Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, et al (2012). The rising challenge of non-AIDS-defining 
cancers in HIV-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of 
America 55(9): 1228-1235. 
 
Deeks SG (2009). Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Topics 
in HIV medicine : a publication of the International AIDS Society, USA 17(4): 118-123. 
 
Doyle KL, Morgan EE, Morris S, Smith DM, Little S, Iudicello JE, et al (2013). Real-world impact of neurocognitive deficits 
in acute and early HIV infection. Journal of neurovirology 19(6): 565-573. 
 
Durazzo TC, Meyerhoff DJ, Nixon SJ (2012). A comprehensive assessment of neurocognition in middle-aged chronic 
cigarette smokers. Drug and alcohol dependence 122(1-2): 105-111. 
 
Durazzo TC, Rothlind JC, Cardenas VA, Studholme C, Weiner MW, Meyerhoff DJ (2007). Chronic cigarette smoking and 
heavy drinking in human immunodeficiency virus: consequences for neurocognition and brain morphology. Alcohol 
(Fayetteville, NY) 41(7): 489-501. 
 
Echeverria V, Yarkov A, Aliev G (2016). Positive modulators of the alpha7 nicotinic receptor against neuroinflammation 
and cognitive impairment in Alzheimer's disease. Progress in neurobiology 144: 142-157. 
 
Ehlis AC, Bahne CG, Jacob CP, Herrmann MJ, Fallgatter AJ (2008). Reduced lateral prefrontal activation in adult patients 
with attention-deficit/hyperactivity disorder (ADHD) during a working memory task: a functional near-infrared 
spectroscopy (fNIRS) study. Journal of psychiatric research 42(13): 1060-1067. 
 
Evans DE, Drobes DJ (2009). Nicotine self-medication of cognitive-attentional processing. Addiction biology 14(1): 32-42. 
 
Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al (1998). Relationship of childhood abuse and 
household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) 
Study. Am J Prev Med 14(4): 245-258. 
 
Freitas K, Carroll FI, Damaj MI (2013). The antinociceptive effects of nicotinic receptors alpha7-positive allosteric 
modulators in murine acute and tonic pain models. J Pharmacol Exp Ther 344(1): 264-275. 
 
Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, et al (2011). High dose atorvastatin decreases cellular 
markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo 
controlled clinical trial. The Journal of infectious diseases 203(6): 756-764. 
 
Gannon P, Khan MZ, Kolson DL (2011). Current understanding of HIV-associated neurocognitive disorders pathogenesis. 
Current opinion in neurology 24(3): 275-283. 
 
Gekonge B, Raymond AD, Yin X, Kostman J, Mounzer K, Collman RG, et al (2012). Retinoblastoma protein induction by 
HIV viremia or CCR5 in monocytes exposed to HIV-1 mediates protection from activation-induced apoptosis: ex vivo and 
in vitro study. Journal of leukocyte biology 92(2): 397-405. 
 
Gershon RC, Wagster MV, Hendrie HC, Fox NA, Cook KF, Nowinski CJ (2013). NIH Toolbox for Assessment of Neurological 
and Behavioral Function. Neurology 80(11 Supplement 3): S2-S6. 
 
Giri MS, Nebozyhn M, Raymond A, Gekonge B, Hancock A, Creer S, et al (2009). Circulating monocytes in HIV-1-infected 
viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J Immunol 
182(7): 4459-4470. 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 40 of 54 
 
Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, et al (2004). Galantamine and nicotine have a synergistic 
effect on inhibition of microglial activation induced by HIV-1 gp120. Brain research bulletin 64(2): 165-170. 
 
Gleason TC, Staelin R (1975). A proposal for handling missing data. Psychometrika 40(2): 229-252. 
 
Gonzalez-Scarano F, Martin-Garcia J (2005). The neuropathogenesis of AIDS. Nature reviews Immunology 5(1): 69-81. 
 
Govind AP, Vezina P, Green WN (2009). Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms 
and relevance to nicotine addiction. Biochemical pharmacology 78(7): 756-765. 
 
Gowayed MA, Refaat R, Ahmed WM, El-Abhar HS (2015). Effect of galantamine on adjuvant-induced arthritis in rats. 
European journal of pharmacology 764: 547-553. 
 
Guo Y, Zhao S, Li CI, Sheng Q, Shyr Y (2014). RNAseqPS: A Web Tool for Estimating Sample Size and Power for RNAseq 
Experiment. Cancer informatics 13(Suppl 6): 1-5. 
 
Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al (2008). Estimation of HIV incidence in the United States. Jama 
300(5): 520-529. 
 
Hamano R, Takahashi HK, Iwagaki H, Yoshino T, Nishibori M, Tanaka N (2006). Stimulation of alpha7 nicotinic 
acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human monocytes. Shock (Augusta, Ga) 
26(4): 358-364. 
 
Hardin JW, Hilbe JM (2003). GENERALIZED ESTIMATING EQUATIONS, 2nd edn. Chapman and Hall/CRC: Boca Raton, FL. 
 
Harrison J, Dochney J, Blazekovic S, Leone F, Metzger D, Frank I, et al (under review). Cognitive Function among Smokers 
with HIV: Predictors of Function and Comparison to Smokers without HIV. 
 
Haughey NJ, Mattson MP (2002). Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J 
Acquir Immune Defic Syndr 31 Suppl 2: S55-61. 
 
Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, Vaida F, et al (2010). HIV-associated neurocognitive disorders 
persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75(23): 2087-2096. 
 
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al (2011). HIV-associated neurocognitive 
disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. 
Journal of neurovirology 17(1): 3-16. 
 
Heaton RK, Franklin DR, Jr., Deutsch R, Letendre S, Ellis RJ, Casaletto K, et al (2015). Neurocognitive change in the era of 
HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 60(3): 473-480. 
 
Heishman SJ, Kleykamp BA, Singleton EG (2010). Meta-analysis of the acute effects of nicotine and smoking on human 
performance. Psychopharmacology 210(4): 453-469. 
 
Hong S, Banks WA (2015). Role of the immune system in HIV-associated neuroinflammation and neurocognitive 
implications. Brain, behavior, and immunity 45: 1-12. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 41 of 54 
Hughes JR, Hatsukami DK (2007). Instructions for use of the Minnesota Withdrawal Scale-Revised  Retrieved from 
www/uvmedu/~hbpl (last accessed 3/12/15). 
 
Hunt PW, Lee SA, Siedner MJ (2016). Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. The 
Journal of infectious diseases 214 Suppl 2: S44-50. 
 
Jones CK, Byun N, Bubser M (2012). Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators 
for the treatment of schizophrenia. Neuropsychopharmacology 37(1): 16-42. 
 
Kalkman HO, Feuerbach D (2016). Modulatory effects of alpha7 nAChRs on the immune system and its relevance for CNS 
disorders. Cellular and molecular life sciences : CMLS 73(13): 2511-2530. 
 
Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, Li C, et al (2012). A plasma biomarker signature of immune activation in HIV 
patients on antiretroviral therapy. PloS one 7(2): e30881. 
 
Kooij KW, Wit FW, Booiman T, van der Valk M, Schim van der Loeff MF, Kootstra NA, et al (2016). Cigarette smoking and 
inflammation, monocyte activation and coagulation in HIV-infected individuals on antiretroviral therapy compared to 
uninfected individuals. The Journal of infectious diseases. 
 
Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW (2013). Residual immune dysregulation syndrome in 
treated HIV infection. Advances in immunology 119: 51-83. 
 
Leiser SC, Bowlby MR, Comery TA, Dunlop J (2009). A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is 
geared towards improving cognitive deficits. Pharmacology and Therapeutics 122(3): 302-311. 
 
Leng SX, Margolick JB (2015). Understanding frailty, aging, and inflammation in HIV infection. Current HIV/AIDS reports 
12(1): 25-32. 
 
Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al (2004a). Individualizing nicotine 
replacement therapy for the treatment of tobacco dependence: a randomized trial. Annals of internal medicine 140(6): 
426-433. 
 
Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al (2004b). Individualizing nicotine 
replacement therapy for the treatment of tobacco dependence: a randomized trial. Annals of internal medicine 140(6): 
426-433. 
 
Lerman C, Schnoll RA, Hawk LW, Jr., Cinciripini P, George TP, Wileyto EP, et al (2015). Use of the nicotine metabolite 
ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a 
randomised, double-blind placebo-controlled trial. The Lancet: Respiratory Medicine 3(2): 131-138. 
 
Levin ED, McClernon FJ, Rezvani AH (2006). Nicotinic effects on cognitive function: behavioral characterization, 
pharmacological specification, and anatomic localization. Psychopharmacology 184(3-4): 523-539. 
 
Liang KY, Zeger SL (1986). Longitudinal Data-Analysis Using Generalized Linear-Models. Biometrika 73(1): 13-22. 
 
Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al (2013). A randomized exploratory trial of an 
alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 
38(6): 968-975. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 42 of 54 
Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV (1998). CD8+ T-lymphocyte activation in HIV-1 disease 
reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. Journal of acquired immune 
deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 18(4): 
332-340. 
 
Lockhart IA, Mitchell SA, Kelly S (2009). Safety and tolerability of donepezil, rivastigmine and galantamine for patients 
with Alzheimer's disease: systematic review of the 'real-world' evidence. Dementia and Geriatric Cognitive Disorders 
28(5): 389-403. 
 
Logan GD, Schachar RJ, Tannock R (1997). Impulsivity and inhibitory control. Psychological science 8(1): 60-66. 
 
Loram LC, Harrison JA, Chao L, Taylor FR, Reddy A, Travis CL, et al (2010). Intrathecal injection of an alpha seven nicotinic 
acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine 
profiles in rats. Brain, behavior, and immunity 24(6): 959-967. 
 
Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, et al (2011). Plasma sCD14 is a biomarker associated with 
impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic 
Syndr 57(5): 371-379. 
 
Maelicke A, Albuquerque EX (2000). Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy 
for Alzheimer's disease. European journal of pharmacology 393(1-3): 165-170. 
 
Mahy M, Autenrieth CS, Stanecki K, Wynd S (2014). Increasing trends in HIV prevalence among people aged 50 years and 
older: evidence from estimates and survey data. AIDS (London, England) 28(4): S453-S459. 
 
Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR (2010). Chronic exposure to nicotine and saquinavir decreases 
endothelial Notch-4 expression and disrupts blood-brain barrier integrity. Journal of neurochemistry 115(2): 515-525. 
 
McGuire JL, Gill AJ, Douglas SD, Kolson DL (2015). Central and peripheral markers of neurodegeneration and monocyte 
activation in HIV-associated neurocognitive disorders. Journal of neurovirology 21(4): 439-448. 
 
Mudd JC, Brenchley JM (2016). Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease 
Progression. The Journal of infectious diseases 214 Suppl 2: S58-66. 
 
Nahvi S, Cooperman NA (2009). Review: the need for smoking cessation among HIV-positive smokers. AIDS education 
and prevention : official publication of the International Society for AIDS Education 21(3 Suppl): 14-27. 
 
Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al (2016). Ageing and inflammation in patients with HIV 
infection. Clinical and experimental immunology. 
 
Nesil T, Cao J, Yang Z, Chang SL, Li MD (2015). Nicotine attenuates the effect of HIV-1 proteins on the neural circuits of 
working and contextual memories. Molecular brain 8(1): 1. 
 
Neuhaus J, Jacobs DR, Jr., Baker JV, Calmy A, Duprez D, La Rosa A, et al (2010). Markers of inflammation, coagulation, 
and renal function are elevated in adults with HIV infection. The Journal of infectious diseases 201(12): 1788-1795. 
 
Owen AM, McMillan KM, Laird AR, Bullmore E (2005). N-back working memory paradigm: a meta-analysis of normative 
functional neuroimaging studies. Human brain mapping 25(1): 46-59. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 43 of 54 
Pacek LR, Cioe PA (2015). Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV. 
Current HIV/AIDS reports 12(4): 413-420. 
 
Palella FJ, Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al (2006). Mortality in the highly active 
antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic 
Syndr 43(1): 27-34. 
 
Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al (1998). Declining morbidity and 
mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. 
The New England journal of medicine 338(13): 853-860. 
 
Paul RH, Brickman AM, Cohen RA, Williams LM, Niaura R, Pogun S, et al (2006). Cognitive status of young and older 
cigarette smokers: data from the international brain database. J Clin Neurosci 13(4): 457-465. 
 
Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al (2009). Brain acetylcholinesterase activity 
controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain, behavior, and immunity 
23(1): 41-45. 
 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al (2011). The Columbia-Suicide Severity Rating 
Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. The 
American journal of psychiatry 168(12): 1266-1277. 
 
Prevention. CfDCa (2010). HIV surveillance reports. Atlanta: Centers for Disease Control and Prevention. 
 
Quick MW, Lester RA (2002). Desensitization of neuronal nicotinic receptors. Journal of neurobiology 53(4): 457-478. 
 
Ragin AB, Wu Y, Storey P, Cohen BA, Edelman RR, Epstein LG (2006). Monocyte chemoattractant protein-1 correlates 
with subcortical brain injury in HIV infection. Neurology 66(8): 1255-1257. 
 
Ray R, Rukstalis M, Jepson C, Strasser A, Patterson F, Lynch K, et al (2009). Effects of atomoxetine on subjective and 
neurocognitive symptoms of nicotine abstinence. Journal of psychopharmacology (Oxford, England) 23(2): 168-176. 
 
Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D (2005). Acetylcholinesterase inhibitors effects on oncostatin-
M, interleukin-1β and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Experimental Gerontology 
40(3): 165-171. 
 
Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al (2010). Single-molecule enzyme-linked 
immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nature biotechnology 28(6): 595-599. 
 
Robertson K, Yosief S (2014). Neurocognitive assessment in the diagnosis of HIV-associated neurocognitive disorders. 
Seminars in neurology 34(1): 21-26. 
 
Rock RB, Gekker G, Aravalli RN, Hu S, Sheng WS, Peterson PK (2008). Potentiation of HIV-1 expression in microglial cells 
by nicotine: involvement of transforming growth factor-beta 1. Journal of neuroimmune pharmacology : the official 
journal of the Society on NeuroImmune Pharmacology 3(3): 143-149. 
 
Rubinstein PG, Aboulafia DM, Zloza A (2014). Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. 
AIDS 28(4): 453-465. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 44 of 54 
Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, et al (2016). Prevalence of HIV-associated 
neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology 86(4): 334-340. 
 
Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, et al (2003). Galantamine is an allosterically 
potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. The Journal of pharmacology and 
experimental therapeutics 305(3): 1024-1036. 
 
Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, et al (2011). Galantamine alleviates 
inflammation and other obesity-associated complications in high-fat diet-fed mice. Molecular medicine (Cambridge, 
Mass) 17(7-8): 599-606. 
 
Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al (2016). HIV-associated neurocognitive 
disorder--pathogenesis and prospects for treatment. Nature reviews Neurology 12(4): 234-248. 
 
Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, et al (2015). Long-term nicotine replacement 
therapy: a randomized clinical trial. JAMA internal medicine 175(4): 504-511. 
 
Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al (2010). Effectiveness of extended-duration 
transdermal nicotine therapy: a randomized trial. Annals of internal medicine 152(3): 144-151. 
 
Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P (2011). HIV-1 infection and cognitive impairment in the cART era: a 
review. AIDS 25(5): 561-575. 
 
Schrier RD, Hong S, Crescini M, Ellis R, Perez-Santiago J, Spina C, et al (2015). Cerebrospinal fluid (CSF) CD8+ T-cells that 
express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND). PloS one 10(2): e0116526. 
 
Seoane E, Resino S, Micheloud D, Moreno A, de Quiros JC, Lorente R, et al (2008). Lipid and apoprotein profile in HIV-1-
infected patients after CD4-guided treatment interruption. J Acquir Immune Defic Syndr 48(4): 455-459. 
 
Shapiro AM, Benedict RH, Schretlen D, Brandt J (1999). Construct and concurrent validity of the Hopkins Verbal Learning 
Test–revised. The Clinical neuropsychologist 13(3): 348-358. 
 
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Jarnavs J, Weiller E, et al (1998). The Mini-International 
Neuropsychiatric Interview (M.I.N.I.):  the development and validation of a structured diagnostic psychiatric interview 
for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20: 20-23; quiz 34-57. 
 
Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, et al (2014). Cigarette Smoking and Variations 
in Systemic Immune and Inflammation Markers. Journal of the National Cancer Institute 106(11). 
 
Sofuoglu M, DeVito EE, Waters AJ, Carroll KM (2013). Cognitive enhancement as a treatment for drug addictions. 
Neuropharmacology 64: 452-463. 
 
Sopori M (2002). Effects of cigarette smoke on the immune system. Nature reviews Immunology 2(5): 372-377. 
 
Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, et al (2004). Effects of cigarette smoke on the human airway 
epithelial cell transcriptome. Proceedings of the National Academy of Sciences of the United States of America 101(27): 
10143-10148. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 45 of 54 
Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA (2011). Chronic nicotine restores normal Abeta levels and 
prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease. Neurobiology of aging 
32(5): 834-844. 
 
Stampfli MR, Anderson GP (2009). How cigarette smoke skews immune responses to promote infection, lung disease 
and cancer. Nature reviews Immunology 9(5): 377-384. 
 
Sugano N, Shimada K, Ito K, Murai S (1998). Nicotine inhibits the production of inflammatory mediators in U937 cells 
through modulation of nuclear factor-kappaB activation. Biochemical and biophysical research communications 252(1): 
25-28. 
 
Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K, et al (2006). Microglial alpha7 nicotinic acetylcholine 
receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. Journal 
of neuroscience research 83(8): 1461-1470. 
 
Swan GE, Lessov-Schlaggar CN (2007). The effects of tobacco smoke and nicotine on cognition and the brain. 
Neuropsychology review 17(3): 259-273. 
 
Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, et al (2010). Galantamine-induced amyloid-{beta} 
clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. The Journal of biological chemistry 
285(51): 40180-40191. 
 
Thames AD, Arentoft A, Rivera-Mindt M, Hinkin CH (2013). Functional disability in medication management and driving 
among individuals with HIV: a 1-year follow-up study. Journal of clinical and experimental neuropsychology 35(1): 49-58. 
 
Tiraboschi JM, Munoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, et al (2015). Viral and 
inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during 
antiretroviral treatment switch. HIV medicine 16(6): 388-392. 
 
Tsaur S, Strasser AA, Souprountchouk V, Evans GC, Ashare RL (2015). Time dependency of craving and response 
inhibition during nicotine abstinence. Addiction research & theory 23(3): 205-212. 
 
Uteshev VV (2014). The therapeutic promise of positive allosteric modulation of nicotinic receptors. European journal of 
pharmacology 727: 181-185. 
 
Vaccher E, Serraino D, Carbone A, De Paoli P (2014). The evolving scenario of non-AIDS-defining cancers: challenges and 
opportunities of care. The oncologist 19(8): 860-867. 
 
Venkatachari NJ, Jain S, Walker L, Bivalkar-Mehla S, Chattopadhyay A, Bar-Joseph Z, et al (2016). Transcriptome analyses 
identify key cellular factors associated with HIV-1 associated neuropathogenesis in infected men. AIDS. 
 
Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, et al (2010). Microbial translocation induces 
persistent macrophage activation unrelated to HIV-1 levels or T cell activation following therapy. AIDS (London, England) 
24(9): 1281. 
 
Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH (2005). Associations between cigarette 
smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular 
disease. Eur Heart J 26(17): 1765-1773. 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 46 of 54 
Wei P, Liu Q, Li D, Zheng Q, Zhou J, Li J (2015). Acute nicotine treatment attenuates lipopolysaccharide-induced cognitive 
dysfunction by increasing BDNF expression and inhibiting neuroinflammation in the rat hippocampus. Neuroscience 
letters 604: 161-166. 
 
Weiser M, Zarka S, Werbeloff N, Kravitz E, Lubin G (2010). Cognitive test scores in male adolescent cigarette smokers 
compared to non-smokers: a population-based study. Addiction 105(2): 358-363. 
 
Williams DW, Byrd D, Rubin LH, Anastos K, Morgello S, Berman JW (2014a). CCR2 on CD14(+)CD16(+) monocytes is a 
biomarker of HIV-associated neurocognitive disorders. Neurology(R) neuroimmunology & neuroinflammation 1(3): e36. 
 
Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW (2014b). Monocytes mediate HIV 
neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Current HIV research 12(2): 
85-96. 
 
Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al (2016). The Simoa HD-1 Analyzer: A Novel Fully 
Automated Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing. Journal of laboratory 
automation 21(4): 533-547. 
 
Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, et al (2013). Allosteric alpha-7 nicotinic receptor 
modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 64: 197-204. 
 
Wittebole X, Hahm S, Coyle SM, Kumar A, Calvano SE, Lowry SF (2007). Nicotine exposure alters in vivo human responses 
to endotoxin. Clinical and experimental immunology 147(1): 28-34. 
 
Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, et al (2004). Interrater reliability of clinical ratings and 
neurocognitive diagnoses in HIV. Journal of clinical and experimental neuropsychology 26(6): 759-778. 
 
Yadav A, Collman RG (2009). CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. 
Journal of neuroimmune pharmacology 4(4): 430-447. 
 
Yang Z, Nesil T, Connaghan KP, Li MD, Chang SL (2016). Modulation Effect of HIV-1 Viral Proteins and Nicotine on 
Expression of the Immune-Related Genes in Brain of the HIV-1 Transgenic Rats. Journal of Neuroimmune Pharmacology: 
1-10. 
 
Zachary RS (2000). Shipley Institute of Living Scale - Revised Manual Western Psychological Services. 
 
 
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 47 of 54 
Recruitment & Retention Pilot References 
 
Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, Wang XF, Sargent DJ, Wickerham DL, Cronin W, 
Djulbegovic B, Slingluff CL, Jr. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from 
U.S. Cooperative Oncology Groups. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2012;18(1):256-62. PMCID: PMC3977198. 
 
Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrøm M, Johansen M, Taskila TK, Sullivan FM, Wilson S, Jackson C, 
Jones R, Mitchell ED. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and 
meta-analysis. BMJ open. 2013;3(2):e002360. PMID: 23396504. 
 
Meeker M. Internet Trends 2015. Kleiner Perkins Caufield & Byers website. [Epub accessed May 17, 2017]. Available 
from: http://www.kpcb.com/internet-trends. 
 
Free C, Phillips G, Galli L, Watson L, Felix L, Edwards P, Patel V, Haines A. The effectiveness of mobile-health technology-
based health behaviour change or disease management interventions for health care consumers: a systematic review. 
PLoS medicine. 2013;10(1):e1001362. PMCID: PMC3548655. 
 
VanEpps EM, Volpp KG, Halpern SD. A nudge toward participation: Improving clinical trial enrollment with behavioral 
economics. Science translational medicine. 2016;8(348):348fs13. PMCID: PMC6134397. 
 
Godskesen T, Hansson MG, Nygren P, Nordin K, Kihlbom U. Hope for a cure and altruism are the main motives behind 
participation in phase 3 clinical cancer trials. European Journal of Cancer Care. 2015;24(1):133-41. PMID. 
 
Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a 
meta-analysis. Drug Alcohol Depend. 2000;58(1-2):55-66. PMID: 10669055. 
 
Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for 
substance use disorders. Addiction. 2006;101(2):192-203. PMID: 16445548. 
 
Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use 
disorders: a meta-analysis. Addiction. 2006;101(11):1546-60. PMID: 17034434. 
 
Cerasoli CP, Nicklin JM, Ford MT. Intrinsic motivation and extrinsic incentives jointly predict performance: A 40-year 
meta-analysis. Psychological Bulletin. 2014;140(4):980-1008. PMID. 
 
Norris T, Schiller JS, Clarke TC. Early release of selected estimates based on data from the National Health Interview 
Survey. National Center for Health Statistics. June 2018. Available from: https://www.cdc.gov/nchs/nhis.htm. Epub., 
PMID. 
 
Reid JL, Hammond D, Boudreau C, Fong GT, Siahpush M, Collaboration ITC. Socioeconomic disparities in quit intentions, 
quit attempts, and smoking abstinence among smokers in four western countries: findings from the International 
Tobacco Control Four Country Survey. Nicotine & tobacco research : official journal of the Society for Research on 
Nicotine and Tobacco. 2010;12 Suppl:S20-33. PMCID: PMC2948137. 
 
Health PDoP. AIDS Activities Coordinating Office Surveillance Report, 2014. Philadelphia, PA: City of Philadelphia: 2015. 
 
Petry NM, Tedford J, Martin B. Reinforcing compliance with non-drug-related activities. J Subst Abuse Treat. 
2001;20(1):33-44. PMID: 11239726. 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 48 of 54 
Petry NM, Martin B. Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. J 
Consult Clin Psychol. 2002;70(2):398-405. PMID: 11952198. 
 
Plebani JG, Lynch KG, Yu Q, Pettinati HM, O'Brien CP, Kampman KM. Results of an initial clinical trial of varenicline for 
the treatment of cocaine dependence. Drug and alcohol dependence. 2012;121(1-2):163-6. PMCID: PMC3262950. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 49 of 54 
Sample Analysis Addendum 
Version 1: 06/22/2018 
 
Analysis led by: Mohamed Abdel-Mohsen, Ph.D. 
  Assistant Professor, Vaccine and Immunotherapy Center 
 The Wistar Institute 
 
Background 
All living cells assemble a diverse repertoire of glycan (carbohydrate) structures on their surface.1 Recent advances in the 
emerging field of glycobiology show that this repertoire, the glycome, plays critical roles in defining immune responses2 
and in cell-cell3 and cell-pathogen interactions.4 The specific structure of a glycan allows it to bind to a specific type of 
glycan-binding proteins called lectins, leading to activation of downstream signaling pathways. For example, galactose 
binding to galectins (β-galactoside-binding lectins), promotes immune evasion by inducing T-cell exhaustion and 
apoptosis, expanding regulatory T cells, and inhibiting natural killer cells.5-9  Sialic acid binding to siglecs (sialic acid-
binding Ig-like lectins), plays an essential role in inflammation, differentiation of self and non-self, and cell death.6,10-20 
Fucosylated glycans have shown to be involved in cell-cell interactions, T-cell exhaustion, angiogenesis, malignancy, and 
metastasis.21-24 In addition, within the host glycome, glycans on circulating glycoproteins and antibodies 
(immunoglobulins G; IgGs), are known to play an important role in regulating several immunological functions.25  Glycans 
associated with IgGs are of particular interest because these regulate/control the binding of IgG to its various Fc 
receptors, which defines antibody function, e.g., antibody-dependent cell-mediated cytotoxicity, or anti-inflammatory 
activities.26-29 Several studies revealed that altered glycosylation is closely linked to several diseases, including, 
rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, cancer, and diabetes.30-45  
Glycoimmunology is increasingly being translated into the clinical setting, revealing the mostly untapped potential of the 
glycome in novel therapeutics.  Smoking is associated with several glycomic alterations in the general population, 
including induction of fucose metabolism.  Increased level of cell-surface fucose is known to mediate and drive immune 
activation/inflammation by inducing TCR signaling in T cells and TLR4 signaling in monocyte/macrophages. Furthermore, 
increased fucose level on antibodies (immunoglobulin G; IgG) is known to reduce the antibody-dependent cell-mediated 
cytotoxicity (ADCC).  We will be taking advantage of recent advances in the emerging field of glycomics to establish a 
relationship between glycomic profiles, smoking with HIV, and smoking without HIV.  We will compare host glycomic 
profiles (cell-surface and cell-free) between smokers (HIV+ ART+, or HIV-) and non-smokers (HIV+ ART+, or HIV-).  
 
Cell-surface Glycomic Analysis  
The PBMCs will be separated into CD4+ T cells and CD8 T+ T cells using magnetic bead separation technology from Stem 
Cell.  We will employ a lectin microarray platform to profile 96 different glycan structures on the cell-surface of 
unfractionated PBMCs and isolated CD4+ T cells and CD8+ T. The lectin microarray is an emerging comprehensive novel 
technology, enabling high-throughput, rapid, and sensitive analysis of carbohydrate structures on a variety of samples.  
The lectin array employs a representative panel of immobilized lectins with known glycan structures binding specificity, 
subsequent monitoring of a binding event in pre-labeled samples, resulting in a specific map, often termed "the glycan 
signature." 46-54 In the HIV field, lectin microarrays have been used thus far for detailed analysis of the glycome of intact 
HIV-1 virions.  The results from that study showed strikingly similar glycan fingerprints between HIV virions and cell-
derived microvesicles, suggesting that HIV-1 shares a common exocytic pathway with microvesicles.55,56  Cell-surface 
molecules from 105-106 cells will be purified using ProteoExtract Subcellular Proteome Extraction Kit (Merck). 2 µg of 
fractionated cell-membrane proteins will be labeled with Cy5, and hybridized to a lectin microarray.  The resulting lectin 
chip will be scanned for fluorescence intensity on each lectin-coated spot using an evanescent-field fluorescence scanner 
GlycoStation Reader 1200. Data will be normalized using the global normalization method. Samples will be run in 
triplicates and will be repeated when the coefficient of variance is > 10%. The lectin array can assess eight samples in 
triplicate.   
 
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 50 of 54 
Cell-free Glycomic Analysis  
Total IgGs will be isolated from the plasma using Protein G. For screening N-glycans we will use UPLC. N-glycans will be 
released with PNGase F, labeled with 2-aminobenzamide, and excess reagents will be removed using hydrophilic 
interaction liquid chromatography solid phase extraction.57,58 Fluorescently labeled and purified N-glycans will be 
separated by HILIC-UPLC using an Acquity UPLC instrument as described in our recent publication.59   
 
 
 
 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 51 of 54 
References 
 
1 
Williams, G. J. & Thorson, J. S. Natural product glycosyltransferases: properties and applications. Advances in 
enzymology and related areas of molecular biology 76, 55-119 (2009). 
2 
Barrera, C., Espejo, R. & Reyes, V. E. Differential glycosylation of MHC class II molecules on gastric epithelial cells: 
implications in local immune responses. Human immunology 63, 384-393 (2002). 
3 
de Freitas Junior, J. C., Silva Bdu, R., de Souza, W. F., de Araujo, W. M., Abdelhay, E. S. & Morgado-Diaz, J. A. 
Inhibition of N-linked glycosylation by tunicamycin induces E-cadherin-mediated cell-cell adhesion and inhibits 
cell proliferation in undifferentiated human colon cancer cells. Cancer chemotherapy and pharmacology 68, 227-
238, doi:10.1007/s00280-010-1477-8 (2011). 
4 
Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. Targeting glycosylation as a therapeutic approach. Nature 
reviews. Drug discovery 1, 65-75, doi:10.1038/nrd708 (2002). 
5 
Mendez-Huergo, S. P., Blidner, A. G. & Rabinovich, G. A. Galectins: emerging regulatory checkpoints linking 
tumor immunity and angiogenesis. Curr Opin Immunol 45, 8-15, doi:10.1016/j.coi.2016.12.003 (2017). 
6 
Zhuo, Y. & Bellis, S. L. Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and 
function. J Biol Chem 286, 5935-5941, doi:10.1074/jbc.R110.191429 (2011). 
7 
Barondes, S. H., Cooper, D. N., Gitt, M. A. & Leffler, H. Galectins. Structure and function of a large family of 
animal lectins. J Biol Chem 269, 20807-20810 (1994). 
8 
Gordon-Alonso, M., Hirsch, T., Wildmann, C. & van der Bruggen, P. Galectin-3 captures interferon-gamma in the 
tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nature communications 8, 
793, doi:10.1038/s41467-017-00925-6 (2017). 
9 
Smith, L. K., Boukhaled, G. M., Condotta, S. A., Mazouz, S., Guthmiller, J. J., Vijay, R., Butler, N. S., Bruneau, J., 
Shoukry, N. H., Krawczyk, C. M. & Richer, M. J. Interleukin-10 Directly Inhibits CD8(+) T Cell Function by 
Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. Immunity 48, 299-312 e295, 
doi:10.1016/j.immuni.2018.01.006 (2018). 
10 
Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses 
inflammation through a novel T(H)2 pathway. Nature 475, 110-113, doi:10.1038/nature10134 (2011). 
11 
Anthony, R. M. & Ravetch, J. V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG 
Fcs. J Clin Immunol 30 Suppl 1, S9-14, doi:10.1007/s10875-010-9405-6 (2010). 
12 
Byrne, B., Donohoe, G. G. & O'Kennedy, R. Sialic acids: carbohydrate moieties that influence the biological and 
physical properties of biopharmaceutical proteins and living cells. Drug discovery today 12, 319-326, 
doi:10.1016/j.drudis.2007.02.010 (2007). 
13 
Jandus, C., Simon, H. U. & von Gunten, S. Targeting siglecs--a novel pharmacological strategy for immuno- and 
glycotherapy. Biochemical pharmacology 82, 323-332, doi:10.1016/j.bcp.2011.05.018 (2011). 
14 
Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc 
sialylation. Science 313, 670-673, doi:10.1126/science.1129594 (2006). 
15 
Matzinger, P. The danger model: a renewed sense of self. Science 296, 301-305, doi:10.1126/science.1071059 
(2002). 
16 
Pillai, S., Netravali, I. A., Cariappa, A. & Mattoo, H. Siglecs and immune regulation. Annual review of immunology 
30, 357-392, doi:10.1146/annurev-immunol-020711-075018 (2012). 
17 
Rabinovich, G. A., Rubinstein, N. & Toscano, M. A. Role of galectins in inflammatory and immunomodulatory 
processes. Biochimica et biophysica acta 1572, 274-284 (2002). 
18 
Rempel, H., Calosing, C., Sun, B. & Pulliam, L. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and 
enhances infectivity. PloS one 3, e1967, doi:10.1371/journal.pone.0001967 (2008). 
19 
Toscano, M. A., Bianco, G. A., Ilarregui, J. M., Croci, D. O., Correale, J., Hernandez, J. D., Zwirner, N. W., Poirier, 
F., Riley, E. M., Baum, L. G. & Rabinovich, G. A. Differential glycosylation of TH1, TH2 and TH-17 effector cells 
selectively regulates susceptibility to cell death. Nature immunology 8, 825-834, doi:10.1038/ni1482 (2007). 
20 
von Gunten, S. & Simon, H. U. Cell death modulation by intravenous immunoglobulin. J Clin Immunol 30 Suppl 1, 
S24-30, doi:10.1007/s10875-010-9411-8 (2010). 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 52 of 54 
21 
Ma, B., Simala-Grant, J. L. & Taylor, D. E. Fucosylation in prokaryotes and eukaryotes. Glycobiology 16, 158R-
184R, doi:10.1093/glycob/cwl040 (2006). 
22 
Miyoshi, E., Moriwaki, K. & Nakagawa, T. Biological function of fucosylation in cancer biology. J Biochem 143, 
725-729, doi:10.1093/jb/mvn011 (2008). 
23 
Miyoshi, E., Moriwaki, K., Terao, N., Tan, C. C., Terao, M., Nakagawa, T., Matsumoto, H., Shinzaki, S. & Kamada, 
Y. Fucosylation is a promising target for cancer diagnosis and therapy. Biomolecules 2, 34-45, 
doi:10.3390/biom2010034 (2012). 
24 
Okada, M., Chikuma, S., Kondo, T., Hibino, S., Machiyama, H., Yokosuka, T., Nakano, M. & Yoshimura, A. 
Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune 
Responses of T Cells. Cell reports 20, 1017-1028, doi:10.1016/j.celrep.2017.07.027 (2017). 
25 
Pucic, M., Knezevic, A., Vidic, J., Adamczyk, B., Novokmet, M., Polasek, O., Gornik, O., Supraha-Goreta, S., 
Wormald, M. R., Redzic, I., Campbell, H., Wright, A., Hastie, N. D., Wilson, J. F., Rudan, I., Wuhrer, M., Rudd, P. 
M., Josic, D. & Lauc, G. High throughput isolation and glycosylation analysis of IgG-variability and heritability of 
the IgG glycome in three isolated human populations. Molecular & cellular proteomics : MCP 10, M111 010090, 
doi:10.1074/mcp.M111.010090 (2011). 
26 
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., 
Dilhuydy, M. S., Illmer, T., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K. A., Stilgenbauer, S., Dohner, H., 
Langerak, A. W., Ritgen, M., Kneba, M., Asikanius, E., Humphrey, K., Wenger, M. & Hallek, M. Obinutuzumab 
plus chlorambucil in patients with CLL and coexisting conditions. The New England journal of medicine 370, 
1101-1110, doi:10.1056/NEJMoa1313984 (2014). 
27 
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., 
Totpal, K., Kelley, R. F. & Sliwkowski, M. X. Superior in vivo efficacy of afucosylated trastuzumab in the treatment 
of HER2-amplified breast cancer. Cancer research 70, 4481-4489, doi:10.1158/0008-5472.CAN-09-3704 (2010). 
28 
Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer. Nature reviews. Cancer 12, 278-287, 
doi:10.1038/nrc3236 (2012). 
29 
Sondermann, P. & Szymkowski, D. E. Harnessing Fc receptor biology in the design of therapeutic antibodies. 
Current opinion in immunology 40, 78-87, doi:10.1016/j.coi.2016.03.005 (2016). 
30 
Trbojević Akmačić, I., Ventham, N. T., Theodoratou, E., Vučković, F., Kennedy, N. A., Krištić, J., Nimmo, E. R., 
Kalla, R., Drummond, H., Štambuk, J., Dunlop, M. G., Novokmet, M., Aulchenko, Y., Gornik, O., Campbell, H., 
Pučić Baković, M., Satsangi, J., Lauc, G. & Consortium, I.-B. Inflammatory bowel disease associates with 
proinflammatory potential of the immunoglobulin g glycome. Inflamm Bowel Dis 21, 1237-1247, 
doi:10.1097/MIB.0000000000000372 (2015). 
31 
Vučković, F., Krištić, J., Gudelj, I., Artacho, M. T., Keser, T., Pezer, M., Pučić-Baković, M., Štambuk, J., Trbojević-
Akmačić, I., Barrios, C., Pavić, T., Menni, C., Wang, Y., Zhou, Y., Cui, L., Song, H., Zeng, Q., Guo, X., Pons-Estel, B., 
McKeigue, P., Patrick, A. L., Gornik, O., Spector, T. D., Harjaček, M., Alarcon-Riquelme, M. E., Molokhia, M., 
Wang, W. & Lauc, G. Systemic lupus erythematosus associates with the decreased immunosuppressive potential 
of the IgG glycome. Arthritis & Rheumatology 67, 2978-2989, doi:10.1002/art.39273 (2015). 
32 
Vuckovic, F., Theodoratou, E., Thaci, K., Timofeeva, M., Vojta, A., Stambuk, J., Pucic-Bakovic, M., Rudd, P. M., 
Derek, L., Servis, D., Wennerstrom, A., Farrington, S. M., Perola, M., Aulchenko, Y., Dunlop, M. G., Campbell, H. & 
Lauc, G. IgG Glycome in Colorectal Cancer. Clinical cancer research : an official journal of the American 
Association for Cancer Research 22, 3078-3086, doi:10.1158/1078-0432.CCR-15-1867 (2016). 
33 
Lemmers, R. F. H., Vilaj, M., Urda, D., Agakov, F., Simurina, M., Klaric, L., Rudan, I., Campbell, H., Hayward, C., 
Wilson, J. F., Lieverse, A. G., Gornik, O., Sijbrands, E. J. G., Lauc, G. & van Hoek, M. IgG glycan patterns are 
associated with type 2 diabetes in independent European populations. Biochimica et biophysica acta 1861, 
2240-2249, doi:10.1016/j.bbagen.2017.06.020 (2017). 
34 
An, H. J. & Lebrilla, C. B. A glycomics approach to the discovery of potential cancer biomarkers. Methods in 
molecular biology 600, 199-213, doi:10.1007/978-1-60761-454-8_14 (2010). 
35 
Moremen, K. W., Tiemeyer, M. & Nairn, A. V. Vertebrate protein glycosylation: diversity, synthesis and function. 
Nature reviews. Molecular cell biology 13, 448-462, doi:10.1038/nrm3383 (2012). 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 53 of 54 
36 
Thompson, A. J., Kennard, C., Swash, M., Summers, B., Yuill, G. M., Shepherd, D. I., Roche, S., Perkin, G. D., 
Loizou, L. A., Ferner, R. & et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment 
of acute relapse in MS. Neurology 39, 969-971 (1989). 
37 
Brinkman-van der Linden, E. C., de Haan, P. F., Havenaar, E. C. & van Dijk, W. Inflammation-induced expression 
of sialyl LewisX is not restricted to alpha1-acid glycoprotein but also occurs to a lesser extent on alpha1-
antichymotrypsin and haptoglobin. Glycoconj J 15, 177-182 (1998). 
38 
Goodarzi, M. T., Axford, J. S., Varanasi, S. S., Alavi, A., Cunnane, G., Fitzgerald, O. & Turner, G. A. Sialyl Lewis(x) 
expression on IgG in rheumatoid arthritis and other arthritic conditions: a preliminary study. Glycoconj J 15, 
1149-1154 (1998). 
39 
Ryden, I., Pahlsson, P., Lundblad, A. & Skogh, T. Fucosylation of alpha1-acid glycoprotein (orosomucoid) 
compared with traditional biochemical markers of inflammation in recent onset rheumatoid arthritis. Clin Chim 
Acta 317, 221-229 (2002). 
40 
Ma, B., Audette, G. F., Lin, S., Palcic, M. M., Hazes, B. & Taylor, D. E. Purification, kinetic characterization, and 
mapping of the minimal catalytic domain and the key polar groups of Helicobacter pylori alpha-(1,3/1,4)-
fucosyltransferases. J Biol Chem 281, 6385-6394, doi:10.1074/jbc.M511320200 (2006). 
41 
Rillahan, C. D., Antonopoulos, A., Lefort, C. T., Sonon, R., Azadi, P., Ley, K., Dell, A., Haslam, S. M. & Paulson, J. C. 
Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol 8, 661-668, 
doi:10.1038/nchembio.999 (2012). 
42 
Okeley, N. M., Alley, S. C., Anderson, M. E., Boursalian, T. E., Burke, P. J., Emmerton, K. M., Jeffrey, S. C., 
Klussman, K., Law, C. L., Sussman, D., Toki, B. E., Westendorf, L., Zeng, W., Zhang, X., Benjamin, D. R. & Senter, P. 
D. Development of orally active inhibitors of protein and cellular fucosylation. Proc Natl Acad Sci U S A 110, 
5404-5409, doi:10.1073/pnas.1222263110 (2013). 
43 
Li, J., Hsu, H. C., Ding, Y., Li, H., Wu, Q., Yang, P., Luo, B., Rowse, A. L., Spalding, D. M., Bridges, S. L., Jr. & Mountz, 
J. D. Inhibition of fucosylation reshapes inflammatory macrophages and suppresses type II collagen-induced 
arthritis. Arthritis Rheumatol 66, 2368-2379, doi:10.1002/art.38711 (2014). 
44 
Pham, T. A., Clare, S., Goulding, D., Arasteh, J. M., Stares, M. D., Browne, H. P., Keane, J. A., Page, A. J., 
Kumasaka, N., Kane, L., Mottram, L., Harcourt, K., Hale, C., Arends, M. J., Gaffney, D. J., Sanger Mouse Genetics, 
P., Dougan, G. & Lawley, T. D. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization 
resistance to an opportunistic pathogen. Cell Host Microbe 16, 504-516, doi:10.1016/j.chom.2014.08.017 (2014). 
45 
Allen, J. G., Mujacic, M., Frohn, M. J., Pickrell, A. J., Kodama, P., Bagal, D., San Miguel, T., Sickmier, E. A., Osgood, 
S., Swietlow, A., Li, V., Jordan, J. B., Kim, K. W., Rousseau, A. C., Kim, Y. J., Caille, S., Achmatowicz, M., Thiel, O., 
Fotsch, C. H., Reddy, P. & McCarter, J. D. Facile Modulation of Antibody Fucosylation with Small Molecule 
Fucostatin Inhibitors and Cocrystal Structure with GDP-Mannose 4,6-Dehydratase. ACS Chem Biol 11, 2734-2743, 
doi:10.1021/acschembio.6b00460 (2016). 
46 
Angeloni, S., Ridet, J. L., Kusy, N., Gao, H., Crevoisier, F., Guinchard, S., Kochhar, S., Sigrist, H. & Sprenger, N. 
Glycoprofiling with micro-arrays of glycoconjugates and lectins. Glycobiology 15, 31-41, 
doi:10.1093/glycob/cwh143 (2005). 
47 
Carlsson, J., Mecklenburg, M., Lundstrom, I., Danielsson, B. & Winquist, F. Investigation of sera from various 
species by using lectin affinity arrays and scanning ellipsometry. Analytica chimica acta 530, 167-171, 
doi:10.1016/j.aca.2004.09.022 (2005). 
48 
Fromell, K., Andersson, M., Elihn, K. & Caldwell, K. D. Nanoparticle decorated surfaces with potential use in 
glycosylation analysis. Colloids Surf B Biointerfaces 46, 84-91, doi:10.1016/j.colsurfb.2005.06.017 (2005). 
49 
Kuno, A., Uchiyama, N., Koseki-Kuno, S., Ebe, Y., Takashima, S., Yamada, M. & Hirabayashi, J. Evanescent-field 
fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2, 851-856, 
doi:10.1038/nmeth803 (2005). 
50 
Pilobello, K. T., Krishnamoorthy, L., Slawek, D. & Mahal, L. K. Development of a lectin microarray for the rapid 
analysis of protein glycopatterns. Chembiochem 6, 985-989, doi:10.1002/cbic.200400403 (2005). 
51 
Zheng, T., Peelen, D. & Smith, L. M. Lectin arrays for profiling cell surface carbohydrate expression. J Am Chem 
Soc 127, 9982-9983, doi:10.1021/ja0505550 (2005). 


University of Pennsylvania, Office of Regulatory Affairs 
3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 
 
Version 16: February 22, 2021 
 
 
    page 54 of 54 
52 
Chen, P., Liu, Y., Kang, X., Sun, L., Yang, P. & Tang, Z. Identification of N-glycan of alpha-fetoprotein by lectin 
affinity microarray. J Cancer Res Clin Oncol 134, 851-860, doi:10.1007/s00432-008-0357-7 (2008). 
53 
Chen, S., Zheng, T., Shortreed, M. R., Alexander, C. & Smith, L. M. Analysis of cell surface carbohydrate 
expression patterns in normal and tumorigenic human breast cell lines using lectin arrays. Anal Chem 79, 5698-
5702, doi:10.1021/ac070423k (2007). 
54 
Matsuda, A., Kuno, A., Ishida, H., Kawamoto, T., Shoda, J. & Hirabayashi, J. Development of an all-in-one 
technology for glycan profiling targeting formalin-embedded tissue sections. Biochem Biophys Res Commun 370, 
259-263, doi:10.1016/j.bbrc.2008.03.090 (2008). 
55 
Hirabayashi, J. Glycome 'fingerprints' provide definitive clues to HIV origins. Nature chemical biology 5, 198-199, 
doi:10.1038/nchembio0409-198 (2009). 
56 
Krishnamoorthy, L., Bess, J. W., Jr., Preston, A. B., Nagashima, K. & Mahal, L. K. HIV-1 and microvesicles from T 
cells share a common glycome, arguing for a common origin. Nature chemical biology 5, 244-250, 
doi:10.1038/nchembio.151 (2009). 
57 
Akmacic, I. T., Ugrina, I., Stambuk, J., Gudelj, I., Vuckovic, F., Lauc, G. & Pucic-Bakovic, M. High-throughput 
glycomics: optimization of sample preparation. Biochemistry (Mosc) 80, 934-942, 
doi:10.1134/S0006297915070123 (2015). 
58 
Trbojevic-Akmacic, I., Ugrina, I. & Lauc, G. Comparative Analysis and Validation of Different Steps in Glycomics 
Studies. Methods Enzymol 586, 37-55, doi:10.1016/bs.mie.2016.09.027 (2017). 
59 
Vadrevu, S. K., Trbojevic-Akmacic, I., Kossenkov, A. V., Colomb, F., Giron, L. B., Anzurez, A., Lynn, K., Mounzer, K., 
Landay, A. L., Kaplan, R. C., Papasavvas, E., Montaner, L. J., Lauc, G. & Abdel-Mohsen, M. Frontline Science: 
Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. 
Journal of leukocyte biology, doi:10.1002/JLB.3HI1217-500R (2018). 
 

ICF_001.pdf: 
Version 16: February 22, 2021 
 
Page 1 of 10 
 
UNIVERSITY OF PENNSYLVANIA  
RESEARCH STUDY SUMMARY FOR POTENTIAL SUBJECTS 
 
Protocol Title: Targeting the Cholinergic Pathway in HIV-associated Inflammation 
and Cognitive Dysfunction (IRB# 828125) 
Principal Investigator: Rebecca Ashare, Ph.D., Phone: 215-746-5789  
Department of Psychiatry, University of Pennsylvania  
Emergency Contact: Ian Frank, M.D., Phone: 215-964-1077  
University of Pennsylvania 
 
You are being invited to participate in a research study. Your participation is voluntary, and you should only 
participate if you completely understand what the study requires and the risks of participation. You should ask 
the study team any questions you have before agreeing to join the study. If you have any questions about your 
rights as a human research participant at any time before, during or after participation, please contact either, the 
Penn Institutional Review Board (IRB) at (215) 898-2614 for assistance, or the Research Participant Coordinator at 
the Philadelphia Department of Public Health IRB at (215) 685-0869. 
 
The main purpose of this research study is to examine whether a medication called galantamine hydrobromide 
(Razadyne) may enhance performance on measures of memory and attention and may affect inflammation in 
people living with HIV. 
 
If you agree to join the study, you will be asked to complete tasks to determine your eligibility, either in-person or 
remotely by phone/video call. If you are deemed eligible to participate you will be asked to complete 8 in-person visits 
and 6 monitoring phone calls, over the course of two identical 12-week study periods. Four of the in-person visits will 
include blood draws, cognitive tasks and questionnaires; the remaining in-person visits will only include cognitive tasks 
and questionnaires. The monitoring phone calls serve to track study medication use, as well as any side effects you 
may experience. The two study periods will be separated by a 4 week “Washout Period”, during which you will not 
take any study medication or complete study sessions. 
 
Your participation in the study will last approximately 7 months. If you are deemed eligible, you will be given a study 
schedule that outlines your scheduled sessions. 
 
If enrolled in this study, you may benefit from the knowledge that you are contributing in an important way to 
increasing scientific knowledge about neurocognitive disease and ways to improve its treatment in people living 
with HIV. 
 
The most common risks of study participation are potential side effects from the study medication, galantamine 
hydrobromide. These side effects tend to be mild, and include: nausea, vomiting, diarrhea, dizziness, headache, 
and decreased appetite. You will be monitored for side effects throughout the study.  
 
The alternative to participation in this program is to decide not to participate. If you do not wish to enroll in this 
study, we can provide information on other studies at our center or located in the Philadelphia area. 
 
Please note that there are other factors to consider before agreeing to participate in this study, such as additional 
procedures, use of your personal information, and other possible risks. If you are interested in participating, a 
member of the study team will review the full study information with you. You are free to decline or stop 
participation at any time during or after the initial consenting process.  
 
 


Version 16: February 22, 2021 
 
Page 2 of 10 
 
UNIVERSITY OF PENNSYLVANIA 
RESEARCH SUBJECT  
INFORMED CONSENT AND HIPAA FORM 
 
Protocol Title: Targeting the Cholinergic Pathway in HIV-associated Inflammation 
and Cognitive Dysfunction (IRB# 828125) 
Principal Investigator: Rebecca Ashare, Ph.D., Phone: 215-746-5789  
Department of Psychiatry, University of Pennsylvania  
Emergency Contact: Ian Frank, M.D., Phone: 215-964-1077  
University of Pennsylvania 
 
WHY AM I BEING ASKED TO VOLUNTEER? You are being asked to take part in this research program because you 
have expressed an interest in participating, and meet other program criteria, such as having tested positive for HIV. 
Your participation is voluntary which means you can choose whether or not to participate. Before you make this 
decision, you will need to know the purpose of the research program, the possible risks and benefits of being in the 
research program, and what you will have to do if you decide to participate. The research team is going to talk with 
you about these things today. Please ask them to explain anything you do not understand, including any language 
contained in this form.  
 
You do not have to make a decision about participating in this research program today; you can request a copy of this 
form to review at a later time, or share it with your family, friends, and/or doctor. Whatever you decide, there will be 
no loss of benefits to which you are otherwise entitled. If you do decide to participate, you will be asked to sign this 
form and will be given a copy for your records. 
 
WHAT IS THE PURPOSE OF THIS RESEARCH STUDY? The main purpose of this research study is to examine whether 
a medication called galantamine hydrobromide (Razadyne) may enhance performance on measures of memory 
and attention and may affect inflammation in people living with HIV. 
 
HOW LONG WILL I BE IN THE STUDY? HOW MANY OTHER PEOPLE WILL BE IN THE STUDY? Overall, 120 people 
will complete this research program over an approximately 5-year period. Your individual participation will last 
about 7 months. 
 
WHAT AM I BEING ASKED TO DO? The study is divided into two identical 12-week study periods. Within each of 
these 12-week periods, you will take study medication, complete questionnaires and cognitive tasks and be asked 
to provide blood and saliva (if applicable) samples for analysis. In one of the study periods, you will take 
galantamine and in the other, you will take a placebo. Neither you nor the study staff will know which medication 
you are taking within each study period; however, we can find out this information if necessary for your medical 
care. Between the 12-week periods, you will not take any study medication for at least 4 weeks or attend any 
study-related appointments; this is called the “Washout Period.” For the duration of the study, you should 
continue your smoking or non-smoking behavior as usual. Overall, you will complete 8 in-person visits and 6 
monitoring phone calls throughout this study. Study visits are described in more detail below. 
 
Intake Session. Tasks listed below that can be completed remotely will be done by phone/video call to reduce the 
length of in-person tasks. The in-person tasks at our center will last about 1-1.5 hours. You will be asked to: 
• 
Provide a urine sample (at least 30mL [two tablespoons]) for drug and (if applicable) pregnancy tests. If 
you test positive for any of the following drugs: cocaine, amphetamines, methamphetamines, 
benzodiazepines, PCP, methadone, barbiturates, ecstasy (MDMA), oxycodone, or opiates, you may not be 
eligible to participate in this study. Results from this testing are used for research purposes only. They will 
not be shared with you and will not be placed in your electronic medical record. You will be informed of 
your eligibility status after testing. 


Version 16: February 22, 2021 
 
Page 3 of 10 
 
• 
(Females of child-bearing potential only): Be provided with a urine pregnancy screen and will be asked 
to perform the screening independently. For safety purposes, if you think you are pregnant, we advise 
that you discontinue study participation. There is no penalty for withdrawing from the study at this point 
and you will still receive travel reimbursement. 
• 
Provide a breath sample for a carbon monoxide (CO) assessment to confirm your smoking status. Carbon 
monoxide is a poisonous gas that comprises less than 1% of the air we breathe and is also produced 
through smoking a cigarette.  
• 
Complete brief psychiatric assessments called the ‘MINI’ and ‘CSSRS’ interviews. During these interviews, 
we will ask you about any current and past depressed mood symptoms as well as other psychiatric 
symptoms. 
• 
Complete a medical history, where you will be asked about any past medical conditions that you may have 
been diagnosed with. You will have your blood pressure measured and be asked about any medications 
that you are currently taking or discontinued taking within the last 2 weeks. You will also complete a brief 
physical examination, led by a medical professional. 
• 
Complete a brief mental ability test called the ‘Shipley Institute of Living Scale’. 
• 
Complete assessments of your demographics, alcohol and smoking history and rate (if applicable), 
behaviors, and mood. 
• 
Provide an 8.5 mL blood sample (less than 2 teaspoons) that will be used to assess liver and kidney 
function. This is required to ensure it is safe for you to take the study medication. When the results of the 
test are received (within 2-7 days of the Intake visit), a member of our staff will contact you to let you 
know if you are eligible to participate in the study.  
 
Study eligibility criteria have been established for data quality and/or safety purposes. As you complete the tasks 
listed above, there is a chance you may not meet all of the study eligibility criteria (i.e., conditions). If this occurs, 
you will be deemed ineligible for the study. 
 
Final Eligibility Phone Call: A staff member will call you to inform you of your final eligibility. If you are eligible, 
you will confirm the proposed study schedule discussed at Intake. If you are ineligible, we can refer you to other 
programs at our center, or in the Philadelphia area. 
 
Laboratory Visits (Weeks 0, 12, 16 and 28): Four times throughout the study (twice during each treatment period), 
you will attend in-person laboratory visits at our center that will last about 2 hours. During this time, you will: 
• 
Provide a urine sample (at least 30mL [two tablespoons]) for drug and (if applicable) pregnancy tests. If you 
test positive for any of the following drugs: cocaine, amphetamines, methamphetamines, benzodiazepines, 
PCP, methadone, barbiturates, ecstasy (MDMA), oxycodone, or opiates, you may not be eligible to 
participate in this study. Results from this testing are used for research purposes only. They will not be 
shared with you and will not be placed in your electronic medical record. You will be informed of your 
eligibility status after testing, but specific results will not be shared.  
• 
Smokers only: Provide a saliva sample to verify smoking status.  
• 
Provide a breath sample for a carbon monoxide (CO) assessment. 
• 
Complete a blood pressure assessment. 
• 
Complete questionnaires that assess smoking behavior (if applicable), mood, and sleep quality.  
• 
Complete computer tasks that test your memory and attention. 
• 
Provide a blood sample (up to 80 mL). 
• 
Receive instructions on how to use your initial supply of medication at the beginning of each treatment 
period (weeks 0 and 16 only). Medication will be mailed to you prior to the start of treatment or provided 
at the visit. 
 
Monitoring Phone Calls (Weeks 2, 6, 10, 18, 22 and 26). Six times throughout the study (three times during each 
treatment period), you will participate in a phone call designed to track your medication use and to monitor any 


Version 16: February 22, 2021 
 
Page 4 of 10 
 
side-effects you may be experiencing. These phone calls will be scheduled in advance and will last about 15 
minutes.  
 
Mid-treatment Visits (Weeks 4, 8, 20 and 24). Four times throughout the study (twice during each treatment 
period) you will attend in-person mid-treatment visits at our center that will last about 1.5 hours. During this time, 
you will: 
• 
Complete carbon monoxide (CO), blood pressure, and smoking rate assessments (if applicable). 
• 
Complete questionnaires that assess smoking behavior (if applicable) and mood. 
• 
Complete computer tasks that test your memory and attention. 
• 
Review instructions for your additional supplies of medication, which will be mailed to you or provided at 
the visit. 
 
Washout Period (Between Weeks 12-16). After your first treatment period, you will not take any study medication 
for the next 4 weeks. The Washout Period will allow the study medication to be eliminated from your body. 
 
End of Study Phone Call (within a week of last completed visit). Participants will be contacted within a week of 
their last completed visit for the study. This call will be to discuss any final details of participation and to answer 
any questions the participant may have. 
 
Sample Analyses. 
Some of the blood collected will be used to examine viral load. The remaining blood will be analyzed by testing 
monocytes and plasma proteins. Monocyte and plasma protein testing will determine if treatment has changed 
the behavior of monocytes in the blood. The Wistar Institute will conduct additional glycomic analyses on blood 
samples already collected for the purposes of this study. This additional analysis will not require additional blood 
samples, and your samples will be completely de-identified before being sent to the Wistar Institute. The results 
of these analyses are exploratory which means we do not yet understand their role in inflammation or cognitive 
function, and they will not be shared with you. 
 
Saliva samples will be analyzed for cotinine after collection. Cotinine is a biomarker for exposure to tobacco 
smoke. The results of these analyses will not be shared with you. 
 
Viral Load and Anti-Retroviral Information. We will ask that you complete a brief questionnaire about your anti-
retroviral use at laboratory and mid-treatment visits. For Intake, we will ask you to provide viral load results and 
may contact your clinic or provider for this purpose. If you are not able to provide these results, we may ask that 
you review and sign a HIPAA short form for the release of this information for the research study. 
 
HOW WILL I RECEIVE COMMUNICATIONS FROM THE STUDY? As discussed during your initial phone screening, 
the primary mode of communication throughout the study will be text via the Way 2 Health software platform. 
You will be contacted up to several times a week with study reminders and 3 times throughout the study for short 
text-based surveys. You may change your communication preference at any time during the study. If you do not 
wish to receive text reminders or if you do not have a phone that is compatible with text reminders, you can opt 
to receive phone call or email reminders. 
 
WHAT ARE THE POSSIBLE RISKS OR DISCOMFORTS? While enrolled in this research program, you will be asked 
not to use any smoking cessation therapy or other treatments for nicotine dependence, including Chantix®, 
nicotine gum, nicotine spray, nicotine lozenge, nicotine inhaler and the e-cigarette. The likelihood and severity 
of the potential risks to you are described below: 
 
Study Medication: The following side effects have been reported by some people who take galantamine 
(Razadyne). The most common were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. All 
of these side effects have been mild and temporary in nature with the doses of galantamine (8mg, 16mg and 
24mg/day) you will receive in the study.  
 


Version 16: February 22, 2021 
 
Page 5 of 10 
 
In addition to those listed above, less common (<5% of patients) side effects include depression, stomach 
discomfort, stomach pain, heartburn, weight loss, extreme tiredness, tremors, slowed heartbeat, and muscle 
spasms. Rare, but potentially serious side effects occurring in <1% of patients include dysgeusia (change in sense 
of taste), burning or tingling sensation in hands, arms, legs, or feet, fainting, shortness of breath, difficulty falling 
asleep or staying asleep, and excessive sweating. To help minimize these side effects galantamine will be 
prescribed at 8mg per day for the first 4 weeks and then increased to 16mg per day for the following 4 weeks 
before beginning to take the final dose of 24mg per day for 4 weeks. Because some people may need more time 
to adjust to the medication, you may be asked to remain on a lower dose of the study medication for a longer 
amount of time. Remember, neither you nor the study staff will know which treatment period you will be taking 
galantamine or placebo.  
 
We have compiled stringent exclusion criteria to limit the chance of side effects. You will be assessed for these 
criteria at the Intake session. We will also monitor all of these side effects regularly using a side effect checklist. If 
you, as a participant, becomes aware of these symptoms, report them as soon as possible to the research staff so 
that we can limit any adverse reactions. You should refrain from taking any new prescription or over the counter 
medications while in the study. Please inform a member of our research staff if you start taking any new 
medications during your participation.  
 
If you do experience any severe side effects or related medical issues during your participation in the study, please 
contact the Study Physician (listed on page 1) at the telephone number provided. Dr. Frank’s emergency contact 
information is also on the medication blister pack that you will receive.  
 
Reproductive Risks (Females only): Galantamine (Razadyne) must not be given during pregnancy and/or nursing. 
Therefore, if you are a woman of child-bearing potential, please notify the study physician if you become or intend 
to become pregnant during the study period. Any pregnant or nursing women will be excluded from the study. 
Women of childbearing potential will be provided with a urine pregnancy screen at Intake visit and subsequent 
laboratory visits and will be instructed to perform the screening independently. For safety purposes, we advise 
that participants who think they may be pregnant discontinue study participation. There is no penalty for 
withdrawing from the study at this point and participants will still receive travel reimbursement. By signing this 
form, if you are of childbearing potential, you agree to use an approved method of contraception (such as 
condoms and spermicide or birth control pills) or abstain from having sex during your participation in this study.  
 
Blood draw: Blood draws may result in bruising and/or slight bleeding at the needle site or may cause you to feel 
faint. All of these side effects are rare. Blood will be drawn by a trained professional, reducing the risks of these 
discomforts.  
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE ABOUT THE PROGRAM? During the course of this program, 
we may find more information that could be important to you and your health. When feasible, we will notify you 
as soon as possible if such information becomes available. For example, we would contact you immediately if new 
information became available about the study medication that might cause you to change your mind about being 
in the program. 
 
WHAT ARE THE POSSIBLE BENEFITS OF THE PROGRAM? Participants who enroll in this study will benefit from the 
knowledge that they are contributing in an important way to increasing scientific knowledge about neurocognitive 
disease and ways to improve its treatment in people living with HIV. 
 
WHAT OTHER CHOICES DO I HAVE IF I DO NOT PARTICIPATE? The alternative to participation is to decide not to 
enroll in this program.  
 
WILL I BE PAID IN THIS PROGRAM? To reimburse you for the time and effort needed for completing assessments, 
you may earn up to $590, which includes $10 for travel-related expenses at each in-person session. In place of 
$10/session to cover travel expenses, you may elect to use a round-trip car ride service (i.e., Lyft) which will be 
arranged and paid for in full by the research study. If you choose to use the ride service, you will not receive $10 


Version 16: February 22, 2021 
 
Page 6 of 10 
 
for your travel reimbursement and your total visit compensation may be up to $500. Travel will not be paid for a 
session intended to be in-person if it has to be completed by phone. 
 
The “task completion” compensation will depend on you arriving on time for scheduled sessions and returning 
used blister packs by the end of study participation. If you do not follow the study instructions, the task completion 
compensation may be withheld.  
 
If at any point you are deemed ineligible, you will only be compensated $10 to cover your travel costs, unless you have 
elected to use the ride service for that session.  
 
The Greenphire ClinCard will be the primary form of payment for this study. The ClinCard is a reloadable, pre-
paid card for the purposes of compensation. Compensation will be loaded onto the ClinCard within 24 hours of 
completed visits. Staff may ask you to provide a Social Security Number, or complete a W-9 for this purpose, after 
determining your eligibility so that a ClinCard can be assigned to you. ClinCards may be mailed to you following your 
eligibility determination for the study. 
 
 
You will be eligible for a $40 bonus at the end of each treatment period for successfully completing all visits during 
that period. You may also receive a $20 bonus for each person successfully referred to the program, for a maximum 
of three referrals. This will be paid to you after completing the last study visit (Period 2 Lab Visit 2). 
 
The payment schedule is as follows: 
 
Compensation Schedule 
Week 
Period 
Study Visit 
Visit  
Compensation 
Task 
Completion 
Travel3 
Bonus 
Total 
-2 
N/A 
Intake  
$20  
 
$10  
$30  
0 
1 
Lab Visit 1 
$35  
$15 
$10  
  
$60  
2 
1 
Monitoring Call 1 
$10 
 
$0  
  
$10  
4 
1 
Mid-Tx Visit 1 
$25  
$15 
$10  
  
$50  
6 
1 
Monitoring Call 2 
$10  
 
$0  
  
$10  
8 
1 
Mid-Tx Visit 2 
$25  
$15 
$10  
  
$50  
10 
1 
Monitoring Call 3 
$10 
 
$0  
  
$10  
12 
1 
Lab Visit 2 
$25  
$15 
$10  
$401  
$90  
16 
2 
Lab Visit 1 
$35  
$15 
$10  
  
$60  
18 
2 
Monitoring Call 1 
$10  
 
$0  
  
$10  
20 
2 
Mid-Tx Visit 1 
$25  
$15 
$10  
  
$50  
22 
2 
Monitoring Call 2 
$10 
 
$0  
  
$10  
24 
2 
Mid-Tx Visit 2 
$25  
$15 
$10  
  
$50  
26 
2 
Monitoring Call 3 
$10  
 
$0  
  
$10  
28 
2 
Lab Visit 2 
$25  
$15 
$10  
$401  
$90  
 
 
 
 
 
Study Total: 
$590 
N/A 
2 
Referral Bonus 
 
 
 
$602 
$60 
 
Total w/ Referrals: 
$650 
1 Bonus awarded to participants that complete every visit in a period, at the end of each period. 
2 Table shows total compensation for three successful referrals 
3 Only paid if you opt out of the round-trip car ride service 
 
 
HOW DOES TRAVELING VIA THE RIDE SERVICE WORK? You may elect to use “Roundtrip”, which is a car ride service 
that collaborates with Lyft to coordinate round-trip rides to study appointments. Study staff will schedule each ride 
using your first name, last name, and phone number via Roundtrip’s HIPAA compliant platform. You will receive a 
reminder call 24-48 hours prior to your study visit to confirm your visit, interest in using the ride service, and preferred 
pickup/drop-off locations. If the study staff cannot reach you by 5pm the day prior to your study visit, your ride will 
be cancelled. You will still be permitted to attend the visit and will receive $10 to cover your travel expenses. If you 
need to cancel a previously confirmed ride, you must do so by contacting the study staff immediately, preferably by 


Version 16: February 22, 2021 
 
Page 7 of 10 
 
5pm the day before your appointment. If you fail to notify study staff within this timeframe, you may no longer be 
permitted to use the ride service at future study visits. 
 
WILL I HAVE TO PAY FOR ANYTHING? There will be no charge to you for participating in this research program. 
You and/or your health insurance may be billed for the costs of medical care during this program if these expenses 
would have happened even if you were not in the program or if your insurance agrees in advance to pay. 
 
If you choose to receive text message reminders, you will be responsible for the costs associated with the receipt 
of these text messages. For example, if you have a monthly text-messaging plan, these messages will count 
towards your monthly text-messaging total. If you do not have a plan, you will be charged the standard text 
messaging fees by your wireless provider. You may receive a maximum of 20 text messages from the study each 
month. 
 
WHAT HAPPENS IF I AM INJURED OR HURT IN THE RESEARCH PROGRAM? In the event that you are hurt or injured 
as a result of participation in this research program, please contact the investigator listed on page one of this form. 
We will offer you the care needed to treat injuries directly resulting from participation in this research program. 
We may bill your insurance company or other third parties, if appropriate, for the costs of the care associated with 
these injuries; however, you may also be responsible for some of these costs. There are no plans for the University 
of Pennsylvania to pay you or provide other compensation for the injury. You do not give up your legal rights by 
signing this form. 
 
WHEN IS THE RESEARCH PROGRAM OVER? CAN I LEAVE BEFORE IT ENDS? This research program is expected to 
end after all participants have completed all visits and all information has been collected. This program may also 
be stopped at any time by your physician, the program Sponsor, or the Food and Drug Administration (FDA) 
without your consent if: 
• 
The Primary Investigator feels it is necessary for your health or safety. Such an action would not require 
your consent, but you would be informed if such a decision was made and the reason for this decision. 
• 
You have not followed program instructions.  
• 
The Sponsor or Principal Investigator has decided to stop the program. 
 
If you decide to participate, you are free to leave the research program at any time. Withdrawal will not interfere 
with your future care or participation at our center.  
 
WHAT HAPPENS TO MY COLLECTED SAMPLES AND INFORMATION? Samples collected as part of this study will 
be used for multiple analyses, as described above. We would like to store your information (such as demographic 
information, questionnaire responses etc.) and samples for possible use in future research. This storage may be 
for an indefinite amount of time. The information and samples you provide may be shared with other research 
institutions, e.g. The Abramson Cancer Center at Penn, or researchers working with research institutions who 
want to learn more about neurocognitive disease in people living with HIV. Whole genome sequencing will not be 
conducted on your samples. Whole genome sequencing involves analyzing your entire personal genetic code. We 
will protect your confidentiality by first labeling your information and samples with an identification number only 
(not your name). We will restrict access to the databases that hold your personal information. Your samples will 
be stored in a locked, private bank, accessible only by authorized personnel. Permission to store your information 
and samples for use in future research is optional and you can indicate your choice at the end of this consent form. 
You may withdraw your permission at any time by contacting study staff and letting us know you no longer want 
your information and samples to be stored for use in future research. Your samples may be used to create 
products, including some that may be sold and/or make money for others. If this happens, there are no plans to 
tell you, or to pay you, or to give any compensation to you or your family. Most use of samples or information do 
not lead to commercial products or to profit for anyone. Additionally, we will not follow up with you about the 
specific research that will be done, and individual research results obtained as part of future research will not be 
shared with you. 
 


Version 16: February 22, 2021 
 
Page 8 of 10 
 
WHO CAN SEE OR USE MY INFORMATION? HOW WILL MY PERSONAL INFORMATION BE PROTECTED? While we 
cannot guarantee total privacy, we will do our best to make sure that the personal information in your research 
record is kept private. Your personal information would only be given out if required by law. We will store your 
information in a secure room with limited access. We will also control access to the computer files that hold this 
information. We will identify all results from sample collection and analysis with an identification number only 
(not your name). Only authorized program personnel will be able to link your identification number with your 
name. Your samples will be stored in our private bank, which can be accessed only by authorized study personnel. 
Blood samples will be fully de-identified before being sent to the Wistar Institute for additional analyses. If 
information from this research is published or presented at scientific meetings, your name and other personal 
information will not be used. If you tell us that you are involved in a situation of child abuse or that you are going 
to harm yourself, we will have to break confidentiality and report this to local authorities as required by law. 
 
WHAT INFORMATION ABOUT ME MAY BE COLLECTED, USED OR SHARED WITH OTHERS? 
• 
Name, address, telephone number, email address 
• 
Date of birth 
• 
Social Security Number (W-9 form) 
• 
Some personal information that may be considered sensitive, such as medical history, psychological history, 
alcohol use history, etc.  
• 
Results from physical examinations, tests or procedures, including urine drug screening 
• 
Information on smoking, cognition, or inflammation biomarkers from the blood samples provided at the 
Intake and Laboratory sessions 
• 
Saliva sample for testing by-products of nicotine (smokers only) 
• 
Medical Record Number 
 
WHY IS MY INFORMATION BEING USED? Your contact information is used by the research team to contact you during 
the program. Your personal health information and results of procedures are being collected as part of this research 
program. In some situations, personal health information might be used to help guide your medical treatment.  
 
WHO MAY USE AND SHARE INFORMATION ABOUT ME? The following individuals and organizations may use or 
disclose your personal health information for this research program: 
• 
The Principal Investigator (PI) and research collaborators  
• 
The University of Pennsylvania Institutional Review Boards (the committees charged with overseeing research 
on human subjects) and the University of Pennsylvania Office of Regulatory Affairs 
• 
The University of Pennsylvania Office of Human Research (the office that monitors research studies) 
• 
Way 2 Health team (programming, troubleshooting, monitoring software etc.) 
• 
Authorized members of the University of Pennsylvania and the UPHS, and School of Medicine workforce that 
may need to access your information in the performance of their duties (e.g., research oversight and monitoring) 
 
ELECTRONIC MEDICAL RECORDS AND RESEARCH RESULTS 
What is an Electronic Medical Record? An Electronic Medical Record (EMR) is an electronic version of the record of 
your care within a health system. An EMR is simply a computerized version of a paper medical record.  
 
If you are receiving care or have received care within the University of Pennsylvania Health System (UPHS) (outpatient 
or inpatient) and are participating in a University of Pennsylvania research study, results of research-related 
procedures (i.e. laboratory tests, imaging studies and clinical procedures) may be placed in your existing EMR 
maintained by UPHS. Once placed in your EMR, these results are accessible to appropriate UPHS workforce members 
that are not part of the research team. Information within your EMR may also be shared with others who are 
determined by UPHS to be appropriate to have access to your EMR (e.g. health insurance company, disability provider, 
etc.). No results from this research study or analyses will be placed in your EMR. 
 
 


Version 16: February 22, 2021 
 
Page 9 of 10 
 
WHO, OUTSIDE THE SCHOOL OF MEDICINE, MIGHT RECEIVE MY INFORMATION? 
The following are working with the Principal Investigator: 
• 
Center for AIDS Research (CFAR), University of Pennsylvania 
• 
The Wistar Institute 
 
The following are supporting and overseeing the research and the sponsor: 
• 
The Office of Clinical Research, University of Pennsylvania 
• 
The Food and Drug Administration 
• 
The National Institutes of Health (NIH) 
• 
The Abramson Cancer Center, University of Pennsylvania 
• 
Philadelphia Department of Public Health Institutional Review Board
 
The following entity is managing participant transportation and has access to first name, last name, and phone 
number only: 
• 
Roundtrip 
 
The Principal Investigator or research staff will inform you if there are any changes to the list above during your active 
participation in the trial. Once your personal health information is disclosed to others outside of UPHS or the School 
of Medicine, it may no longer be covered by federal privacy protection regulations. This does not mean that all 
personal identifying information is being disclosed. Generally, if information has to be released it contains only initials 
and birth date, or only a unique number, not complete contact information. Any such additions will be subject to Penn 
UPHS and School of Medicine procedures to protect your privacy. 
 
HOW LONG MAY THE SCHOOL OF MEDICINE USE OR DISCLOSE MY PERSONAL HEALTH INFORMATION (PHI)? Your 
authorization for use of your personal health information for this specific program does not expire. Your information 
may be held in a research repository or database. However, UPHS and the School of Medicine may not re-use or re-
disclose information collected in this program for a purpose other than this program unless: 
• 
You have given written authorization to do so  
• 
The University of Pennsylvania Institutional Review Board grants permission after ensuring that appropriate 
privacy safeguards are in place  
• 
It is required by law 
 
CAN I CHANGE MY MIND ABOUT GIVING PERMISSION FOR USE OF MY INFORMATION? You may withdraw or take 
away your permission to use and disclose your health information at any time. You do this by contacting study staff 
or sending written notice to the investigator for the program. If you withdraw your permission after being enrolled, 
you will not be able to stay in this program. 
 
WHAT IF I DECIDE NOT TO GIVE PERMISSION TO USE AND GIVE OUT MY HEALTH INFORMATION? You will not be 
able to participate in this research program. 
 
WHO CAN I CALL WITH QUESTIONS, COMPLAINTS OR IF I’M CONCERNED ABOUT MY RIGHTS AS A RESEARCH 
SUBJECT? If you have questions, concerns or complaints regarding your participation in this research program or if 
you have any questions about your rights as a research subject, you should speak with the Principal Investigator listed 
on page one of this form. If a member of the research team cannot be reached, or you want to talk to someone who 
is not directly involved with this program, you may contact the Office of Regulatory Affairs with any questions, 
concerns, or complaints at the University of Pennsylvania by calling (215) 898-2614. 
 


Version 16: February 22, 2021 
 
Page 10 of 10 
 
 
 
Name of Research Participant:     
PRINT NAME: 
 
 
 
 
 
 
 
 
 
SIGNATURE: 
 
 
DATE: 
 
 
 
 
 
Name of Person Obtaining Consent:   
 
PRINT NAME: 
 
 
 
 
 
 
 
 
 
SIGNATURE: 
 
 
DATE: 
 
 
 
 
 
Future Use Of Data/Biospecimens: 
Please initial and check YES if you give permission for us to store your information and some of your blood 
from this study for use in future research. Please initial and check NO if you do not give us permission to 
store your information and some of your blood from this study for use in future research. 
 
 YES 
 NO 
Participant Initials: ______________ 
 
When you sign this form, you are agreeing to take part in this research program. This means that you have read 
the consent form, your questions have been answered, and you have decided to volunteer. Your signature also 
means that you are permitting the University of Pennsylvania Health System and the School of Medicine to use 
your personal health information collected about you for research purposes within our institution. You are also 
allowing the University of Pennsylvania Health System and the School of Medicine to disclose that personal health 
information to outside organizations or people involved with the operations of this program. A copy of this form 
will be given to you.